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ABSTRACT 
	  
Bordetella pertussis, the aetiological agent of “whooping cough” an acute upper 
respiratory tract disease of humans, can infect all age groups with adolescents and 
adults acting as major source of transmission of this pathogen to infants. Transmission 
to children is facilitated by the infection in adolescents and adults not exhibiting being 
either asymptomatic or presenting as a mild but persistent ordinary cold-like illness. It 
is well established that both antibodies and cell-mediated immune (CMI) responses 
are crucial for protection against whooping cough, the former being important in the 
early phase of the disease and the latter being crucial for the long-term protection. 
Given that protection offered by vaccination with the currently-used acellular 
pertussis vaccines is due predominantly to antibodies induced by Th2-polarisation of 
immune response, there is urgent need to develop an alternative vaccine capable of 
inducing both antibody and CMI responses. One such alternative is the development 
of live attenuated pertussis vaccines because they mimic natural infections but survive 
in the host for only a relatively short period of time. Their survival is long enough 
however to potentially induce an immune response to all the virulence antigens 
yielding better and longer term protection. One such vaccine is a metabolite-deficient 
B pertussis in which the aroQ gene of the common aromatic biosynthetic pathway has 
been deleted (hereafter referred to as the aroQBP vaccine). The aroQBP vaccine, has 
been reported to colonise airways of mice efficiently and induce both humoral and 
cell mediated immunity and protect mice against aerosol challenge with virulent B 
pertussis. 
 
The main goal of this study was to evaluate the potential of the aroQBP vaccine 
candidate as an alternative vaccine to DTaP for both the primary and secondary 
vaccination in adolescents and/or adults using a mouse model system. Humoral 
immune responses were measured by estimating antibody specific immunoglobulin 
for B pertussis in mouse serum using enzyme-linked immunosorbent assay (ELISA).  
Cell mediated immunity was quantified by measuring INF-γ released from 
splenocytes stimulated in vitro with inactivated whole aroQBP cells and filamentous 
haemagglutinin (FHA) as a model B pertussis protective antigen. The vaccination 
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schedules used were chosen to mimic, in general terms, the multiple immunisations to 
which human infants are subjected. 
 
Secondary and tertiary immunisation with the aroQBP vaccine of mice previously 
vaccinated with three sequential doses of the conventional DTaP vaccine resulted 
significant immune responses.  Of these mice, those receiving two sequential doses of 
the aroQBP vaccine manifested strong anamnestic responses relative to those mice 
receiving one vaccination with aroQBP vaccine candidate.  Further, a change in the 
balance of the immune response was observed from Th2 type (humoral) to an 
enhanced Th1 type (CMI) as assessed by the production of INF-γ. 
 
It was discovered that primary immunisation of mice with aroQBP vaccine candidate 
did not result in a significant immune response.  However such mice displayed an 
anamnestic response to a secondary immunisation with aroQBP. These mice 
produced higher levels of B. pertussis specific IgG, IgG1, and IgG2a immunoglobulin 
compared to mice receiving only a primary immunisation with aroQBP vaccine as 
measured by immunoassay with inactivated aroQBP whole cells (BPWC). These 
mice also manifested a measurable cell mediated immune response (INF-γ). This 
result clearly demonstrated the prior sensitisation of the mice with a single dose of 
aroQBP vaccine. 
 
These results in mice demonstrate that the aroQBP vaccine is capable of eliciting 
CMI responses when used either alone or in conjunction with the conventional DTaP 
vaccine. Since DTaP vaccine alone induces only a predominant humoral immune 
response, aroQBP is an ideal candidate for further genetic detoxification studies to 
render it suitable for trials in humans. Hence, if substantiated by further research, the 
aroQBP vaccine will lead to improved vaccination protocols for both children and 
adults due to its demonstrated potential of complementing the humoral immune 
response to DTaP by induction of a persistent cell mediated immunity believed to be 
essential for long-term protection against whooping cough. 
 
A cognate study was undertaken therefore to investigate genetic detoxification 
mechanisms for adenylate cyclase toxin (ACT), one of the key virulence exotoxins 
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produced by B pertussis. Genetic detoxification of ACT was attempted using two 
different Bordetella suicide vectors harboring a 1kb cyaA gene fragment modified by 
site-directed mutagenesis.  The gene fragment sought encoded methionine in place of 
lysine at position 58 in the cyaA gene of the B pertussis genome. The mutant sought 
was not detected, however a clone showing a random substitution of lysine with 
asparagine was isolated. The toxicity of this clone with random mutation in the cyaA 
gene of ACT was not assessed due to time constraints. Strategies for overcoming the 
problems encountered in achieving genetic detoxification of ACT utilising site 
directed mutagenesis as well as the chances of accomplishment of this goal are 
discussed in this thesis. 
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Whooping cough was recognized as an acute respiratory disease of humans in the 16th 
century and the aetiological agent, Bordetella pertussis, was isolated and identified by 
Bordet and Gengou in 1906 (Cherry 1999). Although all age groups are susceptible to 
infection, the disease is pronounced in infants due to the severe systemic 
complications that can accompany the characteristic paroxysmal cough (Kerr and 
Matthews 2000). The severe and potentially fatal complications include convulsions, 
bronchopneumonia, and encephalopathy (Olson 1975). Protection, albeit claimed as 
variable in duration, can be conferred by vaccination with killed whole cell vaccines. 
As the recommended vaccination schedule does not commence until 2 months of age 
and the immune system remains immature throughout the first year of an infant’s life, 
children less than 1 year-old being the highest risk group (Kerr and Matthews 2000). 
Typical pertussis, as defined by the World Health Organization (WHO) (Anonymous 
2005) consists of the catarrhal, paroxysmal and convalescent phases. The catarrhal 
phase manifests as a cold-like illness with coryza and a mild cough with the onset of 
these symptoms usually 7 to 10 days after exposure. Whooping cough is highly 
contagious during the catarrhal phase. Proliferation of B pertussis and their 
subsequent abundance in nasopharyngeal secretions provides a means of aerosol 
transmission via droplet spread or direct contact (Kerr and Matthews 2000). 
Progression from a mild asymptomatic cough to convulsive or violent attacks 
(paroxysmal cough) indicates onset of the paroxysmal phase. Excessive mucous 
production, vomiting and lymphocytosis are additional manifestations that are 
commonly observed during this period of infection. A feature of the paroxysmal 
cough is the characteristic ‘whoop’ sound that occurs as a result of inhalation through 
a narrow glottis. Coughing attacks can occur frequently and can be so severe that 
exhaustion and apnoea result. This stage can last for up to 4 weeks, after which time 
the majority of sufferers enter a convalescent phase that is characterised by a gradual 
recovery. However, the severe cough can re-emerge in the presence of an 
opportunistic infection (Olson 1975). 
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Apart from the classical pertussis syndrome, there are several forms of an atypical 
infection. Although the cough is the defining symptom of pertussis, it has been 
reported that culture-positive neonates and infants have presented with symptoms 
such as apnoea and seizures in the absence of paroxysms (Kerr and Matthews 2000). 
Adolescents and adults do not exhibit the characteristic cough and infection can be 
either asymptomatic or manifested as a mild but persistent cold-like illness (Cromer et 
al. 1993; Birkebaek et al. 1999). B parapertussis can also infect humans but the 
disease state is often milder and far less common than the B pertussis aetiology, 
whereas the remaining Bordetella spp, B bronchiseptica, B holmesii, B avium, B 




Whooping cough, caused by B pertussis, has the most severe consequences in infants 
and children and is one of the ten most common causes of death from infectious 
disease (McIntyre and Wood 2009). Although vaccination with either the whole cell 
(wP) or acellular pertussis (aP) vaccines, administered in combination with diphtheria 
and tetanus toxoids (DTwP or DTaP), has reduced morbidity and mortality 
significantly, pertussis remains an endemic disease. It is the major cause of vaccine-
preventable deaths today, with WHO estimates of 40-50 million cases and 
approximately 297,000 - 409,000 death each year worldwide (Anonymous 2005; 
Elahi, Holmstrom, and Gerdts 2007; Fennelly et al. 2008), albeit majority of them 
being in developing countries. The incidence of pertussis was clearly influenced by 
the advent of effective prophylactic and therapeutic intervention in the mid 1940’s. 
During the pre-vaccine era, pertussis was highly endemic with cyclic epidemics that 
occurred every 2 to 5 years (Cherry 1999). Although the introduction and wide-spread 
use of the pertussis vaccines caused a dramatic reduction in the incidence of pertussis, 
the incidence of whooping cough has risen recently despite high vaccine coverage in 
developed countries such as Australia, Canada, the United States and the Netherlands 
despite high levels of immunization rates (Mooi, Van Loo, and King 2001; de Melker 
et al. 1997). In Australia, pertussis has been endemic since 1993 with notifications 
rising from 1.8/100,000 population in 1991 to a peak of 127.8/100,000 in 2009 
despite a high rate of vaccine coverage (Anonymous 2009). 
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Recently, incidence of this disease in adolescents and adults has become an area of 
increasing interest over the last decade because of the obvious consequence of 
undetected and untreated pertussis, although not often clear, in the mature age groups 
to transmit pertussis to other adults, and more importantly to highly susceptible 
infants (Cagney et al. 2008). The recent deaths attributed to pertussis in Australia 
have been restricted to infants under 2 months to less than 1 year of age (Andrews, 
Herceg, and Roberts 1997). Although these infants were too young to be vaccinated, 
it was concluded that a reduction in the level of pertussis within the community, 
particularly from reservoirs such as asymptomatic adults would have diminished the 
risk of exposure. 
 
There have been numerous suggestions as to the reasons for the recent and 
widespread re-emergence of pertussis. Although a number of factors such as 
increased public awareness, improvement in notification accuracy, decreased or 
delayed vaccine coverage and a reduction in vaccine quality could be applicable for 
developing countries, these possibilities have been largely excluded for the 
industrialised countries (Kolos, Menzies, and McIntyre 2007). The adaptation of B 
pertussis to vaccination has been suggested as a reason for the rise in developed 
countries. Mooi et al. (2001) DNA fingerprinted Dutch strains collected from 1949 to 
1996 and found notable changes between the pre-vaccine and post-vaccine 
populations of B pertussis. This divergence was observed as polymorphisms within 
the pertussis toxin and pertactin antigens, both of which are dominant immunogens 
and components of acellular vaccines. 
 
More recently, pertussis has re-emerged even in vaccinated populations confirming 
that pertussis is not only a childhood disease but is also highly prevalent in adults 
(Cagney et al. 2008; He and Mertsola 2008), latter being accepted now as the major 
reservoir of infection for majority of the pertussis cases in infants and young children 
(Cagney et al. 2008). Several reasons offered to explain the increasing incidence of 
this disease syndrome in adolescents and adults include better diagnosis, cyclic 
variation in disease patterns, waning of vaccine-induced immunity in adolescents and 
adult over time due to the limited protection offered by the currently used vaccines 
(Mooi, Van Loo, and King 2001; von Konig et al. 2002; Cherry 2003; Mills 2001) and 
loss of vaccine efficacy due to the emergence of new B pertussis strains 
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overproducing pertussis toxin (Mooi et al. 2009). It is therefore apparent that the 
immunisation of the adolescent and adult population is one aspect that needs 
addressing to control the spread of pertussis. The increased risks of potential side 
effects, excessive cost of expanded vaccination programs particularly in developing 
countries and the perceived mild nature of the disease in adults are factors that have 
hindered the notion of vaccination beyond infancy (Cherry 1999; Roduit et al. 2002; 
Singh and Lingappan 2006). 
 
B pertussis is a complex and highly adapted non-invasive respiratory pathogen, which 
localises to the tracheobronchial tree and produces a large array of potential virulence 
factors including toxins, outer membrane proteins and other virulence determinants, 
which contribute to the disease process and immune system subversion (Fennelly et 
al. 2008). Clearly, an ideal effective pertussis vaccine should be able to neutralise or 
abrogate the effects of all the virulence factors associated with the pathogenesis of 
pertussis as well as induce, considered to be important in imparting long-term 
protection against whooping cough (Mills 2001; Mahon, Brady, and Mills 2000). 
However, no such vaccine capable of fulfilling this attribute has been developed and 
hence the urgency to develop an improved pertussis vaccine capable of delivering this 
desired outcome. 
 
1.3. Virulence factors 
	  
B pertussis produces an array of virulence factors (Table 1), some of which are 
considered to play a key role in the establishment of B pertussis infection. These 
include filamentous hemagglutinin (FHA), pertactin (P69), pertussis toxin (PT), 
adenylate cyclase toxin (ACT) (Mills 2001; Weiss and Hewlett 1986), with other 
factors such as fimbriae, dermonecrotoxin, tracheal cytotoxin, tracheal colonisation 
factor, serum resistance factor and lipopolysaccharide also playing important roles 
leading to clinical manifestations of pertussis.  
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Table 1.3. Accredited virulence factors of B pertussis. 
 
Factor Molecule Major role Inclusion in Pa 
Pertussis toxin 
(ptx) 
A and B subunits Toxin, ADP 





Yes, as inactive 
toxin 
















Pertactin (prn) 69kDa OMP Adhesion factor Yes 
Adenylate cyclase 
(cya) 



























resistance to killing 
factor (brk) 
OMP (32kDa) Resistant to classic-
complement killing 
NO 
Lipopolysaccharide  Endotoxin; 
Resistance to host 
defence molecules 
NO 
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1.3.1. Filamentous hemagglutinin (FHA) 
	  
Filamentous hemagglutinin (FHA), a large 220-kDa outer membrane-associated 
protein, is one of the earliest protein expressed by B pertussis that is detected within 
few minutes of infection (Scarlato et al. 1991). It binds to the complement receptor 
type 3 (CR3) on surface of macrophages via conserved a tripeptide sequence RGD 
(arginine, glycine, aspartate) (Relman et al. 1990) and induces secretion of IL-6 and 
IL-10. These cytokines down-regulate production of IL-12 from the cells leading to a 
delayed T-cell response in the lungs of mice (McGuirk et al. 1998). Further, FHA is 
implicated in suppression of Th1 cell-mediated response by inhibiting IL-12 
production upon infection with B pertussis potentially leading to waning of host 
immunity against pertussis (Preston 2005). 
	  
The diminished ability of an FHA-deficient mutant to adhere in vivo or to in vitro 
cultured epithelial cells, and the ability of anti-FHA antibodies to inhibit the 
attachment of virulent microorganisms indicates an important role for FHA in the 
adhesion of B pertussis to ciliated epithelia (Urisu, Cowell, and Manclark 1985; 
Simondon et al. 1998). High titers of anti-FHA antibodies have been detected in 
human convalescent sera (Simondon et al. 1998) and are elicited to protective levels 
following immunisation with commercial pertussis vaccines (Mills et al. 1998). 
Similarly, antibodies generated against purified FHA have been shown to be 
protective in animal models (Sato and Sato 1984) and in human clinical trials 
(Edwards et al. 1995). 
 
1.3.2. Pertactin (PRN) 
	  
Brennan et al. (1988) identified a 69-kDa membrane-associated protein (P.69 or 
pertactin) using a library of monoclonal antibodies generated against the surface 
antigens of B pertussis. Unlike FHA-deficient mutants, B pertussis mutants deficient 
in pertactin were not inhibited in attachment to ciliated respiratory epithelial cells 
(Roberts et al. 1991). However, the identification of an RGD tripeptide, which is 
present in other bacterial adhesins, including FHA, indicated that pertactin may also 
have a role in attachment to eukaryotic cells (Leininger et al. 1991). 
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As with FHA, pertactin is also a potent immunogen of B pertussis. Anti-P69 
antibodies with bactericidal and opsonic properties have been detected in the serum of 
patients recovering from infection, whilst high titers of serum antibodies have been 
observed following immunisation with the wP (Hellwig et al. 2003; Thomas, 
Redhead, and Lambert 1989). In addition, De Magistris et al. (1988) demonstrated 
that P69 was recognised by B pertussis-specific T cell clones isolated from a 
convalescent donor. However, thirteen variants of PRN through genotyping have been 
identified (Mooi et al. 2000), variation being mainly restricted to the N-terminus 
(Hijnen et al. 2007).  
 
1.3.3. Pertussis toxin (PT) 
	  
The term pertussis toxin was coined by Margaret Pittman (Pittman 1979). All B 
pertussis, B parapertussis and B bronchiseptica have genes for encoding the toxin but 
only B pertussis is able to produce functional PT (Arico et al. 1987). Other names that 
have been suggested for the toxin include lymphocytosis-promoting factor, islet-
activating factor, and pertussigen (Munoz, Arai, and Cole 1981). Regarded as the 
central virulence factor during infection, pertussis toxin elicits a number of 
deleterious consequences including leukocytosis, splenomegaly, histamine 
sensitisation, hypoglycaemia and hypoproteinemia (Hewlett 1999). PT is an exotoxin 
composed of five subunits (S1- S5) arranged in a manner that is consistent with the A-
B family of toxins (Locht and Antoine 1995). Subunits S2, S3, S4 and S5 present in a 
1:1:2:1 ratio forms the B oligomer, which has been demonstrated to provide two 
functions: receptor-mediated binding to the surface of target cells and translocation of 
the catalytic domain across the plasma membrane. In addition to upregulating 
macrophage integrin CR3, which acts as a receptor for FHA, it acts as a toxin by ADP 
ribosylating G regulatory proteins inhibiting their coupling to receptors of 
intracellular transduction pathways, and causing blockage of phosphatidyl inositol 
hydrolysis, arachidonate release and calcium mobilisation (Locht and Antoine 1995; 
Weiss and Hewlett 1986). B pertussis is the only member of the genus that produces 
the ADP-ribosylating exotoxin which emphasises the importance of pertussis toxin 
considering that infection with B parapertussis often results in a milder or atypical 
whooping cough syndrome (Linnemann and Perry 1977). The presence of anti-PT 
antibodies in convalescent sera and the detection of high titers following 
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immunisation with the wP vaccine provided an indication of the protective potential 
of PT (Trollfors et al. 1999). The subsequent development and assessment of acellular 
pertussis vaccines has provided further insight into the immune response and 
protective efficacy of PT. Phase 1 and 2 clinical trials of a mono-component pertussis 
toxoid vaccine revealed a statistically significant correlation between toxin 
neutralising antibodies and protection against pertussis (Taranger et al. 2001). 
However, the protection observed with the monocomponent vaccine was only partial 
(Trollfors et al. 1995). 
 
1.3.4. Adenylate cyclase toxin (ACT) 
	  
Glaser et al. (1988) identified an 8.7 kb DNA fragment from a B pertussis 
recombinant gene library, which encoded a calmodulin-sensitive adenylate cyclase. 
Sequence analysis of the cloned DNA revealed an open reading frame consisting of 
five genes arranged in an operon, denoted as cya. The cyaA gene encodes an inactive 
protoxin that exhibits AC activity but is devoid of haemolytic or cell-invasive activity 
(Sebo et al. 1991). An alcyltransferase encoded by an upstream cyaC gene activates 
the protoxin by palmitolyation of the lysine (K) 983 residue, which confers the 
invasive and haemolytic activities that are absent in the precursor. Considering the 
absence of an N-terminal signal sequence in the protoxin, the three accessory genes 
downstream of cyaA (cyaB, cyaD and cyaE) have a postulated role in secretion of the 
active toxin (Hanski 1989). 
 
The adenylate cyclase-hemolysin toxin (AC-Hly) performs a crucial role in lung 
colonisation and the establishment of infection. The C-terminal haemolytic domain 
penetrates mammalian phagocytes (neutrophils, monocytes, NK cells and 
macrophages) and facilitates translocation of the N-terminal adenylate cyclase across 
the plasma membrane, which subsequently catalyses the conversion of the energy-
deficient cyclic adenosine monophosphate (cAMP) from the high-energy compound 
adenosine triphosphate (Weiss and Hewlett 1986). A unique feature of AC-Hly is its 
interaction with the eukaryotic regulatory protein calmodulin, which increases the 
catalytic activity of the toxin up to a thousand-fold (Weiss and Hewlett 1986). The 
dramatic reduction of ATP within the infected phagocyte causes a severe impairment 
of normal cellular functions, arising from an inadequate supply of cellular energy 
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(Sebo et al. 1991). The resulting inhibition of a phagocyte response is an essential 
factor in the establishment of infection considering that mutants defective in AC-Hly 
production have been shown to be avirulent, unable to proliferate, and are rapidly 
cleared from the lungs (Weiss et al. 1984). 
 
Phagocytosis and killing of B pertussis by neutrophils is an effective innate defence 
mechanism against infection.  Lenz et al. (2000) used B pertussis labelled with green 
fluorescent protein (GFP) to demonstrate that up to 99 % of the bacteria phagocytosed 
by neutrophils are killed following internalisation. In view of the inhibitory effect of 
AC-Hly on neutrophils, the generation of toxin neutralising antibodies should enhance 
phagocytosis and thus the clearance of B pertussis. High titers of anti-AC-Hly 
antibodies have been detected in both the sera of convalescent patients and in adults 
and children immunised with the whole cell vaccine (Farfel et al. 1990). Although the 
neutralising potential of antibodies present capable of neutralising toxin in vitro was 
not determined, the protective humoral response elicited by immunisation of mice 
with native and recombinant AC-Hly suggested that neutralising polyclonal 
antibodies generated in vivo are equally effective in enhancing phagocytosis as the in 
vitro assay using monoclonal antibodies (Hormozi, Parton, and Coote 1999). 
 
1.3.5. Fimbriae (Fim) 
 
These are long filamentous protrusions, with helical structure of pentameric repeat 
units, extend which permit B pertussis to bind to their target cells (Steven et al. 1986). 
B pertussis possesses two serotypes fimbriae. The major fimbriae, Fim2 and Fim3, 
(22.5 and 22 kDa), are encoded by fim2 and fim3, respectively (Locht, Geoffroy, and 
Renauld 1992; Willems, van der Heide, and Mooi 1992). The major fimbriae helices 
are bundled to form long filaments with minor subunit FimD on their tip as epitopes 
(binding site to perspective receptor on host cell). FimD is expressed from fimD 
(Geuijen et al. 1997). FimD is ligand for very late antigen-5 (VLA-5) on monocytes 
and macrophages and up regulates the expression of CR3 on the cells (Geuijen et al. 
1997; Hazenbos et al. 1995). Fim2 and Fim3, have been shown to mediate the binding 
of non-opsonized B pertussis to host cells (Locht, Geoffroy, and Renauld 1992; 
Willems, van der Heide, and Mooi 1992). FimD has been shown to bind to sulphated 
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sugars, which is ubiquitous on the surface of respiratory cells and secretions (Geuijen 
et al. 1997).  FimX and fimA are considered pseudogenes related to major fimbriae 
subunits (Willems, van der Heide, and Mooi 1992; Pedroni et al. 1988). In B pertussis 
fimX is expressed at a very low level and FimA gene is a silent gene (Boschwitz et al. 
1997). 
 
The minor fimbriae genes in B pertussis include fimB, fimC and fimD (Locht, 
Geoffroy, and Renauld 1992; Willems, van der Heide, and Mooi 1992). FimB is 
transported to the periplasm after cleavage and maturation whereas FimC is involved 
in anchorage of pertussis to its host cells and acts as the molecular syringe for B 
pertussis to inject toxins into neutrophils and macrophages. 
 
Although the complete role of fimbriae in pathogenesis remains unclear, deletion 
mutants are less persistent than the wild type (Mooi et al. 1992). Fim2 and Fim3 have 
been incorporated into some licensed acellular vaccines; however their inclusion does 
not appear to augment the protective efficacy of DTaP (Mills et al. 1998). In contrast, 
an early clinical trial of a pertussis whole cell vaccine (WCV) in the UK found a 
correlation between serum agglutinin titers and protection against whooping cough in 
infants (Anonymous 1956). Of these serum agglutinin titers, antibodies to FIM were 
found to be main contributors, along with antibodies to pertactin (van den Berg et al. 
1999). 
 
1.3.6. Dermonecrotic toxin (DNT) 
 
Identified by Bordet and Gengou in 1909, DNT was one of the first known virulence 
factors of B pertussis. DNT is a heat-labile toxin that when injected intradermally 
causes necrotic lesions in animals and has been observed to be lethal in mice when 
given intravenously (Livey and Wardlaw 1984). It is a single polypeptide of 140 kDa 
that appears to be cytoplasmic rather than secreted (Matsuzawa et al. 2004). It is 
believed to cause inflammation, vasoconstriction and lesions around the areas of 
colonisation but the precise mode of action is not well understood.  In fibroblastic cell 
lines, DNT has been reported to inhibit both alkaline phosphatase activity and 
expression of type-I collagen and to also stimulate DNA and protein synthesis in the 
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absence of cell division, resulting in polynucleation (Matsuzawa et al. 2004).  Unlike 
other virulence factors, a deficiency of DNT in a mutant strain did not affect its 
virulence or pathogenicity compared to the parent wild type (Weiss and Goodwin 
1989). 
 
1.3.7. BrkA proteins (Bordetella resistance to killing) 
 
The brk locus was identified as a source of resistance following the characterisation of 
a Tn5-induced mutant that showed a dramatic increase in sensitivity to immune serum 
(Weiss et al. 1983). Subsequent cloning and sequencing of the locus revealed two 
open reading frames (Fernandez and Weiss 1998), the brkA ORF encoding a 103-kDa 
precursor that is processed at the C-terminal domain to yield the mature 30-kDa 
BrkA, a putative outer membrane protein, and BrkB which encodes a protein 
predicted to be a cytoplasmic membrane protein.  Both BrkA and BrkB proteins have 
been implicated in this property. 
 
The importance of BrkA to pathogenesis has been demonstrated by two 
investigations. Weiss & Goodwin (1989) found that a brkA-depleted mutant had 
significantly decreased virulence in mice compared to a wild type strain. It was later 
demonstrated that neutralising antibody to BrkA enhanced the bactericidal activity of 
B pertussis anti-serum (Oliver and Fernandez 2001). 
 
1.3.8. Tracheal cytotoxin  
 
Tracheal cytotoxin (TCT) is believed to be responsible for destruction of ciliated 
tracheal epithelial cells, an early and significant feature in the onset of whooping 
cough (Parton 1999). Although the precise mechanisms of epithelial damage have not 
yet been determined, the cytopathic effect of B pertussis infection has been mimicked 
in vitro by the addition of purified TCT to cultured tracheal epithelial cells (Cookson 
et al. 1989). Characterisation of TCT revealed that it is a soluble fragment of cell wall 
peptidoglycan (Rosenthal et al. 1987) composed of N-acetylglucosaminyl-1,6-
anhydro-N-acetylmuramyl-(L)-alanyl-γ-(D)-glutamyl-meso-diaminopimelyl-(D) 
alanine, a small 921Da disaccharide-tetrapeptide monomer (Cookson et al. 1989). Of 
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interest is the range of biological activities that these muramyl peptides exhibit in 
addition to cytotoxicity, such as adjuvanticity, pyrogenicity, arthritogenicity and 
modulation of cell-mediated immune responses (Adam and Lederer 1984). 
 
1.3.9. Tracheal colonization factor (TCF) 
 
This factor is encoded by the tcfA gene and is important in the pathogenesis of 
pertussis as demonstrated by the fact that infection of mice with B pertussis lacking 
this protein strains is decreased 10-fold as compared to the parent strain (Finn and 
Stevens 1995). Based upon the derived amino acid sequence, TCF is a 64kDa proline-
rich protein that contains the RGD motif shows 50% identity with the pertactin 
precursor. However, B pertussis culture supernatants reveal the 60 kDa form of the 
secreted protein. This protein is unique to B pertussis since it is not present in either B 
bronchiseptica and B parapertussis. 
 
1.3.10. Lipopolysaccharide  
 
As with the endotoxin of other gram-negative bacteria, the lipopolysaccharide (LPS) 
of B pertussis is pyrogenic, mitogenic and toxic to host cells (Watanabe et al. 1990). 
B pertussis LPS is composed of a lipid A portion linked to a branched oligosaccharide 
core and a trisaccharide and is structurally unique from other Bordetella spp. in that it 
lacks a repetitive O antigen (Peppler 1984). Allen and Maskell (1996) identified the 
12-gene wlb locus that was required for the biosynthesis of the trisaccharide 
component.  Mutants with targeted disruptions to these wlb genes were shown to be 
defective in colonisation of the respiratory tract compared to a wild-type strain 
(Harvill et al. 2000). These mutants were also significantly more sensitive to 
antibody-mediated killing in vitro, which indicated that LPS, in particular the 
trisaccharide component, may provide the organism with an additional means (other 
than BrkA) for resistance to the classical complement pathway. LPS-specific IgA and 
IgM have also been detected in the serum of infected or convalescent children 
(Harvill, Cotter, and Miller 1999). 
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1.3.11. Type III secretion 
 
Twenty type 3 secretion protein homologues similar to those in B bronchiseptica, 
Yersinia and Pseudomonas in select physicochemical properties have been amplified 
from B pertussis but are not expressed (Kerr and Matthews 2000; Preston 2005). The 
potential role of the protein homologues in virulence is not known. 
 
1.4. History of whooping cough prophylaxis 
 
Whooping cough was responsible for widespread morbidity and mortality during the 
pre-immunisation era. In response to the high incidence and severity of the disease, a 
whole cell vaccine for whooping cough was developed, tested and combined the 
whole-cell pertussis vaccine with diphtheria and tetanus toxoids to generate the first 
DTwP combination vaccine (Baker and Katz 2004). Many different types of wP 
vaccine formulations containing varying numbers of microorganisms, killed using 
different methods and delivered in 2 or 3 doses, have been evaluated with different 
efficacies claimed or analysed to range from 14-59% with 2 doses to 55-85% for 3 
dose vaccination regime in cohort studies (Storsaeter et al. 1998; Fine and Clarkson 
1987). In another analysis, absolute efficacy of the whole cell pertussis vaccine was 
found to vary from 37-92% with the efficacy of the 1 and 2-component acellular 
pertussis vaccine at 67-70% versus 80-84% for ≥3- component vaccines (Jefferson, 
Rudin, and DiPietrantonj 2003). To overcome this variability, a standard dose of 4.0 
International Units (IU)/standard human dose (SHD) based on potency determined 
using the Kendrick test has been suggested (World Health Organization 2007). 
 
Although the incidence of pertussis disease quickly diminished following introduction 
of the DTwP vaccine, a gradual reduction in wP vaccine compliance and coverage 
due to the perceived risk of severe side effects resulted in the subsequent re-
emergence of whooping cough (Frits R. Mooi 2001; Andrews, Herceg, and Roberts 
1997; He and Mertsola 2008). Observed side effects, attributed to the wP component 
of the DTwP vaccine included fever, prolonged crying, irritability, rare neurologic 
side effects (Donnelly et al. 2001) most likely associated febrile seizures particularly 
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if the body temperature is not kept under surveillance, hypotonic-hypo-responsive 
episodes and local reactions at the site of injection (Mills 2001; Poland 1996; Rowe et 
al. 2005). LPS has been implicated, albeit without any definitive evidence, as a 
possible cause of the wP-mediated reactogenicity (Rowe et al. 2005). 
 
In response to public uncertainty surrounding the wP vaccine, research was focussed 
on the development of an alternative and safer prophylactic. Various aP vaccine, 
which consisted of a combination of the immunogenic antigens filamentous 
hemagglutinin, pertussis toxoid, pertactin with or incorporation of fimbrial antigens 
have been evaluated in mice and humans. Favourable results from various human 
clinical trials led to the acceptance of the aP vaccine, which is delivered in 
combination with the established tetanus and diphtheria toxoids, to produce the 
contemporary triple antigen vaccine, referred to as DTaP. The currently marketed 
vaccines may also contain additional vaccine candidates including hepatitis B, 
Haemophilus inflenzae type B and inactivated poliovirus. 
 
Since the introduction of DTaP, numerous studies have evaluated and compared the 
efficacy and safety of the acellular versus the whole cell vaccine. The consensus was 
that aP vaccines conferred a level of protective immunity comparable to that of wP 
vaccines but with a decrease in the incidence and severity of adverse side reactions 
(Fine and Clarkson 1987; Novotny et al. 1991; Keitel 1999; Gustafsson et al. 1996). 
As with many other vaccines, local side reactions were observed in infants following 
multiple booster doses of the aP vaccine, with reportable adverse events following 
immunization over a period of 7 years (2000-2006) ranging from 3.8 per 100,000 
population (Lawrence et al. 2007). These side effects were reported elsewhere to be 
due to reactivation of Th2-associated local reactions (Rowe et al. 2005; Decker et al. 
1995) in which study large local reactions [≥ 50-mm diameter] were recorded, 24-72 
hours after delivery of the DTap booster, in 43% of exclusively DTaP-primed 
children, in contrast to 6% of those primed with DTwP. There are currently no 
published data on the incidence of local or systemic reactions in adolescents or adults 
boosted with dTap (see below). All these studies indicate that side effects do occur 
but the benefits of vaccination outweigh the risks recorded. It is thus clear research 
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aimed at developing an entirely side reaction free pertussis vaccine must be carried 
out. 
However, it has been reported that B pertussis is capable of infecting individuals 
previously vaccinated with either the wP or aP. Storsaeter et al. (1998) reported that 
33% of individuals that received the licensed five-component acellular vaccine had 
evidence of post-immunisation infection following exposure to B pertussis. In the 
same study, 82% of individuals immunised with wP were protected. One potential 
reason for the observed variance may be the composition particularly of the acellular 
pertussis vaccines containing different and/or variable quantities of the potential 
protective antigens. Different vaccines evaluated have ranged from one protective 
antigen viz., chemically inactivated pertussis toxin (PTXoid) to 2 (PTXoid + FHA), 3 
(Chemically or genetically inactivated PTXoid + FHA + PRN) or 4-5 potential 
protective antigens (PTXoid + FHA + PRN + Fim 2 and/or Fim3), which information 
is available in a communication reported elsewhere (Edwards et al. 1995). Reviews 
describing the concentrations of the different potential protective antigens in different 
vaccines in the marketplace, suboptimal vaccines and potential reasons for waning 
immunity was published recently (Edwards et al. 1995; Berbers, de Greeff, and Mooi 
2009). 
 
Although the duration of immunity imparted by both the wP or aP has been claimed 
not appear to differ markedly (Wendelboe et al. 2005; Guiso et al. 2007), of particular 
concern has been the recent upward trend in the global incidence of pertussis with a 
six-fold increase in reported cases over the last two decades (He and Mertsola 2008; 
Cherry et al. 2005; Tan, Trindade, and Skowronski 2005). The fact that young adults 
(vaccinated during their childhood) with none or waning immunity against whooping 
cough may serve as a reservoir for the pathogen and pass it on to their children (He 
and Mertsola 2008), has stimulated interest in the development of an alternative 
vaccine which can also be used safely in the adolescent and adult populations. To 
overcome this problem, acellular pertussis vaccine formulations with reduced antigen 
content, which was recently reported to induce cellular immunity in adolescents and 
adults (Meyer 2007), for use in adolescents have been introduced. Although the 
effectiveness of this vaccine [dTap] in reducing the transmission of pertussis to 
children is not known, in a clinical trial the vaccine efficacy of the DTwP for 
transmission of infection to children vaccinated with three doses of the whole cell 
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vaccine was 85% in comparison with 6%, for the DTaP vaccine indicating the 
ineffectiveness of the latter (Preziosi and Halloran 2003). Evaluation of the 
“cocooning” strategy (Berbers, de Greeff, and Mooi 2009; McIntyre and Wood 2009) 
in which parents and carers of the newborns are recommended to receive dTap 
vaccine around the time of the birth may help clarify the effectiveness of this 
approach in reducing pertussis transmission to vulnerable infants. 
 
1.5. Potential mechanisms underpinning Immunity to 
 infection with B pertussis 
 
1.5.1. Importance of antibody-mediated immunity against B pertussis  
 
Most investigations on the potential mechanisms of protection against infection with 
B pertussis have been carried out using mouse as model system. Both wP and aP 
vaccines confer protection against virulent B pertussis following immunisation 
(Gustafsson et al. 1996; Cherry et al. 1998). In some clinical trials with DTaP, a direct 
correlation between a serological antibody response and protective immunity could 
not be verified (Cherry et al. 1998), whereas in the mouse model the importance of a 
humoral immune response against pertussis was clearly evident (Sato and Sato 1984). 
Nevertheless, it is now accepted, and as will become evident from the description in 
the text below, that wP and aP vaccines elicit different clinical manifestations in 
humans versus animal models although the immune responses are similar. 
 
Although great emphasis has been placed on the induction of a potent antibody 
response by traditional pertussis vaccines, there have been contradictory views on the 
contribution of humoral response to protection against B pertussis. Passive or active 
immunisation experiments, described below, in immunocompetent versus transgenic 
mice have clearly demonstrated an important role for specific antibodies against 
pertussis. 
 
Transient protection was conferred against an aerosol or intracerebral challenge of 
mice by administration of monoclonal antibodies directed against the either the S1 
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subunit of pertussis toxin (Sato and Sato 1984) or pertactin (Shahin et al. 1990), with 
anti-FHA being the least potent (Sato and Sato 1984; Bruss and Siber 1999). 
Granstrom et al. (1991) reported a significant reduction of whoops in infected patients 
that received a hyperimmune serum preparation raised against a two component 
acellular vaccine compared to a placebo if the antibodies were administered within 7 
days of exposure. 
 
Aside from transient protection imparted by passive immunization with monoclonal 
or polyclonal antibodies, research involving transgenic mice models revealed that 
unlike wild-type mice, B cell and antibody deficient (Ig-/-) mice developed a chronic 
infection and failed to clear bacteria from the lungs after experimental infection (Mills 
et al. 1998; Mahon et al. 1997). Furthermore, immunisation of Ig-/- mice with either 
whole-cell or acellular pertussis vaccines failed to confer protection against an 
experimental challenge but protection was restored following the transfer of primed B 
cells. These observations were supported by another study (Leef et al. 2000) in which 
intranasal immunisation of Ig-/- mice with formalin-fixed B pertussis (FFBP) was 
reported to provide partial protection against an aerosol challenge compared to 
complete protection in FFBP-immunised wild-type mice. Once again full protection 
was restored following transfer of immune B cells. 
 
The effectiveness of the acellular vaccine provides a strong indication of the 
importance of humoral immunity. Parenteral immunisation of mice with DTaP was 
reported to induce a Th2-biased response characterised by high titers of antibody with 
little or no induction of a cell-mediated response (Redhead et al. 1993; Barnard et al. 
1996). Furthermore, the Th2-biased response following DTaP immunisation was 
demonstrated to be clinically efficacious in humans (Gustafsson et al. 1996; Olin 
1997). Nevertheless, a theoretical shortcoming of Th2-polarised immune response 
would be the inability to clear intracellular pathogens as is the case with non-
opsonised B pertussis phagocytosed by human macrophages in vitro (Friedman et al. 
1992) or in vivo (Hellwig et al. 1999) and neutrophils (Lamberti et al. 2008). In the 
absence of a memory Th1 response, an infection would have the potential to become 
persistent despite the absence of acute symptoms in humans or an apparent clearance 
of bacteria from the respiratory tract of animals. This has been supported by an 
observation that the co-administration of IL-12 with an acellular vaccine, which 
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induced a shift in bias from a Th2 to Th1 response, enhanced the rate of clearance 
following a bacterial challenge (Mahon et al. 1996). However, given the demonstrated 
absolute need for antibody in successful clearance (Leef et al. 2000) and the discovery 
that B pertussis can also survive and persist within macrophages and neutrophils 
(Friedman et al. 1992; Hellwig et al. 1999) suggests that both antibody and cell-
mediated immune response may be central to long term immunity, as the latter is 
associated with CMI rather than humoral responses (Mahon et al. 1996; Mills et al. 
1993). 
 
1.5.2. Importance of CMI against B pertussis 
	  
The lack of correlation between protection and antibody levels observed following 
clinical trials of a two-component acellular pertussis vaccine suggested a lack of 
insight into the true nature of immunity to B pertussis (Cherry et al. 1998). Since then 
many investigations have been carried out using naive and transgenic mouse models 
to demonstrate the importance of CMI against infection with B pertussis. Redhead et 
al. (1993) observed variable T cell proliferative responses in mice following 
convalescent infection or immunisation with whole-cell or acellular vaccines. High 
levels of IFN-γ and IL-2 but no or low IL-4 or IL-5 were produced from the 
splenocytes of convalescent mice. The low or undetectable antibody response that 
accompanied these cytokines indicated a CD4+ Th1 response (Feunou, Bertout, and 
Locht). Conversely, after two doses of an acellular vaccine, a CD4+ Th2 response 
characterised by elevated IL-5 secretion from splenocytes and high titers of anti-B 
pertussis IgG was observed. Immunisation of mice with the whole cell vaccine (wP) 
induced a dichotomous response with evidence of both IFN-γ/IL-2 secretion and 
serum antibody, and importantly the clearance of bacteria, following an aerosol 
challenge, was enhanced by the Th1 type response. The demonstration that non-
immune wild-type mice developed a prolonged infection that cleared after roughly 35 
days, whilst athymic or T-cell deficient mice failed to clear bacteria from the lungs, 
following aerosol challenge also supports this observation (Mills et al. 1993). Transfer 
of primed T cells to either athymic or irradiated naïve mice restored the capacity for 
clearance; however transfer of serum from convalescent mice could not restore the 
ability to completely eradicate pathogens from the respiratory tract. Finally, the 
observation of an uncharacteristic disseminated infection in IFN-γR-/- mice 
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accompanied with a high mortality rate, in contrast to wild-type mice that contained 
the infection to the respiratory tract with no deaths indicates the importance of CMI in 
protection against pertussis (Mahon et al. 1997). On the other hand, analysis of human 
samples from Phase 3 clinical trials were used to demonstrate that natural infection or 
vaccination with the wP vaccine elicited a predominantly Th1-type cell-mediated 
response, whereas aP vaccines typically induced a strong humoral response with a 
Th2-polarised cytokine pattern in infants and children at 4-6 years of age (Ryan et al. 
1998; Esposito et al. 2001). However, studies claiming the induction and/or 
maintenance of CMI after vaccination with Pa vaccines pre- and post-booster to be at 
least as good as that induced by the Pw vaccines have also been reported (Cassone et 
al. 1997; Ausiello et al. 1998; Ausiello et al. 1999; Zepp et al. 1996). Although the 
subjects used in these studies reported no history of infection with B pertussis, the 
potential contribution of subclinical pertussis infections, silent boosters albeit masked 
or difficult to detect, to induce and/or maintain high levels of CMI should not be over 
ruled. 
 
1.6. Experimental vaccines 
 
While current acellular and whole cell pertussis vaccines have been found to 
apparently provide relatively short to medium term protection in neonatal and older 
children (Wendelboe et al. 2005; Wearing and Rohani 2009), it is also anticipated to 
do so in adults (Rieber et al. 2008). Regardless, there is a need to develop vaccines 
that will provide longer-term protection, at least as long as that estimated theoretically 
for recovery from natural infection estimated at 20 years (Wearing and Rohani 2009). 
Given the importance of CMI in protection against and possibly transmission of 
pertussis, there are a number of novel vaccines currently under development, which 
represent potential alternatives to Pw and Pa vaccines. These include DNA vaccines 
constructed using genes encoding genetically modified pertussis toxin, filamentous 
haemagglutinin and pertactin, live attenuated mutants and pertussis antigens 
encapsulated in biodegradable particles. Potential reasons for development of 
alternative whooping cough vaccines include: 
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1) Cost-ineffectiveness of the currently marketed acellular pertussis vaccines 
particularly in developing countries. 
 
2) Development of a vaccine that can be delivered by a non-invasive route such that it 
will be side reaction free and also generate both antibody as well as CMI responses 
for induction of potential long-term protection, and potentially increase in compliance 
with the recommended vaccination schedules e.g. live attenuated or biodegradable 
particulate vaccines for delivery by the intranasal route. 
 
3) Development of a vaccine that can be tailored to induce either antibody and/or 
CMI responses and not require availability of cold chain for storage e.g. DNA 
vaccines. 
 
1.6.1. DNA vaccines 
 
DNA vaccines may provide a means of generating complete and long-lasting 
immunity against B pertussis, because of their potential to generate both antibody and 
cell-mediated responses (Donnelly et al. 1997). Genetically-inactivated pertussis toxin 
pcDNA3.1-based DNA vaccine administered using a gene gun revealed induction of 
both antibody and CMI responses (Kamachi, Konda, and Arakawa 2003). Li et al. 
(2006) reported that a recombinant pertussis DNA vaccine expressing the pertussis 
toxin subunit 1 (PTS1), FHA gene and PRN in pVAX1 were reported to elicit both 
antibody and CMI responses in NIH strain of mice upon delivery by a parenteral 
route. This was in contrast to our studies (Fry et al. 2008) in which a genetically 
inactivated pertussis toxin pcDNA3.1-based DNA vaccine administered by the 
intramuscular route was found to generate a purely cell-mediated immune response. 
We have further found that boosting DNA vaccine-primed mice with pertussis toxoid 
yielded excellent antibody as well as cell-mediated immune responses (Fry 2006). 
Unfortunately, such a vaccination schedule may not cost-effective particularly in the 
developing world. It is imperative therefore to investigate effect of different DNA 
vaccine vectors, with or without co-encoded molecular adjuvants such a cytokines 
and different modes of delivery that will induce both arms of the immune response. 
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1.6.2. Biodegradable micro- and nano-particle vaccines  
 
The use of inert carriers such as liposomes and biodegradable particles for delivery of 
antigens is another potential vaccine development pathway (Guzman et al. 1993; 
Conway et al. 2001; Sharma et al. 2009). Both oral and parenteral delivery of purified 
pertussis toxoid and filamentous hemagglutinin encapsulated in poly-lactide-co-
glycolide (PLG) polymers were demonstrated to protect mice from an aerosol-
induced B pertussis infection (Guzman et al. 1993). However, several factors were 
found have a critical effect on the immunogenicity of the biodegradable formulations, 
specifically the size of the particles used and the route of delivery. Conway et al. 
(2001) evaluated the immunogenicity and protective efficacy of systemically and 
orally delivered pertussis antigens (pertussis toxoid and filamentous haemagglutinin) 
entrapped in either microparticle PLG or nanoparticle PLG formulations using a 
murine respiratory challenge model for infection with B pertussis and reported a high 
level of protection against an aerosol challenge. Furthermore protection could be 
generated with a single parenteral immunization with a combined microparticle and 
nanoparticle formulation, dependent upon the route of immunization and the size of 
the particles, which affected the type of T cell response induced. However, 
nanoparticle formulations were found to favor the induction of Th2 immunity. 
Regardless, this approach warrants further investigations (Sharma et al. 2009). 
 
1.6.3. Live attenuated vaccines  
 
Roberts et al. (1990) developed an auxotrophic B pertussis mutant by insertion of a 
kanamycin resistance cassette into the aroA gene.  Mice immunised with the aroA 
mutant via inhalation of aerosols induced an IgM, IgA and IgG response that 
conferred protection against a subsequent aerosol challenge with the virulent parental 
strain. However, the mutant strain survived in reasonable numbers in the host for 
essentially only 4 days [detectable at day 8 in low numbers]. However, the potential 
induced CMI responses were not investigated. On the other hand, aroA mutants of 
Salmonella species were reported to be protective (Hoiseth and Stocker 1981) and 
induced both antibodies as well as CMI (Hoiseth and Stocker 1981; Mukkur et al. 
1987). In contrast, the aroA mutants of Shigella species were found to be less 
effective vaccines than the aroD deletion mutants of the same species (Verma and 
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Lindberg 1991) suggesting that the level of attenuation of a given gene may depend 
upon the bacterial species under investigation thereby suggesting variation between 
bacterial species. 
 
B pertussis in which the PT gene was deleted reported to be attenuated due to its 
inability to cause severe infection in mice without affecting the ability of the bacteria 
to colonize the respiratory tract and protect mice against challenge with the wild type 
(Mielcarek et al. 1998). More recently, a live attenuated B pertussis mutant strain 
(BPZE1) in which PT was genetically detoxified PT, DNT gene deleted and B 
pertussis ampG replaced by E coli ampG to minimize its activity, was reported to 
induce protection in young mice after a single nasal administration (Mielcarek, 
Debrie, Raze, Bertout, et al. 2006) and reported to be safe in adult interferon-γ 
receptor deficient adult mice (Skerry et al. 2009). However, this strain survived in 
lungs as long as the wild type strain leaving the door open to possibility reversion of 
back to virulence because no essential gene had been deleted. Dr Mukkur’s laboratory 
while at the University of South Queensland, developed a metabolite deficient 
aroQBP, non-reverting deletion mutant of B pertussis as a live attenuated vaccine 
candidate.  When delivered by the intranasal route, this strain has been found to be 
safe in mice and survive long enough (about 2/5th as long as the wild type parent 
strain) to induce a significant IgA and IgG responses in both the serum and 
respiratory secretions (Cornford 2003). The mutant also induces a systemic cell-
mediated immune response as indicated by the production of IFN-γ and IL-12. Mice 
immunised with this mutant vaccine were protected against challenge with sub-lethal 
or lethal dose infections. The major potential advantage of using metabolite deficient 
mutants is their inability to revert to virulence in vertebrates because of the lack of 
availability of essential metabolites required by the pathogen for replication in the 
host (Hoiseth and Stocker 1981). 
 
The main advantage of live attenuated vaccines is that they offer a non-invasive 
means of vaccinating infants and children, which closely resembles the natural 
infectious disease process with potential to provide long-lasting immunity (Locht et 
al. 2004). However, the concerns with this mode of vaccination include the risk of 
reversion to virulence, the presence of multiple toxins, and antibiotic resistance 
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markers used in genetic modification, particularly if the selection markers used in 
genetic manipulation processes represent the class of antimicrobials to which B 
pertussis is susceptible. 
 
1.6.4. Adjuvants  
 
The only approved adjuvants for use with human vaccines in infants are alum-based 
(aluminium hydroxide or aluminium phosphate), which promote induction of 
excellent antibody responses.  However, many studies carried out with other killed 
bacterial vaccines in animal models show that alum-based adjuvants can induce CMI 
responses, the latter being important for protection against infection with most 
intracellular pathogens and also B pertussis. For example, mice and sheep immunised 
with killed S typhimurium neither elicited any CMI response or were protected against 
oral challenge infection whereas those vaccinated with live aroA S typhimurium 
stimulated CMI response and were protected against oral challenge infection with the 
parent strain (Mukkur et al. 1987). Thus the lack of induction of CMI by vaccines 
absorbed on alum-based adjuvants, which has been known for sometime now, was not 
a surprise (Gupta 1998). Therefore, the basis of the reported CMI induction in 
children vaccinated with aP warrants further investigations. Although the mechanism 
of action of the alum-based is still largely unknown, activation of antigen-presenting 
cells by an IL-4-dependent mechanism is one possibility (Ulanova et al. 2001).  
However, the mechanism of induction of both Th2- as well as Th1-polarised immune 
responses following vaccination of children with the alum-based adjuvanted acellular 
pertussis vaccine warrants further investigations. In some other countries including 
Europe, other adjuvants have been approved for use vaccines for adults, for example, 
M59, a squalene-based adjuvant, and more recently ASO3, an oil-in-water emulsion, 
and combination adjuvant comprised of monophosphoryl lipid A (MPL) and 
aluminium hydroxide, named ASO4 for use with hepatitis B (Fendrix) and human 
papillomavirus (HPV) vaccine (Cervarix) (Tritto, Mosca, and De Gregorio 2009). 
Clearly, high priority research is warranted to identify an acceptable nontoxic 
adjuvant that enhances both arms of the immune response. 
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Chapter 2: Materials and methods 
	  
2.1. Bacterial strains, growth conditions and storage 
	  
2.1.1. Bacterial strains 
	  
Complete list of bacterial strains that were used in this study are listed in Table 2.1.1. 
 
Table 2.1.1. Bacterial strains list used in this study. 
 
Strains Genotype/Phenotype Source or Reference 
Bordetella pertussis 
aroQ (aroQBP) 
Vaccine candidate:  
aroQBP -, cannot survive 
in vertebrate, Kmr, Smr 
 
In house; developed in 
Assoc. Prof. Trilochan 
Mukkur’s lab, University 
of Southern Queensland 
E coli XL10-Gold Tetr Δ(mcrA) 183 Δ 
(mcrCB-hsdSMR-mrr) 173 
endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac The 
 
Stratagene 
E coli DH5α Cloning host, F- 
φ80lacZΔM15 Δ(lacZYA-
argF) U169 recA1 endA1 
hsdR17 (rk-, mk+) phoA 
supE44 λ- thi-1 gyrA96 
relA1 
 
Professor Grant Daggard, 
University of South 
Queensland  





Naresh Verma, Australian 
National University 
E coli JM109 Cloning host, endA1, 
recA1, gyrA96, thi, 
hsdR17 (rk-, mk+), relA1, 
supE44, Δ(lac-proAB), 
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2.1.1.1.  Bordetella pertussis aroQ 
 
The aroQBP strain is derivative of Tohama I. The aroQBP strain was generated in Dr 
Mukkur’s laboratory, University of South Queensland (Australian Patent Number AU 
2002357406 B2). The aroQBP strain was produced by deletion of the aroQ gene the 
common aromatic biosynthesis pathway such that aromatic amino acids including 
phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Try) and aromatic compounds 
including para-aminobenzoic acid (PABA), dihydroxybenzoic acid (DHB), and para-
hydroxybenzoic acid (PHB) and orthosuccinylbenzoate (OSB) are not synthesised. 
The aroQBP metabolite-deficient strain was found to be avirulent and survived in the 
mouse lung from ten to twelve days. In comparison, the virulent parent strain survived 
more than thirty days post-infection in mice infected by the intranasal route 
(Mielcarek et al. 2010; Mielcarek, Debrie, Raze, Bertout, et al. 2006). 
 
2.1.1.2. Escherichia coli strains 
 
E coli XL10-Gold strain: The XL10-Gold is an E coli strain that was provided as 
component of Quick-Change XL Site-Directed Mutagenesis Kit (Stratagene). E coli 
strain XL10-Gold is derived from E coli K12 strain XL1-Blue (Stratagene) and has 
been engineered to repair nicked plasmid DNA efficiently. 
 
E coli DH5α strain: The DH5α strain is a broad host E coli cells and suitable for gene 
bank or the generation of cDNA libraries using plasmid vectors such as pUC19 
(invitrogen). DH5α cells contain φ80lacZΔM15 markers that complement the β-
galactosidase gene from pUC19 or similar vectors. When the cells transformed with a 
vector the transformed cells can be screened based on blue/white colonies on LA 
plates containing X-gal. According to invitrogen, efficiency of competent DH5α 
cells are > 1.0 x109 transformants/µg pUC19 with non-saturating amounts (50pg) of 
DNA. Saturating amounts of pUC19 (25ng) generates > 1.0 x 106 ampicillin 
resistance colonies in a 100µl reaction (invitrogen). This stain was generously 
donated by Professor Grant Daggard, University of Southern Queensland, 
Toowoomba, Queensland. 
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 E coli SM10 λ pir: SM10 λ pir is derivative of E coli K12.  It is donor strain 
containing the transfer genes of the broad host range genes IncP-type plasmid RP4 
integrated in its genome (Simon 1983). This strain was generously donated by Dr 
Naresh Verma, Australian National University, Canberra, ACT. 
 
E coli JM109 strain: JM109 is an E coli strain which made competent for 
transformation with transformation efficiency of 1x 108 Colony Forming Units (CFU) 
(Promega). JM109 was provided as component of the pGEM-T Easy Vector System 
(Promega). 
 
2.1.2. Media and growth conditions 
 
Handling and manipulation of B pertussis strains were carried out under sterilized 
condition in a Biohazard Class II Cabinet. The identity of the E coli strains was 
confirmed by Gram Staining and use of API20E (BioMerieux). Identification of 
aroQBP confirmed using oxidase test (positive) and amplification of IS-481 with 
PCR (Light Cycler 2.0, 48011 PCR Thermocycler). 
 
The aroQBP strain was routinely grown on modified Cohen-Wheeler (CW) agar 
(Cohen and Wheeler 1946), Bordet-Gengou (BG) agar (Oxoid), supplemented with 
15% (v/v) defibrinated horse blood and following aromatic amino acids (aromix) and 
kanamycin (Km):  Phe 40µg/ml, Try 40µg/ml, Tyr 40µg/ml, PHB 10µg/ml, DHB 
10µg/ml, PABA 10µg/ml and Km 50µg/ml. The inoculated plates were placed in 
sealable plastic bag containing autoclaved moist tissues and incubated at 370C for 
four to five days; the growth was used for subsequent study. 
 
For conjugation experiments, the aroQBP strain was grown in Cyclodextrin Liquid 
medium (CLM) (Imaizumi et al. 1983) (see Appendix A, page 152) and Stainer 
Scholte medium (SS) broth (Stainer and Scholte 1971) (see Appendix A, page 152) 
supplemented with the aromix and Km for conjugation. The inoculated plates were 
placed in sealable plastic bag containing autoclaved moist tissues and incubated at 
370Cfor four to five days. Broth was incubated at 370C on orbital shaker (BOECO-
PSU-10i) at 225rpm for two to five days. The growth was used for subsequent study. 
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CW and BG agar supplemented with the aromix, Km, and with or without 
streptomycin (Sm) 200µg/ml, ampicillin (Amp, only for use with the pSS1129 
plasmid) 100µg/ml and gentamicin 10µg/ml for propagation of the pSS1120 and 
pJQ200 mp-18 plasmids (Bordetella suicide vector) and for conjugation experiments 
carried out using nitrocellulose membrane. 
 
Cohen-Wheeler supplemented with the aromix, Km, and cephalexin (Ceph) 40µg/ml 
was used to culture pulmonary homogenates for detection of aroQBP growth. 
Cephalexin was used to prevent overgrowth of normal respiratory microflora. Plates 
were incubated as above. 
 
E coli SM10 λ pir was cultured on Lura Britani (LB) agar or LB broth supplemented 
with 50µg/ml Km. E coli DH5α was cultured on plain LB agar and LB broth.  E coli 
strain-harbouring vector(s) were cultured in LB agar/broth with relevant antibiotic(s) 
(Table 2.11.2) incubated at 370C for 16-18 hours and the growth was used for 
subsequent studies. Inoculated LB broth was incubated at 370C on orbital shaker 
(Ratek) at 225rpm for 16-18 hours and growth was used for subsequent studies. 
 
2.1.3. Preparation and maintenance of bacterial stocks 
	  
For the preparation of aroQBP strain stock, the mutant microorganisms were grown 
on CW or BG supplemented with defibrinated horse blood, aromix, and Km, grown 
as described in section 2.1.2. Growth from about one and a half plates picked up with 
sterile disposable 50µl loop (BD) and suspended into CryoCare™ Bacterial preservers 
tube with beads (Blackaby Diagnostics, Perth, Australia) according to manufacturer’s 
recommendation (Key Scientific Products, USA). The prepared stock tubes were 
stored at -800C. For E coli-vector harbouring strains (Table 2.1.1) stocks, the 
microorganisms were grown on LB agar-Amp or LB agar-Amp/Gm and stocks made 
and stored at -800C as described above. 
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2.2. Establishment of a growth curve for aroQBP 
	  
Suspension of aroQBP was made in about 5ml 1% autoclaved phosphate buffer saline 
(PBS) from three CW-aromix-(Km 50µg/ml) plates. The plates were incubated for 
five days as described (Section 2.1.2). The optical density (OD) of the suspension 
adjusted to 1.303 at 600nm (Shimadzu spectrophotometer UV-120-02).  Serial two-
fold dilutions were made, their ODs taken as above (Table 2.2). Colony forming units 
of individual dilutions determined by making further decimal 10-fold dilutions and 
plating on CW-aromix-(Km 50µg/ml) according to Miles and Mishra (1938). The 
plates were incubated for five days as described in Section 2.1.2. 
 
 
Table 2.2. The OD600nm of undiluted and double dilutions of aroQBP used for 
growth curve establishment. 
 










2.3. Pertussis animal model 
	  
Mice were used as a pertussis animal model (Elahi, Holmstrom, and Gerdts 2007) 
assuminging the fact mice do not cough following infection by the intranasal route 
either as drops or by aerosolisation (Canthaboo, Xing, et al. 2000). All experiments 
involving the use of animals were carried out after approval from the Curtin 
University’s Animal Ethics Committee (AEC) and Institutional Biosafety Committee 
(IBC). 
 
 Female specified pathogen free Balb/c mice aged 6-8 weeks were purchased from the 
Animal Resource Centre, Perth, Australia, and housed in 5mice/cage in the ventilated 
cabinet in Animal House Facility. 
 
 All the mice used in this study were six week-old Balb/c female. Weight of mice 






















O.D. at 600nm 
Growth curve of B pertussis aroQBP strain 
Figure 2.2. Growth profile of aroQBP. The diagram drawn is based on CFU of aroQBP 
serial dilution. 
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experiment mice were checked daily for wellness and stress signs such as puffy fur, 
isolation from group or moribund state. 
 
2.4. Immunological investigation 
	  
Reagents used for immunological investigations and their preparation is described 
below. 
2.4.1. Inactivation of aroQBP 
	  
Inactivation of aroQBP was carried out using 1% formaldehyde follows: Briefly, 
growth of bacteria was picked up from three CW-aromix/Km plates and suspended in 
8.8ml PBS. To the suspension 0.237ml of 37% formalin was added and incubated at 
370C for six hours. Then the cells were pelleted by centrifugation at 8,000rpm 
(7741xg) (BECKMAN Coulter, Avanti® J-E) for twenty minutes. The pellet was 
washed three times with PBS.  Washed pellet was resuspended in PBS at 1x109 CFU 
per ml using an established standard curve for use in the ELISA assay. A CW-aromix 
plate was inoculated with 500µl of the suspension and incubated at 370C for five days 
to check for sterility of the culture. The rest of the bacterial suspension was stored at 
40C. 
 
2.4.2. DTaP  
	  
Infanrix (GlaxoSmithKline) Combined Diphtheria, Tetanus, Acellular pertussis and 
Poliovirus vaccine used in the study. Product code N8343.  www.gsk.com.au/infanrix, 
lot/expiry date: AC20B093DA/ 01-2010. 
 
One dose (0.5ml) of vaccine contained: Diphtheria toxoid (Corynebacterium 
diphtheriae) ≥ 30lU, Tetanus toxoid (Clostridium tetani) ≥ 40lU, PTxoid 25 
microgram, FHA 25 microgram, PRN (Bordetella pertussis) 8 microgram, Poliovirus 
type 1 (Mahoney) 40 DAgU, Poliovirus type 2 (MEF-1) 8 DAgU, poliovirus type 3 
(Saukett) 32 DAgU, Aluminium hydroxide equivalent to 500 micrograms of 
aluminium (as adjuvant), Phenoxyethanol 2.5mg as preservative, sodium chloride 
4.5mg, Medium 199 (M199) 1.15mg including Amino acids 90 microgram, 
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Polysorbate 80 ≤  100 micrograms, Formaldehyde ≤ 10micrograms, Glycine ≤ 200 
micrograms, Potassium chloride ≤ 40micrograms, Sodium phosphate diabasic 
dihydrate ≤ 100 micrograms, Potassium phosphate monobasic ≤ 20 micrograms, 
Neomycin sulfate ≤ 0.05 nanograms, Polymyxin B sulfate ≤ 0.01 nanograms and 




A total of 63 mice were used in this study. Fifteen of these mice were used to produce 
hyperimmune sera (see Section 2.4.4 for description). The remaining 48 mice were 
divided into four groups of 10 mice each (A to D; 10 mice/Group) and a fifth group 
(Group E) comprising 8 mice. Group E mice were used as a sentinel group and were 
left untreated. Three of the eight mice were subjected to euthanasia at the start of the 
experiment whereas the remaining five mice were euthanased at the end of the 
experiment on day 42. To ensure their lack of exposure to the aroBP vaccine 
candidate that was used in different vaccination regimes in different groups (see 
Table. 2.4.5). 
 
Five mice in Groups A to D were used for vaccination whereas the remaining five 
mice in each group were sham-vaccinated with PBS as controls. Vaccination mice 
with the DTaP vaccine involved injection with 1/5th of the standard human dose (0.1 
ml per mouse) by the subcutaneously (s.c.) route. On the other hand, 1 x 1010 CFU of 
aroQBP, determined from the growth curve, washed 3 times with PBS, in 1% (w/v) 
analytical grade casein (Difco) was delivered to mice (10µl/nostril) by intranasally 
(i.n.) route. The design of this experiment and the specific procedures used for 
vaccination of different groups of mice is shown in Table 2.4.5 (see Section 2.4.5). 
	  
2.4.4. Production of anti-DTaP hyperimmmune sera 
 
High titer antisera (referred to as hyperimmmune sera) against B pertussis antigens 
was produced in Balb/c mice for use as a standard in the ELISAs designed to measure 
antibody isotypes against different aroQBP antigens. Briefly, ten mice, housed in 
cages (5 mice per cage) were vaccinated with 100µl of the DTaP (1/5th of the SHD) 
on day 7 and 14 where as a 3rd group of 3 mice constituted the unvaccinated controls. 
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On the 23rd day (selected arbitrarily), one mouse from vaccinated group was blood 
sampled for collection of serum to determine the antibody titer with view to 
determining the need for additional vaccinations. A 3rd dose of DTaP was given to the 
remaining 9 mice in the vaccination group on day 28. On day 35, all mice were 
euthanased and blood samples collected to obtain hyperimmmune sera. The titer of 
the pooled hyperimmmune sera against whole inactivated BPWC was determined to 
ensure availability of high titer antisera for use as standard in ELISAs as mentioned 
above and also for normalisation of data to correct for plate-to-plate variation. The 
titer of pooled hyperimmune sera against BPWC was determined as described 
elsewhere (Chen et al., 2006). 
 
2.4.5. Immunization of mice with DTaP and/or aroQBP 
	  
In this experiment, mice were immunised with 1, 2 or 3 doses of 100µl of the DTaP 
(1/5th of the standard human dose) by the s.c. route with or without booster 
vaccination with 1 to 2 doses of live attenuated aroQBP vaccine candidate by i.n. 
route (20 µl [µl/nostril] of the stock 1 x 1010 CFU/ml). The experimental design used 
in this study is shown in Table 2.4.5. 
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Table 2.4.5. Experimental Design: Immunisation and Sampling Regime  
 
  GROUP ID 
Day post-
immunization 
























































  No 
treatment 
35 Sample No 
treatment 
  No 
treatment 
42  Sample   Sample 
5 mice 
 
On the sampling day, blood and lungs-trachea were collected as sources of serum 
and pulmonary secretions for determination of serum and mucosal antibody isotypes 
respectively. Spleens were collected for preparation of splenocytes, which were used 
for determination of IFN- γ levels, as an indicator of CMI induction, after stimulation 
with killed BPWC and FHA as a model pertussis antigen. Mice in Group E were left 
untreated and used as sentinel mice; 3 mice were sampled at day 0 while the 
remaining 5 mice were samples at day 42 (last day for sampling). 
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At the day zero, test mice of each group, A, B, C, were individually vaccinated s.c. 
with 100µl of DTaP. In the same manner, each individual of PBS subjects of 
respective group was given 100µl of PBS s.c. On same day, test subjects of group D 
were inoculated with 10µl of 1 x 1010 CFU of live aroQBP in 1% (w/v) of analytical 
grade casein (DIFCO) per nostril. The CFU were pre-determined based on the growth 
curve of aroQBP (Figure 2.2). The PBS group subjects were inoculated with 10µl of 
PBS per nostril. On day zero, blood, lungs-trachea, and spleen samples were collected 
from three of the eight sentinel mice (Group E). 
 
On day 7, five mice from groups A and B were injected with a second dose of DTaP 
s.c., with the remaining 5 mice in the group receiving sham-vaccination with PBS as 
at day zero. Likewise, mice of group D were given a second dose of the live aroQBP 
i.n. The remaining 5 mice in the group received PBS i.n. as at day zero. Mice in group 
C were left untreated on the day 7. 
 
On day 14, mice of groups of groups A and B were vaccinated with third dose of 
DTaP as the day zero. On day 14, mice in group C were sampled for blood, lung-
trachea, and spleen. 
 
On day 21, mice of groups A and B were inoculated i.n. with 1 x 1010 CFU of 
aroQBP (10 µl/nostril). On same day, blood, lung-trachea, and spleen sampling of 
mice in group D was carried out. 
 
On day 28, mice of group B were re-inoculated with 1 x 1010 CFU of aroQBP vaccine 
candidate (10 µl/nostril). On days 35 and 42, blood, lung-trachea, and spleen 
sampling was carried out for groups A and B, respectively. Likewise, on day 42, 
blood, lung-trachea, and spleen sampling was carried for remaining five sentinel mice 
(Group E). 
 
2.4.6. Anaesthetization and sampling 
	  
Mice were anaesthetized with mixture of ketamine 80mg/kg and xylazine 10mg/kg 
(Fry et al. 2008). One dose of anaesthetic cocktail contained: 0.8µl of ketamine, 0.5µl 
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of xylazine, and 0.7µl of PSB in total of 2µl per gram of mice weight. The anaesthetic 
cocktail was injected intraperitoneally using 26G needle. Anaesthetization of mice 
was confirmed by pinching the foot if no response (about five minutes) observed then 
sampling preceded. However, if any foot response observed after five minutes 
anaesthetisation was repeated with half of the original dose. Upon no foot response, 
the sampling proceeded as described in the following sections. Sampling was done 
under aseptic condition. 
 
2.4.6.1. Blood collection 
 
Mice were anaesthetised as described in section 2.4.6 for collection of blood samples, 
source of serum samples. About 700µl to 800µl blood was collected via incision of 
the subclavian artery of individual mice. Each individual blood sample was collected 
on 1.5ml eppendorf tubes and kept on ice for about one hour for a clot to form. The 
serum separated from red blood cells with 4,000rpm (1,520xg) (Hermle Z 233M) 
centrifugation for ten minutes. The serum samples were stored at -200C for 
subsequent tests. Following collection of blood mice were subjected to cervical 
dislocation to ensure death. 
 
2.4.6.2. Collection and homogenization of pulmonary (lung-trachea) samples 
	  
The pulmonary tissues collected were lungs and trachea. The weight of the tissue in 
combination ranged from 900-1200mg. The organs were homogenized with glass 
homogenizers in 1ml PBS and transferred to a 1.5ml eppendorf tube. Total of twelve 
CW-aromix/Km/Ceph plates inoculated with 20µl of homogenized pulmonary tissues 
of each mouse for all groups and incubated at 370C for five days to check for any 
growth of the aroQBP. To the rest of individual pulmonary tissues 50µl of protease 
inhibitor cocktail (Sigma-Aldrich) was added per ml of homogenized sample to 
prevent antibody degradation by protease. The samples were stored at -200C for 
subsequent tests. 
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2.4.6.3 Preparation of splenocytes 
 
All five spleens from each group were collected on 2ml of Dulbecco’s modified 
Eagle’s medium (CDMEM, Gibco) without foetal bovine serum (FBS). The spleens 
were pooled and mash in strainer (BD) with 10ml syringe piston and cells collected 
into 14ml falcon tube. Collected splenocytes were washed twice with 5ml CDMEM 
without FBS at 1000rmp (Beckman Coulter Avanti J-E) for ten minutes and 
resuspended in 12ml CDMEM with FBS. Viability of the splenocytes was tested 
using trypan blue as described elsewhere (Fry et al. 2008), and the cell concentration 
adjusted to 5 x 106 cells/ml for use in the antigen stimulation assays. 
 
2.5. Splenocyte stimulation with antigens 
	  
Eighteen wells of a twenty-four well tissue culture plate was seeded with 2ml per well 
of splenocyte suspension for each group in quadruplicate. Three antigens that were 
used to stimulate splenocytes, included FHA at 2µg/ml, PT at 2µg/ml, BPWC at 5 x 
106 cfu/ml. ConA a T-cell stimulant 2.5µg/ml was used as a positive control whereas 
PBS (control group) was used as negative control. The volume of the different 
stimulants or sham-stimulant added to wells in the plate given in Table 2.5. The plate 
covered with lose lid and was incubated at 370C with 5% CO2 for 72 hours. The plate 
was checked daily for cloudiness as indicator of contamination and any contaminated 
wells discarded. At 72 hours post-stimulation, the content of each well was removed 
and centrifuged at 4,000rpm (1935xg) (Beckman Coulter Avanti J-E) for ten 
minutes to remove any sediment. Supernatants were removed individually and stored 
at -200C for subsequent estimation of the levels of cytokine IFN-γ. 
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Table 2.5. Concentration of different antigens used for splenocyte stimulation. 
 
Stimulant Volume in ml Final concentration 
FHA 2ml 2µg/well 
PT 2ml 2µg/well 
BPWC 2ml 1x107 CFU/well 
ConA 2ml 2.5µg/well 
PBS 2ml NA 
Untreated 2ml NA 
NA: denotes “not applicable”. 
 
 
2.6.  ELISA assay for identification of antibody isotypes and 
subclasses 
	  
Indirect ELISA was used for detection of whole immunoglobulin (IgG) and IgA 
antibody isotypes. Likewise the assay was employed to detect IgG1 and IgG2a 
antibody subclasses in the sera and pulmonary tissues of all mice in the experimental 
groups. In total three antigens including inactivated BPWC, PT, and FHA were used 
to determine antibodies titers in sera and pulmonary tissues. 
2.6.1. Serial dilutions of serum and pulmonary tissues 
	  
Individual mouse samples from each group were diluted in 0.05% Tween-20 in PBS 
(PBST). Dilution for each serum sample in PBST ranged from 1/50 to 1/6400 
whereas the serial dilutions of homogenised pulmonary tissues ranged from 1/25 to 
1/3200, in duplicate, when inactivated BPWC used as antigen. The range of serial 
dilutions of sera for estimation of anti-PT and anti-FHA ranged from 1/50 to 1/800 
because of the shortage in the availability of serum samples. No anti-PT and ant-FHA 
titer could be determined in homogenised pulmonary tissues for the same reason; 
although, anti-whole cell antibody isotypes titers were determined. 
 
2.6.2. ELISA method for antibody detection and measurement 
	  
The ELISA was essentially carried out as described elsewhere (Fry et al. 2008). In 
general for each ELISA assays two wells per plate were used as positive controls 
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(100µl of 1/100 dilution of pooled hyperimmmune sera) and two well as negative 
controls (100µl of 1/10 dilution of pooled normal mouse sera). One column in the 
ELISA plate was not coated with the antigens (Antigen control). A column adjacent 
to the antigen control column of the plate, no primary antibody of mouse origin was 
added (Antibody control). 
 
Samples used to detect antibodies were antisera and pulmonary homogenates. Briefly, 
Three antigens were used as the coating antigen for the estimation of different 
antibody isotypes or subclass titers. The concentration of antigens used to coat the 
ELISA plates were as follows: 
 
1) Reconstituted 1µg/ml PT in coating buffer (0.1 mole sodium phosphate, pH 7.0, 
0.5 sodium chloride, stock buffer). 
 
2) Reconstituted 1µg/ml FHA in coating buffer (distilled water, stock). 
 
3) Inactivated BPWC 5 x 108 cfu/ml (OD600= 0.88) (predetermined from growth 
curve) in coating buffer. 
 
The antigens were 100µl of 1µg/ml PT or 1µg/ml FHA or inactivated BPWC 
(OD600=0.88) was added to appropriate wells of a 96-well microtiter plate (Maxisorp 
Nunc). The plate was sealed with sealing film and incubated at 40C for overnight at a 
moist chamber. The wells were washed manually with PBST 18-24 hours later using 
300µl of PBST dispensed into each well and left for one minute then PBST was 
disposed by inverting and blotting on paper towel. The washing was repeated for 
second and third time for two and three minutes, respectively. Hundred-fifty 
microliters of bicarbonate blocking buffer was added to each well of the plate and 
incubated at room temperature on orbital shaker (BOECO-PSU-10i) at 100rpm for 
one and a half hour. The plate was washed as above. The primary antibody (antisera 
and pulmonary tissues homogenate) was serially diluted (Section 2.6.1) in PBST 
(prepared at same day), and 50µl of each dilution was added to each well and 
incubated as above for one hour. The plate was washed as above. Hundred microliters 
of respective goat anti-mouse antibody isotype sera (anti-IgG or anti-IgG1 or anti-
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IgG2a conjugated to alkaline phosphatase) diluted 1 in 5000 PBST was added to each 
well and incubated as above for one hour. The plate washed as above and 100µl of 
substrate was added to each well (1mg/ml p-Nitrophenyl phosphate in substrate 
diluent) (Sigma). The plate was covered with aluminium foil and incubated at room 
temperature. The OD of plate was taken at 405/629nm at ten and twenty minutes time 
intervals using the Microplate Reader (Labsystem, Multiskan Ascent). 
 
2.6.3. Normalization of ELISA data 
	  
ELISA data was normalised for plate-to-plate variation when necessary, as described 
previously (Chen et al. 2006), with following modifications. In brief, dilutions of 
hyperimmune sera evaluated for anti-B pertussis titers using inactivated BPWC as the 
antigen. An average±SE was calculated and the ELISA data (OD405) adjusted to the 
average value calculated for the hyperimmune sera (Section 2.4.4). 
 
2.7. Estimation of antibody titers determined by ELISA 
	  
Antibody isotype (IgG, IgG1, IgG2a) titers for sera and pulmonary tissues were 
determined by linear regression of the data that constituted the linear part of the curve 
and extrapolation to the x-axis. A single point titration was used for estimation of the 
serum antibody titers of the IgA and pulmonary homogenate’s IgG1, IgG2a, and IgA.  
The end point titers determined as the reciprocal of the highest dilution multiplied by 
OD405nm. 
 
2.7.1. Anti -PT antibody titer 
	  
Mouse anti-PT IgG titers were determined as follows; a minimum of three dilution 
points which represented the linear segment of the antibody titration curve were 
extrapolated to the x-axis in the line graph (reciprocal of the dilution factors plotted) 
was taken as the antibody titer of individual mice (See Appendix K for line graphs 
used to calculate the ELISA titers, page 222). 
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2.7.2. Anti-FHA titer 
	  
Mouse anti-FHA IgG antibody titers were determined as described above for anti-PT 
IgG antibodies (See Appendix L for line graphs used to calculate the ELISA titers, 
page 237). 
 
2.8. Estimation of IFN-γ  levels in the antigen-stimulated 
splenocyte supernatants 
	  
IFNγ levels were estimated in the splenocyte supernatants using the murine IFNγ 
ELISA kit (abcam) according to the manufacturer’s instruction.  Each sample was 
analysed in quadruplicate by ELISA. The absorbances and concentration were read at 
405nm on microplate reader (Labsystem, Multiskan Ascent). The final concentration 
of the cytokine of each sample was determined as follows. A linear standard curve 
generated by plotting the average absorbance on the y-axis versus the corresponding 
ml IFNγ standard concentration the on x-axis. The concentration of IFNγ in each 
sample was determined by extrapolating OD values to ml IFNγ concentration from 
the standard curve (Figure 2.8) and the value multiplied by appropriate dilution factor. 
 
2.9. Statistical Analysis 
	  
Values for antibody isotype titers were compared using two-tailed unequal variance t-
test (using Microsoft® Excel® for Mac2011 version 14.4). Results were considered 
significant at p values ≤ 0.05. 
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Figure 2.8. Standard curve used to estimate IFN-γ concentration in splenocyte of 
mice vaccinated with different vaccines. Mice were immunised according to the 
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2.10.  Generation of Adenylate Cyclase (ACT) Mutant 
of aroQBP 
	  
2.10.1. Sub-Cloning of cyaA insert into Plasmid Vectors 
	  
Plasmid vectors used in the study for sub-cloning of cyaA and/or CyaMut insert are 
listed in Table 2.10.1. 
 
Table 2.10.1. Vectors used for Cya and/or CyaMut sub-cloning. 
 
Vector’s Name Size/Specification Source/Reference 
pUC19 2.686kb/Contains poly-
linker for different RE; 
Amp+ 
Professor Grant Daggard, 
University of South, 
Townsville, Queensland  
pGEM-T Easy Vector 3.015kb/ Contains poly-
linker for different RE; 
Amp+ 
Promega 
pJQ200mp 18-rpsL 4.799kb/Contains poly-
linker for different RE; 
Gm+, Stp+ 
Dr. Camile Locht, Pasteur 
institute, lille, France 
pSS1129 9.8kb/Specific for B 
pertussis transformation; 
suicidal; RE: BamHI, 
HindIII, EcoRI, SmaI, 
BstEII, SalI, PvUII; Stp+, 
Amp+, Gm+, 
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2.10.1.1. pUC19 
	  
The vector is small in size, 2.686kb (Appendix M, page 251), which allows for large 
DNA insert and replicates in a high number (>200 copy/cell) in E coli The vector 
contains parts of pBR322 and M13mp19 (Yanisch-Perron, Vieira, and Messing 1985; 
Lin-Chao, Chen, and Wong 1992). The vector contains multiple cloning sites (MCS). 
The MCS is in frame within the α-peptide coding region of the enzyme β-
galactosidase (lacZα), the enzyme breaks lactose into glucose and glactose. LacZα 
gene is a part of Lac operon. Inactivation of lacZα by insert within polyliker cloning 
site allows recovery of recombinant vector based on colour change (white) when 
cultured on LA/pGEM/X-gal plate (Promega). The vector also codes for an enzyme 
that binds and degrades ampicillin. Considering above, Cya sequence fragment cloned 
in pUC19 the cloned vector was multiplied in transformed E coli DH5α. The Cya 
sequence fragment was excised from pUC19 using BamHI and EcoRI and 
subsequently ligated into shuttle vectors, pJQ200mp 18-rspL and pSS1129, for details 
see section 2.16 and 2.17. 
 
2.10.1.2. pGEM-T Easy Vector 
	  
pGEM-T Easy Vector (Appendix N, page 252) is constructed specifically for the 
cloning of PCR products (Promega). The vector is constructed by digestion of 
pGEM-T Easy Vector with EcoRV and addition of a 3ʹ′ terminal thymidine (T) to of 
both ends.  Thymidine overhangs of the vector are compatible to deoxyadenine 
overhangs of PCR products generated by some thermostable polymerase (Promega). 
The 3ʹ′-T overhangs prevent recirculation of the vector during ligation reaction and 
improves ligation of PCR products into the pGEM-T Easy Vector (Promega). The 
multiple cloning site of the vector contains sequences on either side of the PCR 
products insert, which are site of restriction for NotI and EcoRI restriction enzymes. 
This allows the PCR products to be removed with a single restriction digest using 
either of these enzymes (Promega). 
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2.10.1.3. pJQ200mp18-rpsL 
	  
pJQ200mp18-rpsL (4799bp) (Appendix O, page 253) is a suicide vector and can be 
utilized in most of gram negative bacteria gene manipulation. As many other E coli 
plasmid’s (ColE plasmid family) derivative vectors; pJQ200mp 18-rspL only replicate 
in enterobacteria. The vector contains E coli rspL (Sm-sensitive [SmS]) and Gm-
resistance (GmR). The vector was developed to study role of iron in B pertussis 
virulence (Stibitz 1994; Pradel et al. 2000). 
 
2.10.1.4. Vector pSS1129 
	  
This Bordetella suicide vector/plasmid, pSS1129, (Appendix P, page 254) was 
generated by Scott Stibitz from pRTP1 (Stibitz 1994). This vector caries a 
gentamicin-resistance cassette insert. The vector was developed for delineating the 
role of the virulence determinants of B pertussis in whooping cough. This vector 
allows replacement of a bacterial gene with a genetically modified gene of interest in 
situ. The vector cannot replicate inside this bacterium because the vector belongs to 
ColE1 (colicin E1) family (Stibitz 1994). In this study this vector, pSS1129, was one 
of the two vectors used in attempts to genetically-detoxify the ACT (exotoxin). 
	  
2.11. Production of different plasmids in E coli strains 
	  
Processes used for production of different vectors in workable quantities for DNA 
manipulation are described in sections below. 
 
2.11.1. Generation of competent E coli strains 
	  
LB broth (10 ml) was inoculated with E coli DH5α stock and incubated overnight 
(16-18 hours) at 370C in shaker (Ratek) at 225rpm. This was used to inoculate 100ml 
of LB medium was inoculated with the 10ml E coli DH5α in LB broth and its 
OD600nm measured. After the OD taken the broth incubated at 370C on an orbital 
shaker (Ratek) at 225rpm and OD600nm measured until it reached 3.2. This broth was 
transferred into 2 x 50ml polyethylene tubes and incubated in ice for ten minutes. The 
broths were centrifuged at 4,000rpm (1935xg) (Beckman Coulter, Avanti® J-E) at 
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40C for 10 minutes and the supernatants discarded. Each of the pellets was suspended 
in 30ml ice-cold 80mM MgCl2-20mM CaCl2 solution followed by re-pelleting by 
centrifugation as above and discarding the supernatant. The pellets were resuspended 
in 2ml of ice-cold 0.1M CaCl2 per 50ml of original culture. The suspensions were 
mixed into one 4ml aliquot and 140µl of dimethyl sulphide oxide (DSMO) added. 
The suspension was mixed gently with fingertip and the tubes left on ice for fifteen 
minutes. An additional 140µl of DSMO was added to the mixture and mixed gently as 
above. The broth was aliquoted in 250µl lots into ice-cold 1.5ml microtubes and snap-
frozen on dry ice to which absolute ethanol had been added. The stocks were stored at 
-800C. 
 
2.11.2. Transformation of E. coli strains with plasmid 
	  
The transformation of E coli strains with plasmids was accomplished using the heat 
shock method described by Sambrook et al. (2001). 
 
In general transformation of E coli strains, namely; E coli DH5α and E coli SM10 λ 
pir with different vectors were carried out as follows. The specific antibiotic(s) used 
to supplement the to media used for cultivation of different transformed clones are 
shown in Table 2.11.2 
The stock of the E coli was transferred from -800C to ice and left on ice for about five 
minutes to thaw. Fifty microliter of stock E coli strain of interest was transferred to 
each of three labelled chilled 14ml polyethylene tube on ice. One microliter vector 
with insert (sample tube), 1µl of vector without insert (negative control), and 1µl of 
pUC19 (5ng/µl) (efficiency tube) were added to test, control and transformation 
efficiency tubes, respectively. The tubes were incubated on ice for 30 minutes. The 
samples transferred to water bath at 420C for 45 seconds and immediately were return 
on ice for 2 minutes. To each tube 450µl of SOC (for composition see Appendix A, 
page 152) broth was added and incubated at 370C on orbital shaker (Ratek) at 225rpm 
for an hour and half. The transformation efficiency tube was serially diluted on SOC 
broth as follows 1:10, 1:100 and 1:1000. Fifty microliter of undiluted and 50µl of 
each diluted broths were spread on LB agar plate supplemented with appropriate 
antibiotic(s) (Table 2.11.2), total of four plates were inoculated. The test and the 
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control broths was spread on four LB agar plates (3 plates per dilution) supplemented 
with appropriate antibiotic(s) (Table 2.11.2.) in volumes of 50, 100, 130 and 150µl 
and incubated at 370C for overnight. 
 
 
Table 2.11.2.  Concentration of different antibiotic(s) in LB media inoculated 
with E coli strains carrying various plasmid vector(s). 
 
Antibiotic Concentration of antibiotic 
in LB medium 
E. coli strain-vector 
combination 
Ampicillin (Amp) 100µg/ml DH5α-pUC19 
DH5α-pUC19Cya (This 
study) DH5α-pCyaMut 
(This study)  
Gentamicin (Gm) 10µg/ml DH5α-pJQ200mp 18-
rspLCyaMut (This study) 
Kanamycin (Km)  50µg/ml SM10 λ pir 
Km, Gm  50µg/ml, 10µg/ml SM10 λ pir- pJQ200mp 
18-rspLCyaMut (This 
study) 
Amp, Km 100µg/ml, 50µg/ml SM10 λ pir-
pUC19CyaMut (This 
study) 
Amp, Km, Gm 100µg/ml, 50µg/ml, 
10µg/ml 
SM10 λ pir-pSS1129Cya 
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2.12. Bacterial DNA Extraction 
 
Methods for preparation/extraction of plasmids from E coli and extraction of 
chromosomal DNA from aroQ B pertussis are described below: 
 
2.12.1. Plasmid Extraction from E coli strains 
	  
Stocks of E coli strains (SM10 λ pir, DH5α harbouring the plasmid pJQ200mp 18-
rspL or pSS1129) maintained at -800C were thawed on ice and 10ml of LB broth 
supplemented with appropriate antibiotic(s) inoculated and incubated at 370C on 
orbital shake (Ratek) for 15-17 hours. A loop full of the growth was subcultured on 
LB agar plate supplemented with appropriate antibiotic(s) and incubated at 370C for 
overnight. The broth was transferred into six 1.5ml microtubes and pelleted at 
10,000rpm (9,500xg) (HERMLE Z 233M) for five minutes. The plasmid was 
extracted from cells using Miniprep (QIAprep® Spin Miniprep Kit using a 
Microcentrifuge) according to manufacturer’s recommendations. Briefly, three of the 
above pellets (from 1.5ml tube) resuspended in 250µl of suspension buffer (P1) and 
transferred into an autoclaved 1.5ml microcentrifuge tube. To the mixture 250µl of 
cell lysis buffer (P2) added mixed thoroughly by inverting 6 times and 350µl of 
neutralisation buffer (N3) added to the tube mixed thoroughly by inverting and 
immediately centrifuged at 13,500rpm (17320xg) (Hermle Z 2233M) for 10 minutes. 
The lysate (supernatant) was transferred to a QlAprep spin column, the column put in 
a 2ml collection tube and centrifuged as above for 1 minute. The flow-through 
discarded and column washed with 750µl wash buffer (PE) and centrifuged as above 
for 1 minute. The flow-through discarded and the column was centrifuged as above to 
remove traces of wash buffer residue. The flow-through discarded. Thirty or 50µl of 
elution buffer (EB) was added to the centre of the column; the column incubated at 
room temperature for one minute and centrifuged for 1minute as above. 
Concentration of eluted plasmid measured by Nano drop and/or by subjecting 2-5µl 
of the plasmid to (0.8%) gel electrophoresis. The rest of the eluted plasmid was stored 
at -200C for subsequent investigations. In general, the above procedure was used for 
plasmid extraction from all the E coli strains used in this study. 
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2.12.2. Chromosomal DNA extraction from aroQBP 
	  
Chromosomal DNA was extracted from aroQBP using DNeasy Blood & Tissue 
Handbook kit (QIAGEN). The protocol was followed according to the manufacturer’s 
instructions. Briefly, aroQBP was grown on three BG-aromix-(Km/50mg/ml, 
Sm/200µg/ml) as described on section 2.1.2. The growth was picked from plates and 
suspended in 10ml PBS and the optical density adjusted to 1.6nm at 600nm 
corresponding to 2x109 CFU using the established growth curve for aroQBP (Figure 
2.2). The suspension was centrifuged at 8,000rpm (6,090xg) (HERMLE Z 233M) for 
10 minutes. The rest of the procedure followed as described in manufacturer’s 
procedure. Briefly, the pellet cells were lysed by addition of 180µl ATL buffer. The 
proteins in the suspension were inactivated by addition of 20µl proteinase K the 
mixture incubated on orbital shaker (Ratek) 150rpm at 560C for two hours. To the 
lysate 4µl ribonuclease (RNase) A (100mg/ml) added and solution mixed briefly by 
vortexing before incubation at room temperature for 2 minutes. The solution vortexed 
for 15 seconds and DNA was precipitated by adding 200µl buffer AL and 200µl 
ethanol (100%) to the solution and a brief vortex of the mixture. The DNA was 
extracted and re-extracted from the mixture as follows: The mixture was pipetted into 
DNeasy Mini spin column that was placed in a 2ml collection tube and centrifuged at 
8,000rpm (6,090xg) (HERMLE Z 233M) for 1 minute. The flow-through from last 
step discarded the DNeasy Mini spin placed in a new 2ml collection tube and 500µl 
of AW1 buffer added to the column the tube was centrifuged as above. The column 
placed in a new 2ml collection tube and 500µl of buffer AW2 added to column and 
was centrifuged at 13,500rpm (1,7320xg) (HERMLE Z 233M) for 3 minutes. A 
further centrifugation carried out as above for 1 minute to prevent any residual 
ethanol carry over to DNA elution step. The DNA was eluted by placing the column 
in to a 1.5ml microcentrifuge tube and addition of 200µl AE buffer to the column. 
The solution incubated at room temperature for 1 minute before it was centrifuged at 
8,000rpm (6,090xg)  (HERMLE Z 233M) for 1 minute. To maximize the DNA yield 
the elution step was repeated with 100µl AE buffer as above. Two microliter of the 
eluted chromosomal DNA was subjected to gel (0.8%) electrophoresis to check the 
quality of the DNA. The DNA did produce a sharp band with minor DNA degradation 
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(smear) on gel. The suspension was stored at -200C. The DNA stock was diluted with 
200-300µl nuclease free water (Promega) to about 5ng/µl when needed. 
 
2.13. Recombinant DNA techniques 
	  
The program described in the National Center for Biotechnology Information 
database (NCBI) (http://www.ncbi.nlm.nih.gov/gene/2664492) was used to identify 
the cyaA, bifunctional hemolysin-adenylate cyclase precursor (5121bp). For 
conformation of the cyaA sequence accuracy whole cyaA sequence was selected and 
blasted against B pertussis using the B pertussis genome sequence database [www. 
sanger.ac.uk/cgi]. The identity of the query sequence (cyaA nucleotide sequence) 
against whole B pertussis nucleotide sequence was 100% (see Appendix Q for 
alignment, page 255). 
	  
Standard PCR, cloning and recombination DNA techniques were used according to 
Sambrook et al. (2001). Restriction and modification enzymes were purchased from 
Geneworks (Adelaide, Australia) and used according to the manufacturer’s 
recommendations. Oligonucleotide primers (10µM) used described in (Table 2.13a.), 
and were purchased from Geneworks (Adelaide, Australia). All oligonucleotide were 
designed from published Genbank (NCBI) sequences of the cyaA gene (NCBI 
reference sequence: NC_002929.2). The primers were designed using PubMed 
software (http://www.ncbi.nlm.nih.gov/tools/primer). 
 
Lyophilised stocks of primers were reconstituted to 100µM working solutions with 
nuclease free water (Gibco). Negative control was run along with every PCR but 
using PCR grade water as a template. When possible a positive internal control was 
also run along PCR reaction. The positive control compromised of the PCR 
component except for template. The template included in PCR reaction was known to 
work under the PCR parameter. PCR reactions were constituted either in 20µl or 50µl 
aliquot (Table 2.13b.). The cycling condition used for PCR is shown on Table 2.13c. 
If more than two PCR reaction aliquot were needed a master mix was made. Master 
mix consisted of PCR grade water, forward and reverse primer, Magic Buffer, and 
Ezway™ Direct Master Mix. Magic Buffer does improve DNA amplification of 
template with a high Glycine (G) + Cytosine (C) content and high degree of 
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secondary structure. The final concentration of the magic buffer did not exceed 25% 
(v/v) of final PCR volume. Ezway™ Direct Master Mix, is a premixed solution 




Table 2.13a.  List of primers used for PCRs in this study.  Oligonucleotide 
primers used for PCR and site-directed mutagenesis. Designation 
is given from 5´ to 3´ direction, and restriction sites are underlined. 
Nucleotide location for the primers at the (NCBI) B pertussis 










RvsCya GAATTCGTATTCCTTCAGTTGCCCGCGCG EcoRI 777226-
777204 
FwdMut GTGGCCACCATGGGATTGGGC _____ 776390-
776411 




GAAGGGGTGGCCACCATG  _____ 776384-
776402 





GAAGGGGTGGCCACCAAA  _____ 776384-
776402 
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Table 2.13b. PCR reaction components and PCR reaction aliquot set up in 
different volume. 
 
PCR component 23µl reaction aliquot (µl)  50µl reaction aliquot (µl) 
PCR grade H2O 7.5 if liquid form of 
template used or 6.5 if 
template was colony touch 
12.5 
Forward primer 1 (10µM) 1 
Reverse primer 1 (10µM) 1 
Template 0.5 (5-10ng) or touch of 
individual colony 
0.5 0f (5-10ng) 
Magic Buffer 4 10 
2x Ezway™ Direct Master 
Mix 
10 25 
Total volume 23 50 
 
 




Stage 1 1 cycle 950C for 5 min 
Stage 2 25 cycle 950C for 30 sec 
570C for 1 min 
720C for 10 min 
Stage 3 1 cycle 140C hold 
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2.13.1. Agarose gel electrophoresis 
	  
Agrose gel electrophoresis was carried our using 0.8% solution of biotechnology 
grade agarose I (Amresco®) in 50ml or 100ml of Tris Acetate EDTA (TAE) buffer 
prepared (see Appendix C, page 158) by heating in a microwave for 1 to 3 minutes 
until dissolved. The gel solution was then cooled to about 550C degree before addition 
of Cyber safe DNA gel stain (invitrogen) to the with gel solution at ratio of 
1:10,000. Twelve or fifty millimetre comb was placed on the casting apparatus and 
gel solution poured slowly into the apparatus cast with the comb in place. The gel was 
allowed to solidify before the comb removed from the gel. The gel was removed from 
casting apparatus and submersed into gel tank (Bio Rad) containing TAE buffer. 
Samples were prepared by adding the required amount of loading dye (Promega) for 
visualisation and then loaded into the wells using fine-tipped pipette. The standards 
used were 1kb DNA Step Ladder (Promega), Lambda DNA/HindIII Markers 
(Promega), 100 base pair (Fermentas), and HyperLadder I (Fermentas). Samples were 
electrophoresed by attaching the tank to power pack (Bio Rad, 1000/500) and 
supplying 100 volts at 100 milliamps for approximately 35 minutes. The power pack 
was switched off and the gel was transferred to a Bio-Rad Gel Doc System for 
visualisation and photographing of DNA under UV light. If DNA bands were to be 
removed from gel then a UV transilluminator (Ultra-Lum, Quantum) was used to 
visualise and cut out the DNA from the gel with appropriate protective steps against 
UV light. 
 
2.13.2. Digestion of the inserts and vectors 
	  
Digestion of the insert, (wild type and mutant cyaA fragment) and respective vectors, 
pUC19, pJQ200mp 18-rspL, and pSS1129 with or without the insert were followed 
according to manufacturer’s instructions. In general, digestion reaction was carried 
out in one double-digestion reaction tube since NEB buffer 4 is suitable to use for 
digestion of DNA with either or both BamHI and EcoRI restriction enzymes, with 
100% activity  (New England Biolabs Inc). Any modification to protocol is 
mentioned in appropriate sections. Digestion reaction was incubated at 370C for five-
to-seven hours in water bath. The digested inserts and vectors were used for 
subsequent cloning of the inserts into the respective vectors. 
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2.13.3. Ligation Condition 
	  
Overall procedure that followed for sub-cloning of the cyaA/cyaMut insert into 
pUC19 is presented in Figure 2.13.3. Same procedure was followed for sub-cloning of 
CyaMut insert into vector pJQ200mp-18 rspL and vector pSS1129. 
	  
Ligation procedures were followed as manufacturer’s protocol, (Promega) and 
(Sambrook and Russell 2001). The ligation of digested wild type cyaA fragment insert 
into digested pUC19 vector and ligation of mutant cyaA fragment insert into, pUC19, 
pJQ200mp 18-rspL, and pSS1129, was accomplished as follows. In general the ligase 
reaction was assembled in 15 or 20µl on 0.5ml autoclaved eppendorf tube. The molar 
ratio of vector: insert for each individual ligation reaction is given below for each 
individual ligation reaction. To vector DNA (ng as required) insert DNA (ng as 
required) was added. To the mixture 1µl (Weiss units) of T4 DNA ligase, ligase 
buffer (Promega) and deionized water to final volume of 15 or 20µl was added. The 
tube was gently flicked between fingers several times. The tube was centrifuged for a 
few seconds and incubated at 160C for overnight. Ligation reaction between cyaA-
(BamHI-EcoRI) and pUC19-(BamHI-EcoRI) was set up with two different 
vector:insert ratios (1:3 and 1:6) in 15µl at 40C and 160C  incubated for overnight. 
  

























Figure 2.13.3. Schematic drawing of overall procedure for sub-cloning of double 
digested CyaA/CyaMut DNA fragments into double digested; pUC19, pJQ200mp 18-
rspL, and pSS1129 vectors. The insert was double digested with BamHI-EcoRI; the 
gel-excised double digested insert subsequently sub-cloned into cleaned up double 














	   1) Double digest of the insert with BamHI and EcoRI. 
2) The digested insert subjected to gel electrophoresis. 
3) The insert excised from the gel. 
1) Double digest of the insert with BamHI and EcoRI. 
2)	  Cleaning	  up	  of	  the	  double	  digested	  vector.	  
Sub-­‐cloning	   of	   the	   double	   digested	   insert	   into	   the	   double	  
digested	  vector.	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2.13.4 Screen of colonies for vector-insert uptake by phenol-
chloroform DNA extraction method 
	  
The method followed was as described by Sambrook et al. (2001). Fifteen microliter 
of 0.5µg/µl RNase A (Sigma) with 1x concentration of methylene blue was dispersed 
in 1.5ml eppendorf tube. About half colony of growth was resuspended in the 
solution. To the mixture 15µl of phenol: chloroform: isoamyl alcohol (25: 24: 1) 
saturated with 10mM Tris, pH 8.0 1mMEDTA was added and centrifuged at 13,500 
rpm (17,320xg) (HERMLE Z 233M) for 1 minute. Fifteen microliter of the organic 
layer (upper aqueous phase) was run on 0.8% gel to check for the uptake of the insert 
with the plasmid. 
 
2.14. Cloning of cyaA insert fragment into pUC19 and  
pGEM®-T easy vector 
 
About 1000µg of pUC19 vector and 1100µg of cyaA fragment insert were digested 
sequentially with BamHI and EcoRI in 50µl reaction tube. Digested products of 
BamHI, pUC19-(BamHI) and cyaA-(BamHI) were cleaned in about 50µl according to 
manufacturer’s instruction (QIAquick® PCR Purification Kit, QIAGEN). Briefly, 
250µl (5 x of the PCR volume) of neutralisation buffer (PB) was added to the PCR 
product and the mixture applied to a QIAquick column. The column was placed over 
a 2ml collection tube and centrifuged at 13,500rpm (17,320xg) (HERMLE Z 233M) 
for 1 minute. The flow-through was discarded and bound DNA washed with 750µl of 
wash buffer (PE) followed by centrifugation as above. The column was then placed in 
an autoclaved 1.5ml microcentrifuge tube. The DNA eluted by adding 50µl of EB 
buffer; the column incubated at room temperature for one minute and centrifuged as 
above. Entire 50µl of cyaA-(BamHI) and 50µl of pUC19-(BamHI) digestions product 
were subjected to second digestion with EcoRI (Table 2.14.a-b). The digestion 
product of pUC19-(BamHI-EcoRI) was cleaned up as above (QIAquick® PCR 
Purification Kit, QIAGEN). Five microliter of pUC19-(BamHI-EcoRI) was subjected 
to electrophoresis on 0.8% gel to verify the purity and concentration of the DNA 
fragment. 
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The entire 50µl digestion product of cyaA-(BamHI-EcoRI) was subjected to 
electrophoresis on 0.8% gel. The fragment was excised from gel matrix and purified 
using gel extraction kit (QIAquick® Gel Extraction Kit, QIAGEN). Briefly, The 
DNA fragment excised from the agarose gel with scalpel. The excised DNA fragment 
from agarose gel was placed in a pre-weighed autoclaved microcentrifuge tube. The 
volume of the gel slice was estimated by weighing the tube, assuming one gram being 
equal to one millilitre. The volume of DNA Purification Kit Binding Buffer (QG) 
added to the microcentrifuge tube containing the excised gel was calculated using the 
following formula: 
[Volume of the gel] x 3 
 
The maximum amount of gel slice per QIAquick column was 400mg; for gel slice 
>400mg more than one column were used. The tube was incubated at 500C for ten 
minutes, vortexing every 2 minutes during the incubation. The matrix-bound DNA 
was pelleted by centrifugation for 1 minute at 13,500rpm (17,320xg) (HERMLE Z 
233M). The supernatant was discarded and 500µl DNA purification buffer (QG) 
added to matrix and centrifuged as above. The DNA complex was pelleted as above, 
the supernatant discarded and 750µl of Wash Buffer (PE) was added and centrifuged 
as above. All traces of Wash Buffer (PE) were removed by an additional 
centrifugation as above. The pellet was resuspended in 30µl of Elution Buffer (EB) 
and incubated at room temperature for 1 minute. The spin column placed in an 
autoclaved 1.5ml microcentrifuge tube and centrifuged as above. Five to 10µl of 
eluted DNA was subjected to electrophoresis on 0.8% gel to verify the purity and 
concentration of the DNA. 
 
Ligation reaction between cyaA-(BamHI-EcoRI) and pUC19-(BamHI-EcoRI) was set 
up with two different vector:insert ratios (1:3 and 1:6) in 15µl at 40C and 160C in two 
0.5ml tubes along with negative control, all three tubes were incubated for overnight 
(Table 2.14c). 
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Table 2.14a. cyaA insert and pUC19 digestion with BamHI restriction enzyme. 
 
Cya insert amplicon, volume (µl) Uncut pUC19 vector, volume (µl) 
d.H2O 34 d.H2O 33 
Buffer 4 5 Buffer 4 5 
Insert 10 vector 11 
BamHI 1 BamHI 1 
Total volume 50 Total volume 50 
 
	  
Table 2.14b. cyaA-(BamHI) insert and pUC19-(BamHI) digestion with EcoRI 
restriction enzyme. 
 
Cya insert amplicon, volume (µl) Uncut pUC19 vector, volume (µl) 
d.H2O 18.5 d.H2O 23.5 
Buffer 4 5 Buffer 4 5 
Insert 25 vector 20 
EcoRI 1.5 EcoRI 1.5 
Total volume 50 Total volume 50 
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Table 2.14c. Ligation condition of cyaA-(BamHI-EcoRI) insert into pUC19-
(BamHI-EcoR1). 
 
Sample vector:insert, 1:3 molar ratio (µl) Negative control (µl) 
10xligation buffer 1.5 10xligation buffer 1.5 
cyaA-(BamHI-
EcoRI) insert 






T4 DNA ligase (3 
Weiss units/µl) 
1.5 T4 DNA ligase (3 
Weiss units/µl 
1.5 
PCR grade water 3.4 PCR grade water 4.9 
	  
	  
2.14.1. Cloning of cyaA insert fragment into pGEM®-T easy vector 
	  
The procedure for cyaA insertion into pGEM-T easy vector was followed as stated in 
manufacturer’s protocol (pGEM®-T Easy Vector System II, Promega), (Figure 
2.14.1). The reaction was assembled in 10µl on 0.5ml autoclaved eppendorf tube. To 
5µl of 2X Rapid Ligation Buffer, T4 DNA Ligase, 50ng (1µl) pGEM®-T easy vector 
was added. To the mixture 49.7µg (0.4µl) of gel extracted cyaA (QIAquick® Gel 
Extraction Kit, QIAGEN) and 1µl T4 DNA ligase (3 Weiss units/µl) was added. The 
reaction volume was adjusted to 10µl with nuclease free water. The reaction mixture 
was mixed gently 5-6 times with pipetting and incubated at 4°C for overnight. The 
molar ratio of vector: insert was 1: 3. 
 
One microliter of ligated sample (cyaA insert + pGEM®-T easy vector) was 
transformed into E coli JM109 as stated in section 2.11.2. The sample (ligation 
reaction) was spread on four LB agar plates that supplemented with 100µg per ml of 
Amp/IPTG/X-Gal. Colonies with white colour indicated of successful transformation 
and insertion (inactivation of lacZ operon). The blue colour colonies on the other 
hand, indicated that the cell was transformed with the pGEM-T Easy vector without 
the insert. Total of forty-four white and blue colonies were picked from LB- 
Amp/IPTG/X-Gal plates and screened for cyaA insert in the vector as described in 
section 2.13.4. Two colonies with cyaA transformed colonies were subcultured in two 
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10ml LB- (100ugAmp/ml) broths and incubated at 370C on orbital shaker for 16 to 18 
hours. Fifty microliters (40ng/µl) of the plasmid (cyaA insert + pGEM®-T easy 
vector) was extracted from each of two colonies (QIAprep® Spin Miniprep Kit using 
a Microcentrifuge) as described in section 2.12.1. Five hundred nanograms of each 
extracted plasmids were double digested with EcoRI and BamHI endonuclease 
restriction enzymes, respectively as described in section 2.13.2. Digested plasmids 
were subjected to electrophoresis on 0.8% gel to confirm the correct size of the cyaA-
(BamHI-EcoRI) insert. Subsequently stock of pGEM-CyaMut in E coli JM109 made 
and stored at -800C as describe in section 2.1.3. 
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Figure 2.14.1. Summary of overall procedure for insertion of cyaA insert fragments 
into pGEM-T Easy Vector System II. The clone was double digested with BamHI-
EcoRI subsequently the digested cyaA-(BamHI-EcoRI) cloned into pUC19-(BamHI-
EcoRI) vector. 
  
Subcloning of insert into pUC19-(BamHI-EcoRI) double digest 
Gel extraction of CyaA-(BamHI-EcoRI) insert with QIAquick Gel Extraction kit  
Selection of 1kb size insert from double digest vectors from gel run  
Double digest of vectors with BamHI-EcoRI 
Extraction of vectors from E coli JM101 with QIAprep Spin Miniprep kit  
Incubation of broth @ 370C on orbital shaker 225 rpm for overnight  
Subculture of suspected vectors with insert on LB-Amp broth  
Screen of about 10 white colonies with phenol-chloroform DNA extraction for 
ligate-insert vector 
Culture of transformed E coli JM10 on LB-Amp/IPTG/X-Gal plate, incubation @ 
370C for overnight 
Transformation of E coli JM109 wih the ligate by heat-shock 
Incubation of ligate reaction @ 40C for overnight 
Subcloning of insert into pGEM-T Easy Vector System II with vector:insert molar 
ratio of 1:3   
Cleaned up PCR amplified 1kb CyaA DNA fragment insert 
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2.14.2. Cloning of cyaA from pGEM-cyaA into pUC19 vector 
	  
About 800ng pGEM-Cya and 500ng of pUC19 products each were double digested 
with EcoRI and BamHI. The whole 50µl of double digested pGEM-cyaAEcoRI-
BamHI was run on 0.8% gel, and was extracted from gel (QIAquick® Gel Extraction 
Kit, QIAGEN). Likewise, double digested pUC19-(EcoRI-BamHI) was cleaned up 
(QIAquick® PCR Purification Kit, QIAGEN). Ligation of pEGEM-cyaAEcoRI-
BamHI into pUC19EcoRI-BamHI was done as stated in section 2.13.3, the molar ratio 
of vector: insert was 1: 3 (50ng: 55.8ng). The resulting vector was pUC19Cya with 
size of 3.648kb (Figure 2.13.3). 
 
2.15. Site-directed mutagenesis of cloned cyaA insert 
	  
The alteration of specific nucleotide(s) in the cloned cyaA insert fragment DNA in 
pUC19Cya vector was carried out using a QuikChange II XL Site-directed 
mutagenesis kit (Stratagene). 
 
Inactivation of cloned cyaA insert involved two point mutations at bases 77640 and 
77641 namely adenine to thymine and adenine to glycine with aim of changing lysine 
codon (AAA) to methionine (M) codon (ATG) (Au, Masure, and Storm 1989) on 
pUC19Cya vector (Figure 2.13.3). The resulting vector was pUC19CyaMut with size 
of 3.648kb. 
 
Point mutation of a 4.5kb pWhitescript plasmid (Stratagene) was used as a positive 
control for mutagenesis protocol. The lacZ insert of the plasmid had an in-frame TAA 
stop codon, which interfered with β-galactosidase expression. Subsequent point 
mutation of the thymidine residue in the stop codon to a cytidine residue using the 
control oligonucleotide generated a glutamine codon switch. Transformation of E coli 
with the mutated pWhitescript conveyed a blue phenotype on selective LB agar 
supplemented with IPTG and X-Gal, by virtue of an unimpeded β-galactosidase 
expression in the mutants. 
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2.15.1. Detection of mutation in lysine 58 codon by sequencing 
	  
In general, when the mutation in manipulated cyaA insert or vector was to be checked, 
the plasmids or the extracted cyaA fragment were sent to the Australian Genome 
Research Facility Ltd (agrf) for sequencing. Products either were cleaned up 
(QIAquick® PCR Purification Kit, QIAGEN) before sending to agrf or sent as 
unpurified samples. Between 30-75ng of cleaned PCR products in 9µl with 3µl of 10 
pico-mole (pM) of perspective primer (forward or reverse), in total of 12µl were sent 
to agrf for sequencing. When a large number of PCR samples (about 10) sent for 
sequencing the PCR reactions were run in 20µl reaction on PCR plate (Axygen PCR-
96 M2-HS). The unpurified PCR reaction plate along with 200µl of 3.2µM of 
perspective primer (forward or reverse) was sent to agrf for sequencing. Vector(s) 
were pre prepared as purified PCR products before sending for the sequence to agrf. 
 
Before sending any batch samples for sequencing, 5-10 samples were subjected to gel 
electrophoresis for samples concentration and their quality. In general, concentration 
of each sample was measured by NanoDrop (Thermo Scientific). 
 
2.16.  Sub-cloning of Mutant cyaA insert (CyaMut) into 
pJQ200mp 18-rspL 
 
Sub-cloning of CyaMut insert fragment into pJQ200mp 18-rspL was carried out as 
described in following sections. For overall sub-cloning procedure, see Figure 2.13.3. 
 
2.16.1. Digestion of pJQ200mp18-rpsL 
	  
One thousand micrograms in (6µl) of pUC19CyaMut double digested with BamHI-
EcoRI in 50µl reaction mixture and was subjected to electrophoresis on 0.8% gel. The 
one kilo-base CyaMut was extracted from the gel using the QIAquick® Gel 
Extraction Kit (QIAGEN). Also about 1000µg of pJQ200mp18-rpsL (20µl) was 
double digested as above with BamHI-EcoRI, pJQ200mp 18-rspL (BamHI-EcoRI), 
and cleaned up using the QIAquick® PCR Purification Kit (QIAGEN). 
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2.16.2.  Ligation of CyaMut-(BamHI-EcoRI) insert and 
pJQ200mp 18-rspL-(BamHI-EcoRI) 
	  
Ligation reaction was set up in 15µl reaction mixture with as described in section 
2.13.3 with vector: insert ratio of 1:3 (50ng pJQ200mp 18-rspLCyaMut in 5µl: 31ng 
CyaMut in 6.2µg). The vector size was 4.788kb. The 0.5ml reaction tube was 
incubated at 40C for overnight. The resultant vector named pJQ200mp 18-
rspLCyaMut. 
 
2.16.3.  Transformation of E. coli SM10 λ  pir with pJQ200mp 
18-rspLCyaMut (pJQ200mp 18-rspLCyaMut) 
	  
E coli SM10 λ pir was transformed with 2µl of pJCyaMut vector as described in 
section 2.11.2. The transformed E. coli SM10 λ pir on 500µl SOC broth was spread 
on 4xLA-(Gm10µg/ml) with 50µl, 100µl, 150µl, and the rest of the broth.  All of four 
plates were incubated at 370C for overnight. Twelve colonies were picked up from 
transformation plate and screened for insert with phenol-chloroform DNA extraction 
method as described in section 2.13.4. 
 
2.16.4. Transformation of aroQBP with pJ200mp 18-rspLCyaMut 
 
A modified conjugation protocol of (Simon 1983) was followed for transfer of the 
pJCyaMut to aroQBP strain (Figure 2.16.4). The aroQBP (recipient) was grown on 
BG-aromix-(Km50µg/ml, Sm 200µg/ml) for three days. A 10ml SS-(Km50µg/ml, 
Sm-200µg/ml) was inoculated with aroQBP from above plate. The OD600nm of the 
broth at time zero was 0.020. The broth was incubated at 370C on orbital shaker 
(Ratek) at 225rpm until the broth got slightly turbid (about 58 hours). The OD600nm of 
broth was taken at different time intervals till OD600nm reached about 0.520 in the log 
growth phase (Appendix D. page 160). 
 
The pJQ200mp 18-rspLCyaMut transformed E. coli SM10 λ pir (donor) was grown 
on LA-(Gm10µg/ml, Km50µg/ml) for 16 to 18 hours. The pJQ200mp 18-
rspLCyaMut transformed was grown in 10ml SS medium containing Gm10µg/ml, 
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Km50µg/ml until the growth curve reached log phase OD600nm of approximate 0.492 
(Appendix E, page 161). 
Mixture of recipient: donor, 1:1, 10:1, and 100:1 ratio were made in about 1ml of SS-
(Km50µg/ml, Sm200µg/ml) medium as follows: Ten fold serial dilutions, 10-1-10-3 
were made for aroQBP (OD600nm) in 1ml SS-(Km50µg/ml, Sm200µg/ml). Ten 
microliter of E coli SM10 λ pir was added to each of the dilutions made above. Each 
individual recipient:donor mixture was loaded (approximately 200µl) onto 
nitrocellulose membranes (0.22µm pore size) that had been placed on six CW-aromix-
(Km50µg/ml, MgCl2) plates. The plates were incubated with the lid facing upwards at 
370C for 4 hours. Growth from each plate in the batch was swept with a sterilised 
dacron swab and suspended in 1ml SS medium. Each individual suspension was 
plated on 4 CW-aromix-(Km50µg/ml, Sm200µg/ml) plates in different volumes viz., 
50µl, 100µl, 200µl and the remaining volume on the 4th plate. The whole twelve 
plates were incubated at 370C in plastic bag with wet tissues for four days. On the 
fifth day isolated colonies were detected on the plate inoculated with 100µl of the 
1:100 recipient:donor ratio. Sixty-three isolated colonies spot-cultured on 3 CW-
aromix-(Km50µg/ml, Sm200µg/ml) and 3 CW-aromix-(Km50µg/ml, Sm200µg/ml, 
Gm10µg/ml) plates were incubated at 370C as above for five days. 






10-­‐fold	  serial	  dilution	  made	  in	  SS-­‐(Km/	  
Sm)	  medium,	  10-­‐1-­‐to-­‐10-­‐3,	  1ml	  per	  
dilution.	  	  
aroQBP	  (recipient)	  grown	  on	  CW-­‐
aromix-­‐(Km/	  Sm)	  plate	  for	  72	  hours.	  
E	  coli	  SM10	  λ	  pir-­‐hourboring	  (pJCyaMut)	  (donor)	  
grown	  on	  LB-­‐(Km/	  Gm)	  plate	  for	  overnight.	  
10ml	  SS-­‐aromix-­‐(Km/	  Sm)	  inoculated	  
with	  growth	  from	  above	  plate.	  
OD600nm	  of	  the	  broth	  taken,	  registered	  as	  
time	  zero.	  
The	  broth	  incubated	  at	  370C	  on	  orbital	  
shaker,	  225rpm	  until	  got	  slightly	  turbid	  
(about	  47	  hours).	  
The	  OD600nm	  of	  the	  broth	  taken	  at	  
different	  time	  intervals	  until	  the	  OD600nm	  
reached	  0.52,	  approximately	  13	  hours.	  
10ml	  SS-­‐(Km/	  Gm)	  medium	  inoculated	  with	  growth	  
from	  above	  plate.	  
OD600nm	  of	  the	  broth	  taken,	  registered	  as	  time	  zero.	  
The	  OD600nm	  of	  the	  broth	  taken	  at	  different	  time	  
intervals	  until	  the	  OD600nm	  reached	  0.492,	  
approximately	  6	  and	  a	  half	  of	  hours.	  
The	  broth	  incubated	  at	  370C	  on	  orbital	  shaker,	  
225rpm.	  
	  
Mixture	  of	  recipient:donor,	  cells	  ratio	  made	  in	  1m	  SS-­‐aromix-­‐(Km)	  medium;	  100:1,	  10:1,	  1:1.	  	  
Each	  of	  dilutions	  (1ml)	  loaded	  on	  cellulose	  membrane	  placed	  on	  CW-­‐aromix-­‐(Km/10mM	  
MgCl2)	  and	  incubated	  at	  370C	  for	  4	  hours.	  	  
Growths	  from	  each	  of	  recipient:donor	  membranes	  picked	  with	  Dacron	  swab	  and	  were	  
suspended	  into	  1m	  SS-­‐aromix-­‐(Km)	  medium.	  	  
50,	  100,	  300µl,	  and	  the	  rest	  of	  each	  of	  the	  1ml	  suspension	  spread	  on	  four	  CW-­‐aromix-­‐(Km/	  Sm)	  
plates	  and	  were	  inoculated	  at	  370C	  for	  5	  days.	  
100	  isolated	  colonies	  were	  picked	  each	  of	  which	  spot-­‐cultured	  on	  CW-­‐aromix-­‐(Km/Sm);	  CW-­‐
aromix-­‐(Km/Sm/Gm)	  plates	  and	  incubated	  at	  370C.	  
Figure 2.16.4. Diagram describing the protocol followed for transformation of B pertussis aroQ strain with 
pJQ200mp 18-rspLCyaMut. 
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2.17. Sub-cloning of CyaMut insert into pSS1129 vector 
 
Sub-cloning of CyaMut insert fragment into pSS1129 was carried out as described in 
following sections. For overall of the sub-cloning procedure see Figure 2.13.3. 
 
2.17.1. Digestion of pSS1129 vector 
 
One thousand (1000) ng pUC19CyaMut vector was digested with EcoRI and BamHI 
in 50µl reaction tube as described in section 2.13.2. The whole 50µl of double 
digested pUC19CyaMut-(EcoRI-BamHI) was run on 0.8% gel. The CyaMut-(EcoRI-
BamHI) was extracted from gel (QIAquick® Gel Extraction Kit, QIAGEN). 
Likewise, about 900ng of pSS1129 was double digested with EcoRI and BamHI.  The 
resultant vector, pSS1129-(EcoRI-BamHI) was cleaned up with (QIAquick® PCR 
Purification Kit, QIAGEN). 
 
2.17.2.  Ligation of CyaMut-(BamHI-EcoRI) insert and pSS1129-
(BamHI-EcoRI) 
 
Ligation reaction was set up in 15µl reaction mixture with as described in section 
2.13.3 with vector: insert ratio of 1:3 and 1:6, 50ng: 17ng and 50ng: 34ng, in a 0.5ml 
microtube respectively. The 0.5ml reaction tube was incubated at 40C for overnight. 
The resulting vector pSS1129CyaMut had an estimated size of 10kb. The size of this 
vector had to be estimated since complete sequence of the pSS1129 vector has not 
been published. 
 
2.17.3. Transformation of aroQBP with pSS1129CyaMut 
	  
A modified conjugation protocol of Stibitz (1994) was followed for transfer of the 
pSS1129CyaMut to aroQBP strain (Figure 2.17.3). A BG-aromix-(Km50µg/ml, 
Sm200µg/ml) was inoculated with -800C aroQBP strain stock and incubated for three 
days. Ten ml CL supplemented with aromix, Km 50µg/ml and Sm200µg/ml in twenty 
ml McCartney tube was inoculated with the aroQBP strain. The OD600nm of the broth 
was taken at zero time was 0.067. The broth was incubated at 370C on orbital shaker 
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(Ratek) at 225rpm until the broth became slightly turbid (about 48 hours). At the 
second day, the OD600nm of broth was taken at different time intervals until OD600nm of 
the broth reached approximately 0.5 in the log phase of the growth curve (Appendix 
F, page 162). 
 
A LB-(Amp100µg/ml, Km50µg/ml, Gm10µg/ml) agar was inoculated with -800C 
stock E coli SM10 λ pir containing pSS1129CyaMut vector. The plate was incubated 
at 370C for 16-18 hours and a 10ml LB-(Amp100µg/ml, Km50µg, Gm10µg/ml) broth 
was inoculated with E coli SM10 λ pir harbouring pSS1129CyaMut vector from the 
plate. The broth was incubated at 370C on orbital shaker (Ratek) at 225rpm until broth 
OD600nm reached 5.0 at OD600nm, which took about 6hours. 
 
The aroQBP (approximate OD600nm of 0.5) and E coli SM10 λ pir (approximate 
OD600 of 0.50) broths were mixed in SS medium at different donor (E coli SM10 λ 
pir-pSS1129CyaMut) to recipient (aroQBP) ratios as shown in Table 2.17.3. 
 
 
Table 2.17.3. Ratio of donor-to-recipient cells number used for conjugation. 
 
Donor: Recipient, Cells 
Number 
E coli SM10 λ pir-
pSS1129CyaMut (µl) 
aroQBP (µl) 
1:10 10 100 
1:25 1 25 
1:50 1 50 
1:100 1 100 
1:500 0.1 50 
 
 
Each individual conjugation mixture broth was spot cultured on one BG-Aromix-
(Km50µg/ml, MgCl210mM). The plate was incubated at 370C for fourteen hours.  
Each growth was suspended in 1ml of SS-aromix-(Km50µg/ml) medium. Each of 1ml 
broth was spread on 7 BG-aromix-(Km50µg/ml, Sm200µg/ml) plates. A volume 20µl, 
30µl, 50µl, 100µl, 200µl, 300µl and remaining mixture were spread plated on 
individual plates. All the 35 plates were incubated at 370C in plastic bags with wet 
	   68	  
tissues for five days. On second day of incubation, fine growth was detected on all 
plates. On fifth day, confluent growth was detected on all plates. One plate of each 
conjugate batch was taken (total of 5 plates) and ten-fold serial dilution was made 
from each conjugate plates.  Suspension was made from each of the five conjugate 
plates in approximately 1ml SS medium and their OD600nm adjusted to approximately 
0.450-0.520. Ten-fold serial dilution in total volume of 500µl for each of the broths 
from 10-1-10-7 dilutions were made. Each of 10-5, 10-6, and 10-7 of each of dilution 
batches was spread plated on 15 BG-aromix-(Km50µg/ml, Sm200µg/ml) plates and 
incubated at 370C in plastic bag with wet tissues for four days. Total of 422 isolated 
colonies growth were picked up from the plates and spot-streaked on 9 BG-aromix-
(Km50µg/ml, Sm200µg/ml), 9 BG-aromix-(Km50µg/ml, Sm200µg/ml, Gm10µg/ml), 
and 9 BG-aromix-(Amp100µg/ml, Km50µg/ml, Sm200µg/ml, Gm10µg/ml). All 27 
plates were incubated at 370C in plastic bag with wet tissues for four to five days. 




AroQBP	  (recipient)	  grown	  on	  BG-­‐aromix	  
(Km)	  plate	  for	  72	  hours.	  
E	  coli	  SM10	  λ	  pir	  -­‐hourboring	  (pSS1129CyaMut)	  
grown	  on	  LB-­‐(Amp/	  Km/	  Gm)	  plate	  for	  overnight.	  
10ml	  CL-­‐aromix-­‐(Km/	  Gm)	  inoculated	  
with	  growth	  from	  above	  plate.	  
OD600nm	  of	  the	  broth	  taken,	  registered	  as	  
time	  zero.	  
The	  broth	  incubated	  at	  370C	  on	  orbital	  
shaker,	  225rpm	  until	  got	  slightly	  turbid	  
(about	  47	  hours).	  
The	  OD600nm	  of	  the	  broth	  taken	  at	  
different	  time	  intervals	  until	  the	  OD600nm	  
reached	  0.497,	  approximately	  13	  hours.	  
10ml	  LB-­‐(Amp/	  Km/	  Gm)	  broth	  inoculated	  with	  
growth	  from	  above	  plate.	  
OD600nm	  of	  the	  broth	  taken,	  registered	  as	  time	  zero.	  
The	  OD600nm	  of	  the	  broth	  taken	  at	  different	  time	  
intervals	  until	  the	  OD600nm	  reached	  0.50,	  
approximately	  6	  and	  a	  half	  of	  hours.	  
The	  broth	  incubated	  at	  370C	  on	  orbital	  shaker,	  
225rpm.	  
	  
Mixture	  of	  donor(µl):	  recipient(µl),	  cells	  ratio	  made	  in	  CL-­‐(Km)	  medium;	  1:10,	  1:25,	  
1:50,	  1:100,	  1:500.	  
Each	  of	  1ml	  mixture	  spread	  on	  7	  BG-­‐aromix-­‐(Km/Sm)	  plate	  with	  20,	  30,	  50,	  100,	  200,	  300µl,	  and	  the	  rest	  
of	  the	  mixture.	  	  The	  plates	  were	  incubated	  at	  370C	  for	  5	  days.	  	  Confluent	  growth	  on	  all	  plates	  detected.	  
Suspension	  made	  from	  a	  plate	  of	  each	  group	  of	  donor:	  recipient	  group	  in	  CL-­‐aromix-­‐(Km/Sm)	  and	  
OD600nm	  adjusted	  to	  approximately	  5.	  
Ten-­‐fold	  serial	  dilution	  of	  each	  suspension	  made,	  10-­‐1-­‐to-­‐10-­‐7.	  	  Fifty	  microliter	  of	  10-­‐6	  and	  10-­‐7	  spread	  on	  
BG-­‐aromix-­‐(Km/Sm),	  respectively;	  plates	  incubated	  at	  370C	  for	  6	  days.	  
	  
Each	  of	  the	  mixture	  spot-­‐cultured	  (10µl	  per	  spot)	  on	  a	  BG-­‐aromix-­‐(KA/10mM	  
MgCl2)	  all	  five	  plates	  incubated	  at	  370C	  for	  14	  hours.	  
Growths	  from	  each	  plate	  picked	  up	  with	  Dacron	  swab	  and	  suspended	  in	  1ml	  CL-­‐
aromix-­‐(Km).	  
Total	  of	  422	  isolated	  colonies	  picked	  up	  from	  plates	  and	  each	  of	  which	  spot-­‐cultured	  on	  BG-­‐aromix-­‐
(Km/Sm);	  BG-­‐aromix-­‐(Km/Sm/Gm);	  and	  BG-­‐aromix-­‐(Km/Sm/Gm/Amp),	  respectively;	  plates	  incubated	  
at	  370C	  for	  6	  	  days.	  
Figure 2.17.3. Diagram describing protocol followed for transformation of B pertussis aroQ strain with 
pSS1129CyaMut. 
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2.18. Colony screen for lysine mutation using PCR 
	  
Two different protocols were followed to detect whether the point mutation had taken 
place at position 58 of adenylate cyclase toxin. A) Amplification of cyaA insert (1kb 
bases) by PCR using FwdCya and RvsCya primers (Table 2.13a) and isolated 
colonies from the conjugation plates as template; B) Amplification of 210 bases of 
cyaA (210-base pair sequence) FwATG-mutant, FwAAA-wild type, RvsATG as 
primers (Table 2.13a) and pooled isolated colonies as template. The cyaA insert PCR 
was designed to amplify first 1kb bases of the ACT, which contains AAA bases, 
lysine codon. FwATG-mutant primer of the 210-base pair sequence had ATG 
(methionine codon) at its 3ʹ′ end. FwAAA-native primer of the 210-base pair sequence 
had AAA (lysine codon) at its 3ʹ′ end. 
 
2.18.1.  Standardization of Cya FwATG-mutant, FwAAA-wild 
type, RvsATG primers using pUC19CyaMut and 
pUC19Cya as positive and negative templates 
respectively 
	  
Two sets of PCR were set up to amplify the 210-base pair sequence using FwATG-
mutant and FwAAA-wild type primers, respectively. Reverse primer for both PCR 
sets was RvsATG. Seventeen 20µl PCR reactions aliquot were made. In eight of the 
aliquot, FwATG-mutant and RvsATG primers included. In the other eight aliquots, 
FwAAA-wild type and RvsATG primers included. pUC19Cya and pUC19CyaMut 
were used as template for each four aliquot of mutant PCR batch, respectively. 
Likewise, each of four aliquot of wild type PCR batches were inoculated with 
pUC19Cya and pUC19CyaMut templates. 
 
2.18.2.  Mutant detection in aroQBP using FwdCya and RvsCya 
primer 
	  
Forty-four colonies growth from BG-aromix-(Km50µg/ml, Sm200µg/ml) were picked 
and amplified by PCR in 23µl individual PCR reaction aliquot wells. Cycling 
condition for the amplification of cya insert followed as in Table 2.13c. All of the 
PCRs amplicons were run on gel at 5µl/well. About 17µl of each of the PCR amplicon 
were sent to agrf. 
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2.18.3.  Mutant detection in aroQBP using Cya FwATG, 
FwAAA, RvsATG as primer 
	  
The whole 422 isolated colonies from BG-aromix-(Km50µg/ml, Sm200µg/ml) were 
divided into 42 batches (ten colonies per batch) except one batch consisting of 12 
colonies. Colonies of each batch was suspended into labelled autoclaved microtubes 
containing 250µl PCR grade water. Each of individual aliquot was used as template 
amplification of 210-base pair sequence in 23µl PCR reaction in 42 aliquot wells with 
FwATG and RvsATG as forward and reverse primers, respectively. 
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Chapter 3: Results 
3a.  Immune response of acellular pertussis vaccine 





The vaccine used in this study was Infanrix (GlaxoSmithKline) vaccine, which is 
currently used to vaccinate infants in Western Australia against whooping cough. 
Infanrix contains the following native or modified components from B pertussis: 
PTxoid, FHA, PRN (Bordetella pertussis); Diphtheria toxoid, Tetanus toxoid. The 
current practice in much of developed world for prevention of whooping cough is 
vaccination of infants at 2, 4, and 6 months followed two booster vaccination at 12 
months and 4-6 years of age with an acellular vaccine pertussis vaccine containing 
diphtheria toxoid, tetanus toxoid, three to five native, recombinant and chemically or 
genetically purified potential protective antigens of B pertussis including: filamentous 
haemagglutinin, pertussis toxoid, and pertactin with or without fimbrial antigens 2 
and 3/6 (Department of Health and Aging 2008). Depending upon the manufacturer, 
additional vaccines that may be included in the DTaP formulation are either Hib, or 
inactivated poliovirus vaccine comprising type 1 and 3. The DTaP replaced the whole 
cell pertussis vaccine, DTwP, comprising diphtheria toxoid, tetanus toxoid and killed 
whole cells of B pertussis. It has been reported (Rennels et al. 2000; Gold et al. 2003; 
Jackson et al. 2002) that vaccination with even DTaP results in induction of side-
reactions, albeit considered/claimed to be milder and hence one of potential reasons 
for the compliance with the recommended schedule of vaccination resulting in an 
increase in incidence of whooping cough in unvaccinated or partially vaccinated 
populations. Even fully vaccinated populations have been now reported to acquire 
infection with B pertussis, which has been attributed to: 
 
 1) PT hyper-producer strains (Frits R. Mooi 2001; de Melker et al. 1997; He and 
Mertsola 2008; Mooi et al. 2009). 
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2) Inability of the acellular pertussis to induce CMI, as verified in the mouse model, 
considered to be necessary for long term protection against whooping cough. 
 
3) Short to midterm immunity offered by the acellular pertussis vaccine (Mills 2001). 
 
There has been an increase in the incidence of pertussis in infants and children 
(Cherry 2005; Tan et al. 2005) attributed mainly to transmission from infected adults. 
In Australia, pertussis has reached an epidemic state showing an increase in its 
incidence in adolescents, adult, and the elderly (Figure 3a.1) (National Notifiable 




Figure 3a.1. Source for compilation: National Notifiable Diseases Surveillance 
System. http://www9.health.gov.au/cda/Source/Rpt_5.cfm, (Courtesy of A/Professor 
Peter Richmond, University of Western Australia) 
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Whooping cough is also believed to be epidemic in many states of the USA (Centers 
for Disease Control and Prevention 2011) as exemplified by a recent dramatic 
increase in the incidence of whooping cough in California (Figure 3a.1b) that has 




Figure 3a.1b. Number of reported pertussis cases, California 1947-1950, to Centers 
for Diseases Control and Prevention. http://www.cdc.gov/pertussis/outbreak.html. 
Source: Centers for Diseases Control and Prevention. 
  








































Figure 2. Number of reported pertussis cases by year of onset -- California 1947-2010*
Cases
Rate per 100,000
*As of 1/31/2011; data for 2010 are still preliminary
8,627 cases
Previous peak in 1947 
number of cases: 9,394
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It has been shown that greater than 70% (Wendelboe et al. 2007) of the pertussis 
cases encountered infants and children are transmitted from the infected household 
contacts including adolescents, adults and elderly. Recently, a new vaccine, dTap, 
containing significantly lower doses of the purified protein antigens was introduced 
for booster vaccination of adults and elderly (Cherry 2005). Although, reason for 
reducing the antigens is not known, it may have been due to perceived anticipated 
side reactions in the target population. 
 
It is well established now that the protection offered by vaccination with acellular 
pertussis vaccines is due to antibodies induced by Th2-polarisation of immune 
response (Canthaboo, Williams, et al. 2000). However, it is also generally accepted 
that induction of CMI induced via Th1-polarisation of immune response is necessary 
for long-term protection against whooping cough (Redhead et al. 1993; Mills 2001; 
Mascart et al. 2003). 
 
It has been reported that live attenuated pertussis vaccines may constitute ideal 
candidates for imparting long-term protection because they mimic natural infection 
(Locht et al. 2004; Mielcarek et al. 2010) providing the potential of inducing immune 
response to all virulence antigens. The currently used DTaP vaccines contains only 3-
5 of B pertussis protective antigens, depending upon the vaccine manufacturer, with 
only one of the major toxins being covered for neutralisation. 
 
Roberts et al. (1990) reported the development of live attenuated B pertussis in which 
the aroA gene of the common aromatic biosynthesis pathway had been insertionally 
inactivated. Because the aroA mutant did not efficiently colonise airways of mice, 
three doses of the mutant vaccine delivered intranasally were required for induction of 
high levels of antibodies of different isotypes, (IgM, IgG, and IgA) and protection 
against challenge. However, no data on either the CMI-indicator cytokines or 
information on pulmonary secretions was presented. 
 
More recently, development of two other live vaccine candidates has been reported. 
Mielcarek et al. (2006) reported the development of B pertussis, which was attenuated 
by genetic detoxification of pertussis toxin, deletion of DNT, and replacement of 
ampG gene with the E coli ampG gene with a view to attenuating the potential 
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cytotoxicity of the TCT. However, no essential gene was deleted leaving the door to 
reversion to virulence of the partially detoxified vaccine candidate open. On the other 
hand, Mukkur et al. (2005) reported the development of a B pertussis vaccine 
candidate in which the aroQ gene of the aromatic biosynthesis pathway has been 
deleted and insertionally inactivated aroQBP vaccine. 
 
Common aromatic biosynthetic pathway is essential for synthesis of aromatic amino 
acids in eukaryotes and prokaryotes, and also precursors of aromatic compounds 
essential for the survival in prokaryotes (Garbe et al. 1991; Bottomley et al. 1996), 
chorismic acid being the precursor of key essential aromatic compounds including 
PABA, DHB and OSB (Hoiseth and Stocker 1981). It has been shown that type II 
dehydroquinase enzymes (Moore et al. 1992) in the aromatic biosynthetic pathway 
are multifunctional enzymes. The enzymes catalyse a second pathway, conversion of 
quinic acid to acetyl-CoA by quinate catabolic pathway (Garbe et al. 1991; Lalonde et 
al. 1994; Bottomley et al. 1996), which catalyse the inter-conversion of 3-
dehydroquinate and 3-dehydroshikimate and are related in sequence to the enzyme 
used in the catabolic pathway (Giles et al. 1985). 
 
The aroQBP vaccine candidate is deficient in synthesis of PABA, DHB, OSB and 
other aromatic compounds (Rossetti 1997; Cornford 1998). These metabolites are 
unavailable in the mammalian tissue and hence the avirulence of the aroQBP. It has 
been reported that aroQBP, in contrast to aroA, can colonise airways of mice 
efficiently and induce both humoral and cell mediated immunity without causing 
disease (Cornford-Nairn, PhD Thesis [under embargo, University of Southern 
Queensland]; Mukkur et al. 2005; Mukkur, Personal communication). Mice 
immunised with a single dose aroQBP were protected against an intranasal challenge 
with parental B pertussis strain. Serum anti-B pertussis antibodies of the IgG1 and 
IgG2 isotypes were induced which were enhanced post-challenge with the virulent 
parent. Vaccination of mice with two and three of the aroQBP vaccine further 
enhanced IgG1 and IgG2 levels and also induced anti-B pertussis pulmonary IgA 
levels. 
 
Given the recent whooping cough outbreaks reaching an epidemic stage despite 
extensive coverage with the acellular pertussis vaccine in developed world, it was 
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important to determine whether the Th2-polarised immune response, induced by the 
acellular pertussis vaccine (delivered as a combination vaccine, DTaP) could be 
polarised towards Th1 type by immunisation with the live attenuated aroQBP vaccine 
candidate. Answer to this question was obtained with the following experimental 
design using the pertussis mouse model (Table 2.4.5) 
 
In order to evaluate the nature of immune response generated following immunisation 
with aroQBP vaccine versus DTaP-immunised mice booster-vaccinated with aroQBP 
vaccine, four groups of 5 mice each were vaccinated with either DTaP with (Groups 
A and B) or without boosting (Groups C and D), with one or two doses of live 
aroQBP vaccine candidate. Mice immunised with the aroQBP only (Groups C and D) 
acted as controls for the booster-vaccinated groups (A and B). Five mice in each 
group were sham-vaccinated with PBS whereas the 5th group (Group E) constituted 
the sentinel group that was left untreated. 
 
3a.2.  Comparison of immune responses of mice 
vaccinated with aroQBP vaccine candidate with 
or without prior vaccination with DTaP 
	  
Due to the composition of the DTaP vaccine, which incorporates significant amounts 
of select B pertussis antigens, varying levels of antibody levels to killed whole cells or 
the selected purified antigens (FHA and PT) were detected using ELISA. Titration 
was carried out on each individual mouse serum sample. Titration for antibody 
isotypes of each individual mouse is presented in appendices I-L (page 165-250). 
However, due to scarcity, antibody, titration of the pulmonary homogenate samples 
for antibody isotypes were only carried out using killed whole B pertussis cells as an 
antigen. Antibody titers against purified pertussis toxin and filamentous 
haemagglutinin were not determined. 
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3a.3. Serum antibody responses 
 
IgG: DTaP-immunised mice that were booster-vaccinated with one dose of the 
aroQBP vaccine (Group A) developed significantly high antibody levels than those 
vaccinated with one dose of the aroQBP vaccine candidate (Group C) (P< 0.00002). 
On the other hand, IgG antibody isotype titers in mice vaccinated with two-doses 
(Group D) of aroQBP vaccine were significantly greater than those in the DTaP-
immunised mice booster-vaccinated with one dose of the aroQBP vaccine candidate 
(Group A) (P< 0.02) (Figure 3a.3). However, there was no significant difference 
between the antibody titers in mice immunised with two-doses of the aroQBP vaccine 
versus DTaP-vaccinated mice that booster-vaccinated with two-doses of the aroQBP 
vaccine candidate. 
  
	   79	  
 
Figure 3a.3. Serum IgG response of mice vaccinated with the aroQBP vaccine versus 
its use as a booster in DTaP-vaccinated mice. IgG titers of mice vaccinated with 
three-doses of DTaP vaccine and one-dose of aroQBP as booster blood sampled two 
weeks after the last vaccination at day 35 (Group A); IgG titers of mice vaccinated 
with three-doses of DTaP vaccine and two-doses of aroQBP as booster blood 
sampled 2 weeks after the last vaccination at day 42 (Group B); IgG titers of mice at 
day 14, two weeks after the last vaccination (Group C); IgG titers of mice vaccinated 
with two-doses of aroQBP blood sampled at day 21, two weeks after the last 
vaccination (Group D). BPWC was used as the coating antigen. 
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IgG1: All the groups except the group vaccinated with PBS (Group E) induced serum 
IgG1 responses against inactivated BPWC aroQ strain. IgG1 antibody level produced 
by Group B mice vaccinated with three-doses of DTaP subcutaneously and booster-
vaccinated with two-doses of aroQBP by i.n. route was significantly different from 
that of group A mice which received three-doses of DTaP subcutaneously and one-
dose booster of the aroQBP by the i.n. route (P< 0.05; Figure 3a.3a). There was no 
significant difference between the IgG1 antibody titers of mice booster-vaccinated 
with one dose of the aroQBP vaccine (Group A) versus those vaccinated with two-
doses of the aroQBP vaccine by the intranasal route (Group D) (P> 0.05; Figure 
3a.3a). However, there was a significant difference (P< 0.005) in the IgG1 antibody 
levels of mice booster-vaccinated with two-doses of the aroQBP vaccine (Group B) 
versus those immunised with two-doses of the aroQBP vaccine (Group D). 
 
Only one of five mice in Group C, vaccinated intranasally with one-dose of the 
aroQBP vaccine, produced detectable level of IgG1 to inactivated aroQ BPWC strain 
as the coating antigens (Table 3a.3). 
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Figure. 3a.3a. Serum IgG1 response of mice vaccinated with the aroQBP vaccine 
versus its use as a booster in DTaP-vaccinated mice. IgG1 titers of mice vaccinated 
with three-doses of DTaP vaccine and one-dose of aroQBP as booster blood sampled 
two weeks after the last vaccination at day 35 (Group A); IgG1 titers of mice 
vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as booster 
blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgG1 titers of 
mice at day 14, two weeks after the last vaccination (Group C); IgG1 titers of mice 
vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks after the 
last vaccination (Group D). BPWC was used as the coating antigen. 
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IgG2a: IgG2a antibody isotype titers of Groups B mice, representing DTaP-
immunised mice booster-vaccinated with two-doses of the aroQBP vaccine candidate 
by the i.n. route were significantly higher than Group A mice vaccinated with one 
booster dose of the aroQBP vaccine candidate (p<0.001). IgG2a response from four 
mice in Group A fell below the cut-off point (0.1, OD405nm) and they were assigned 
the IgG2a titer as zero (Figure 3a.3b, Table 3a.3). However, there was no significant 
difference between the IgG2a antibody titers of Group B versus mice in Group D 
which were vaccinated with two-doses of aroQBP vaccine (p>0.05). The IgG2a titers 
of 4/5 mice in Group A fell below the cut-off point (0.1 OD405nm) and were assigned 
the titer as zero (Figure 3a.3b,Table 3a.3). 
 
Figure. 3a.3b. Serum IgG2a response of mice vaccinated with the aroQBP vaccine 
candidate versus its use as a booster in DTaP-vaccinated mice. IgG2a titers of mice 
vaccinated with three-doses of DTaP vaccine and one-dose of aroQBP as booster 
blood sampled two weeks after the last vaccination at day 35 (Group A); IgG2a titers 
of mice vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as 
booster blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgG2a 
titers of mice at day 14, two weeks after the last vaccination (Group C); IgG2a titers 
of mice vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks 
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IgA: All the absorbance values for the serum IgA response of all the groups at the 
starting dilution (1/100) was below the selected cut-off point (0.1 OD405nm). Hence it 
was decided to estimate antibody titers using the highest single point value x 100 to 
represent relative IgA content. All groups of mice, except the sham-vaccinated mice 
in each group, produced IgA isotype specific antibodies. Mice in Group D that had 
received two-dose of the aroQBP vaccine showed the highest IgA antibody levels 




Figure. 3a.3c. Serum IgA response of mice vaccinated with the aroQBP vaccine 
versus DTaP-immunised, aroQBP-booster vaccinated mice. IgA titers of mice 
vaccinated with three-doses of DTaP vaccine and one-dose of aroQBP as booster 
blood sampled two weeks after the last vaccination at day 35 (Group A); IgA titers of 
mice vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as 
booster blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgA 
titers of mice at day 14, two weeks after the last vaccination (Group C); IgA titers of 
mice vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks after 
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Table 3a.3. Serum antibody titers of DTaP vaccine-immunised mice post-
intranasal booster vaccination with one or two doses of live 



















IgG	   2656±606	   9,480±347	   358±110*	   6560±1371	  
IgG1	   1430±429	   3983±929	   71±71**	   806±161	  
IgG2a	   100±100*	   1009±231	   0*** 	   1204±114	  
IgA	   1.2±0.029 1.2±0.092 1.2±0.026 2.2±0.039 
*Value	  calculated	  from	  one	  mouse;	  antibodies	  in	  other	  mice	  were	  not	  detectable.	  
**Value	  calculated	  from	  one	  subject;	  antibodies	  in	  other	  mice	  were	  not	  detectable.	  
***OD<0.1	  for	  all	  five	  mice.	  
 
 
3a.4. Pulmonary antibody response to aroQBP 
 
IgG: Vaccinated mice in all the groups (A, B, C, D) except sham vaccinated mice in 
each group and the sentinel mice (Group E) produced serum IgG responses against 
inactivated BPWC aroQ.  Mice in Group D, vaccinated with two-doses of aroQBP by 
the i.n. route, produced the highest level of IgG (Figure 3a.4). The second highest 
level of IgG antibody was produced in mice booster-vaccinated with two-doses of the 
aroQBP vaccine (Group B) (Figure 3a.4, Table 3a.4) that was not significantly 
different from that of Group D (P>0.05). However, there was a significant difference 
between the IgG antibody titers of DTaP-vaccinated mice booster-vaccinated with 
one dose of the aroQBP vaccine (Group A) versus those vaccinated with the aroQBP 
vaccine by the i.n. route (Group D) (P< 0.003) which produced higher antibody titers. 
However, there was no significant difference (P> 0.05) in the IgG antibody levels of 
mice booster-vaccinated with two booster doses of the aroQBP vaccine (Group B) 
versus those immunised with two doses of the aroQBP vaccine (Group D) as 
observed with serum antibody responses. 
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Figure. 3a.4. Pulmonary IgG response of mice vaccinated with the aroQBP vaccine 
versus its use as a booster in DTaP-vaccinated mice. IgG titers of mice vaccinated 
with three-doses of DTaP vaccine and one-dose of aroQBP as booster blood sampled 
two weeks after the last vaccination at day 35 (Group A); IgG titers of mice 
vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as booster 
blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgG titers of 
mice at day 14, two weeks after the last vaccination (Group C); IgG titers of mice 
vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks after the 
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IgG1: DTaP-immunised mice booster-vaccinated with two-doses of aroQBP vaccine 
(Group B) produced the highest IgG1 levels in lung homogenates among all the 
vaccinated groups of mice (Figure 3a.4a, Table 3a.4), which were significantly 
different from that produced by mice booster-vaccinated with one dose of the aroQBP 
vaccine candidate (Group A) (P<0.004) or mice vaccinated two-doses of the aroQBP 
vaccine (Group D) (P<0.0004). IgG1 antibody titers of DTaP-immunised mice 
booster-vaccinated with one dose of the aroQBP vaccine (Group A) were also 
significantly greater (P<0.0009) than that in mice vaccinated with two-doses of the 
aroQBP vaccine (Group D). 
	  
	  
Figure. 3a.4a. Pulmonary IgG1 response of mice vaccinated with the aroQBP 
vaccine versus its use as a booster in DTaP-vaccinated mice. IgG1 titers of mice 
vaccinated with three-doses of DTaP vaccine and one-dose of aroQBP as booster 
blood sampled two weeks after the last vaccination at day 35 (Group A); IgG1 titers 
of mice vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as 
booster blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgG1 
titers of mice at day 14, two weeks after the last vaccination (Group C); IgG1 titers of 
mice vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks after 
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IgG2a: The IgG2a levels, albeit low, were significantly higher in groups B and D 
representing 2-dose aroQBP booster-vaccinated (Group B) and aroQBP vaccinated 
mice (Group D) respectively (Figure 3a.4b, Table 3a.4). Essentially no antibody 
response was detectable in Group C mice that had been vaccinated with one dose of 
the aroQBP vaccine candidate. The IgG2a isotype titer of mice in Group A that had 
been booster-vaccinated with only one dose of the aroQBP vaccine candidate was 
significantly lower than that of mice in Groups B (booster-vaccinated with 2 aroQBP 
doses) (P<0.0007). There was no significant difference (P> 0.05) in the IgG antibody 
levels of mice booster-vaccinated with one-dose of the aroQBP vaccine (Group A) 
versus those immunised with two doses of the aroQBP vaccine (Group D). 
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Figure. 3a.4b. Pulmonary IgG2a response of mice vaccinated with the aroQBP 
vaccine versus its use as a booster in DTaP-vaccinated mice. IgG2a titers of mice 
vaccinated with three-doses of DTaP vaccine and one-dose of aroQBP as booster 
blood sampled two weeks after the last vaccination at day 35 (Group A); IgG2a titers 
of mice vaccinated with three-doses of DTaP vaccine and two-doses of aroQBP as 
booster blood sampled 2 weeks after the last vaccination at day 42 (Group B); IgG2a 
titers of mice at day 14, two weeks after the last vaccination (Group C); IgG2a titers 
of mice vaccinated with two-doses of aroQBP blood sampled at day 21, two weeks 
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Secretory IgA (s-IgA): The IgA antibody isotype levels in the lung homogenates were 
almost as low as those observed in the serum in all the experimental groups.  
Regardless of the overall low levels of s-IgA, the levels of this isotype in aroQBP 
vaccinated mice (Group D) or DTaP-immunised mice booster-vaccinated aroQBP 




Figure. 3a.4c. Pulmonary s-IgA response of mice vaccinated with the aroQBP 
vaccine versus DTaP-vaccinated mice. s-IgA titers of mice vaccinated with three-
doses of DTaP vaccine and one-dose of aroQBP as booster blood sampled two weeks 
after the last vaccination at day 35 (Group A); s-IgA titers of mice vaccinated with 
three-doses of DTaP vaccine and two-doses of aroQBP as booster blood sampled 2 
weeks after the last vaccination at day 42 (Group B); s-IgA titers of mice at day 14, 
two weeks after the last vaccination (Group C); s-IgA titers of mice vaccinated with 
two-doses of aroQBP blood sampled at day 21, two weeks after the last vaccination 
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Table 3a.4.  Pulmonary homogenate antibody titers of aP vaccine-immunised 
mice post-intranasal booster vaccinisation with one or two doses of 




















IgG 71±3 281± 60 54±11 321±61 
IgG1 68±2.7 287±67 Not detectable 11±11 
IgG2a 13±13 75±5.5 Not detectable 63±3.4 
IgA 0.6±0.04 1±0.15 0.5±.01 0.7±0.09 
	  
 
3a.5. Serum antibody responses to pertussis toxin 
 
The IgG antibody titers of mice immunised with one (Group C) or two-doses of 
aroQBP vaccine (Group D) were significantly lower (P< 0.05) than those of DTaP-
immunised mice booster-vaccinated with aroQBP vaccine candidate (Figure 3a.5) 
(P< 0.044). While there was a significant difference between the antibody levels of 
mice vaccinated with two versus one booster vaccination with the aroQBP vaccine 
candidate, there was no significant difference in the IgG1 levels between the two 
groups (Figure 3a.5a). The IgG2a antibody levels in all the vaccinated groups were 
quite low (<100) (Figure 3a.5b). There was no significant difference in the IgA 
antibody isotype titers of mice booster-vaccinated with one or 2 doses of the aroQBP 
vaccine candidate (Group A versus B) (Figure 3a.5c). IgA antibody was undetectable 
in groups (Group C and D) that received the one or 2 doses of the aroQBP vaccine 
intranasally respectively (Figure 3a.5c, Table 3a.5). 
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Figure. 3a.5. Serum IgG antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
pertussis toxin. IgG titers of mice vaccinated with three-doses of DTaP vaccine and 
one-dose of aroQBP as booster blood sampled two weeks after the last vaccination at 
day 35 (Group A); IgG titers of mice vaccinated with three-doses of DTaP vaccine 
and two-doses of aroQBP as booster blood sampled 2 weeks after the last vaccination 
at day 42 (Group B); IgG titers of mice at day 14, two weeks after the last vaccination 
(Group C); IgG titers of mice vaccinated with two-doses of aroQBP blood sampled at 
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Figure. 3a. 5a. Serum IgG1 antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
pertussis toxin. IgG1 titers of mice vaccinated with three-doses of DTaP vaccine and 
one-dose of aroQBP as booster blood sampled two weeks after the last vaccination at 
day 35 (Group A); IgG1 titers of mice vaccinated with three-doses of DTaP vaccine 
and two-doses of aroQBP as booster blood sampled 2 weeks after the last vaccination 
at day 42 (Group B); IgG1 titers of mice at day 14, two weeks after the last 
vaccination (Group C); IgG1 titers of mice vaccinated with two-doses of aroQBP 
blood sampled at day 21, two weeks after the last vaccination (Group D). PT was 
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Figure. 3a. 5b. Serum IgG2a antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
pertussis toxin. IgG titers of mice vaccinated with three-doses of DTaP vaccine and 
one-dose of aroQBP as booster blood sampled two weeks after the last vaccination at 
day 35 (Group A); IgG2a titers of mice vaccinated with three-doses of DTaP vaccine 
and two-doses of aroQBP as booster blood sampled 2 weeks after the last vaccination 
at day 42 (Group B); IgG2a titers of mice at day 14, two weeks after the last 
vaccination (Group C); IgG2a titers of mice vaccinated with two-doses of aroQBP 
blood sampled at day 21, two weeks after the last vaccination (Group D). PT was 
used as coating antigen. 
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Figure. 3a.5c. Serum IgA antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
pertussis toxin. IgG titers of mice vaccinated with three-doses of DTaP vaccine and 
one-dose of aroQBP as booster blood sampled two weeks after the last vaccination at 
day 35 (Group A); IgA titers of mice vaccinated with three-doses of DTaP vaccine 
and two-doses of aroQBP as booster blood sampled 2 weeks after the last vaccination 
at day 42 (Group B); IgA titers of mice at day 14, two weeks after the last vaccination 
(Group C); IgA titers of mice vaccinated with two-doses of aroQBP blood sampled at 




Table 3a.5.  Serum antibody titers of aP vaccine-immunised mice post-
intranasal immunisation with one or two doses of the live 

















IgG	   2108±578	   3547±309	   <100	   <100	  
IgG1	   1905±259	   2378±468	   <100	   <100	  
IgG2a	   <100	   <100	   <100	   <100	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3a.6. Serum antibody response to filamentous hemagglutinin 
 
IgG: Mice immunised with one or two doses of the aroQBP vaccine candidate 
produced very low levels of IgG detectable by ELISA. On the other hand, significant 
levels of IgG antibody were produced by DTaP immunised mice booster-vaccinated 
with one (Group A) or two (Group B) doses of the aroQBP vaccine. However, there 
was no significant difference observed in the IgG titers of Groups A and B (Figure 




Figure. 3a.6. Serum IgG antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
filamentous hemagglutinin. IgG titers of mice vaccinated with three-doses of DTaP 
vaccine and one-dose of aroQBP as booster blood sampled two weeks after the last 
vaccination at day 35 (Group A); IgG titers of mice vaccinated with three-doses of 
DTaP vaccine and two-doses of aroQBP as booster blood sampled 2 weeks after the 
last vaccination at day 42 (Group B); IgG titers of mice at day 14, two weeks after the 
last vaccination (Group C); IgG titers of mice vaccinated with two-doses of aroQBP 
blood sampled at day 21, two weeks after the last vaccination (Group D). FHA was 
used as coating antigen. 
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IgG1: IgG1 was the predominant isotype in DTaP-immunised mice booster 
vaccinated with one or two doses of aroQBP vaccine candidate (Figure 3a.6a, Table 




Figure. 3a. 6a. Serum IgG1 antibody isotype response of mice vaccinated with the 
aroQBP vaccine versus DTaP-immunised aroQBP-booster vaccinated mice to 
filamentous hemagglutinin. IgG titers of mice vaccinated with three-doses of DTaP 
vaccine and one-dose of aroQBP as booster blood sampled two weeks after the last 
vaccination at day 35 (Group A); IgG1 titers of mice vaccinated with three-doses of 
DTaP vaccine and two-doses of aroQBP as booster blood sampled 2 weeks after the 
last vaccination at day 42 (Group B); IgG1 titers of mice at day 14, two weeks after 
the last vaccination (Group C); IgG1 titers of mice vaccinated with two-doses of 
aroQBP blood sampled at day 21, two weeks after the last vaccination (Group D). 
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IgG2a: Presence of anti-FHA IgG2a was either not detectable (Group A, C, D) or was 
limited to one of five mice (Group B) (Table 3a.6). 
 
IgA: No anti-FHA IgA antibody isotype was detectable in any of vaccinated groups 
(Table 3a.6). 




Table 3a.6.  Serum antibody titres of aP vaccine-immunised mice post-
intranasal immunisation with one or two doses of the live 

















IgG	   1552±129	   1514±140	   <100	   <100	  
IgG1	   1542±216	   1307±319	   ND	   ND	  
IgG2a	   ND	   595	   ND	   <100	  
s-­‐IgA	   ND	   ND	   ND	   ND	  
ND: Not detectable 
 
 
3a.7.  Evaluation of CMI response in mice immunised 
with the aroQBP vaccine candidate versus DTaP-
immunised mice booster-vaccinated with the 
aroQBP vaccine candidate using interferon- 
gamma as an indirect indicator 
 
Induction of CMI immunity in mice subjected to the different immunisation regimes 
was assessed using IFN-γ as an indirect indicator. One complex antigen comprising 
killed BPWC and one purified antigen, FHA as model antigen, were selected for 
stimulation of splenocytes from immunised mice for assessment of CMI. Production 
of IFN-γ was determined at day 28 post-immunisation. 
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3a.7.1. IFN-γ  levels in BPWC-stimulated splenocyte supernatant 
	  
Mice in Group D that had received two-doses of the aroQBP vaccine candidate by the 
i.n. route were found to produce the highest level of IFN-γ compared to the other 
groups (Figure 3a. 7.1, Table 3a.7). However, there was no substantial difference 
between the levels of IFN-γ produced by DTaP-immunised aroQBP booster-
vaccinated groups of mice that had received either one (Group A) or two doses 
(Group B) of the aroQBP booster. Mice in Group C that had received one-dose of B 
pertussis aroQ by the i.n. route produced the lowest level IFN-γ. No IFN-γ was 
produced by the antigen-stimulated splenocytes of sham-vaccinated mice. For this 
experiment, splenocytes in each group were pooled to ensure availability of adequate 
number of cells for antigen stimulation, thereby precluding calculation of standard 
error estimates. 
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Figure. 3a.7.1. Concentration of IFN-γ produced by BPWC- stimulated splenocytes of 
mice immunised using different vaccination regimes. Group A mice were vaccinated 
with 3 doses of DTaP followed by booster vaccination with one i.n. dose of the 
aroQBP vaccine candidate whereas mice in Group B were given 2 i.n. doses of the 
aroQBP vaccine. Group C had received one i.n. dose of the aroQBP vaccine 
candidate whereas mice in Group D were administered 2 doses of the aroQBP 
vaccine candidate by the i.n. route. 
 
 
Table 3a.7.  Average IFN-γ  levels of DTaP-immunised mice post-intranasal 
immunisation with one or two doses of the live attenuated aroQBP 
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3a.7.2. IFN-γ  levels in FHA-stimulated splenocyte supernatants 
	  
Group D mice that had received two-doses of the aroQBP vaccine by the intranasal 
route were found to produce highest level of IFN-γ compared to the other groups 
(Figure 3a.7.2, Table 3a.7.2). Group C mice that had received one-dose of B pertussis 
aroQBP by intranasal route induced second highest IFN-γ production. On the other 
hand booster vaccination of the DTaP-immunised mice with one or two doses of the 
aroQBP vaccine candidate produced comparable amounts of IFN-γ levels (Figure 
3a.7.2, Table 3a.7.2). 
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Figure. 3a.7.2. Concentration of IFN-γ produced by FHA-stimulated splenocytes of 
mice immunised using different vaccination regimes. Group A mice were vaccinated 
with 3 doses of DTaP followed by booster vaccination with one i.n. dose of the 
aroQBP vaccine candidate whereas mice in Group B were given 2 i.n. doses of the 
aroQBP vaccine. Group C had received one i.n. dose of the aroQBP vaccine 
candidate whereas mice in Group D were administered 2 doses of the aroQBP 
vaccine candidate by the i.n. route. 
	  
 
Table 3a.7.2.  IFN-γ  levels in FHA-stimulated splenocyte supernatants of 
aroQBP vaccinated mice versus DTaP-immunised mice subjected 
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3a.8. Discussion 
	  
A study carried out previously at the University of Southern Queensland (Cornford 
2003) revealed that immunisation of mice with three-doses of DTaP induced a high 
level of IgG, IgG1, and essentially no IgG2a but no production of IL-12 or IFN-γ. 
Therefore, the DTaP group was not included in this study due to the animal ethics 
regulations requiring application of the “Reduce, Refine and Replacement” Strategy 
(National Health and Medical Research Council 2004). It was clear that booster 
vaccination of mice, previously vaccinated with acellular pertussis components-
containing vaccine (DTaP), with the aroQBP vaccine candidate resulted in 
polarisation of immune response from Th2 type to Th1 type as judged by the 
production of IFN-γ as an indirect indicator of CMI as well production of IgG2a, an 
isotype associated with induction of CMI. Mice booster-immunised with two-doses of 
the aroQBP vaccine yielded significantly higher levels of IgG, IgG1, and IgG2a as 
compared with the one-dose booster. Immunisation of mice with two-doses of the 
aroQBP vaccine as the primary vaccine also yielded high levels of anti-BPWC 
antibodies as observed with the DTaP-aroQBP booster vaccinated mice. However, 
the serum and mucosal IgA responses against BPWC were low. On the other hand, 
whereas anti-whole cells B pertussis IgG2a was not detectable in the lung 
homogenates of mice vaccinated with one of the aroQBP B pertussis vaccine 
candidate, low levels of this antibody isotype were detectable in mice either 
immunised with two-doses of the aroQBP B pertussis vaccine or in DTaP-immunised 
mice subjected to booster vaccination with one or two doses of the aroQBP vaccine. 
Low levels of IgA observed in the lung homogenates of immunised mice regardless of 
the immunisation regime were consistent with low serum IgA levels. Previous studies, 
presented as an abstract at the ASM meeting (2005), reported induction of detectable 
moderate levels of anti-FHA and anti-PT antibodies of the isotypes IgG1 and IgG2a 
in mice vaccinated with aroQBP that were measured using dot blotting rather than an 
ELISA assay used in this investigation. This disparity appears to be due to the 
potential lower sensitivity of the ELISA as compared to the dot-blotting assay 
(Gerthoffer and Ba; Lin-Chao, Chen, and Wong 1992). 
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Induction of high levels of IFN-γ by BPWC stimulated splenocyte of DTaP-
vaccinated mice following booster-vaccination with either one or two doses of live 
attenuated aroQBP vaccine candidate clearly indicated polarisation of immune 
response to Th1-type. Similar was the case when FHA of B pertussis was used as the 
model antigen to stimulate splenocytes. The production of IFN-γ by stimulation of 
splenocyte with other virulence antigens such as pertussis toxoid and pertactin was 
not carried out because of shortage in the availability of sufficient number of 
splenocytes. This experiment needs to be carried out but could not be accomplished 
because of time constraints. Subject to confirmation, the polarisation of immune 
response to Th1-type by booster vaccination of DTaP-immunised mice raises the 
possibility of evaluating the efficacy of the aroQBP vaccine candidate in adolescent 
and adults previously immunised with acellular pertussis vaccines. However, it will 
be important to detoxify the aroQBP vaccine candidate, particularly with respect to 
the immunosuppressive toxins particularly adenylate cyclase and pertussis toxin 
(Paccani et al. 2011; Carbonetti et al. 2005), prior to execution of confirmatory 
studies, hence the next phase attempted in this investigation describing the different 
strategies evaluated for detoxification of adenylate cyclase, which was selected 
because a method for the detoxification of pertussis toxin has already been reported 
(Mielcarek, Debrie, Raze, Quatannens, et al. 2006). 
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3b. Evaluation of different strategies for genetic 




Mechanisms of ACT function have been the subject of many investigations due to the 
fundamental role of this enzyme in cellular signalling. It has been established that 
adenylate cyclase is an important virulence factor in the pathogenicity of B pertussis 
(Goodwin and Weiss 1990; Ohnishi et al. 2008). ACT enters eukaryote host cells 
resulting in an abnormal increase in cAMP synthesis in the host, that in turn perturbs 
normal cellular functions (Confer and Eaton 1982; Friedman, Farfel, and Hanski 
1987). Intracellular ACT is activated by binding to calmodulin, a eukaryotic specific 
regulatory protein (Masure, Shattuck, and Storm 1987; Glaser et al. 1988; Wolff et al. 
1980). Moreover, a study carried out by Weiss et al. (1984) has established that ACT 
deficient B pertussis is avirulent. Hence ACT deficient B pertussis is an interesting 
potential candidate for a vaccine. 
 
 In this study site directed mutagenesis of the cyaA gene in aroQBP was attempted to 
generate a double mutant variant of aroQBP that retained broad antigenicity and 
would be less likely to revert to wild type. It is known that the lysine 58 residue 
encoded by cyaA is critical for ACT to catalyse the synthesis of cAMP in eukaryotic 
cells (Au, Masure, and Storm 1989). This function is achieved via the positively 
charged amino group of lysine 58 binding to the negatively charged phosphate group 
of adenosine triphosphate (ATP) (Fry, Kuby, and Mildvan 1985), thereby resulting in 
elevated cAMP in the eukaryotic cell (Gerlt, Coderre, and Wolin 1980). 
 
The following strategy was followed. 
 
1) To achieve the aim the first 1000 bases of the cyaA gene of B pertussis Tohama I 
(NCBI reference sequence NC_0022929.2 bases 776227-777240) was PCR 
amplified with a BamH1 and EcoRI cleavage sites at the flanking 5ʹ′ and 3ʹ′ ends, 
respectively (Figure 3b.1). 
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2) Site directed mutagenesis was then undertaken to mutate the AAA codon for 
lysine 58 to an ATG codon for methionine in the cyaA DNA fragment. 
3) Mutated sequences were confirmed by sequencing as follows. The mutated cyaA 
oligonucleotides were cloned into the following vectors, pJQ200mp 18-rspL, and 
the pSS1129 B pertussis suicide vector. Detection of mutation was initially 
performed by PCR amplification of a 210-base pair amplicon of the cyaA insert 
using putative mutant clones lifted from the conjugation plates as template. 
Finally, the sequence of the 1kb cyaA insert fragment was determined from clones 
also lifted from the conjugation plates. 
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Figure 3b.1. Sequence (5’-3’) of the 1kb fragment of the B pertussis Tohama I cyaA 
locus subjected to site directed mutagenesis. BamHI and EcoRI cleavage sites are 
underlined. The first base of the sequence is shown (776227 from NC_002929.2). 
Yellow highlighted nucleotides show the AAA codon (for lysine 58, sequence 173-
175). Arrows 1 and 2 show primers used for amplification of the 1kb cyaA fragment. 
Arrows 3 and 4 identify primers used for site directed mutagenesis (ATG nucleotides 
were substituted for the AAA nucleotides). Two different primers were used to screen 
for mutants as shown by arrow 5 (FwATG-mutant and FwAAA-wild type) and one 
reverse primer shown by arrow 6. 
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3b.2. Amplification and cloning of cyaA insert fragment into 
different vectors 
	  
The cyaA insert sequence was amplified using primers as described in the 
methodology section (Table 2.13a). PCRs were performed for the cyaA insert at 
temperatures between 560C and 670C. A product of the expected size (1kbp) was 
produced at all temperatures tested. An annealing temperature of 570C was chosen for 
subsequent work since less nonspecific amplification occurred as shown by gel 
electrophoresis.  
 
3b.2.1. Digestion and cloning of cyaA insert into pUC19 
 
The cyaA insert, flanked by 5’ BamHI and 3’ EcoRI cleavage sites, was amplified, 
double digested with BamHI and EcoRI and cloned into similarly digested pUC19 
plasmid. Ligation of excised cyaA-(BamHI-EcoRI) fragment with the pUC19-
(BamHI-EcoRI) fragment was attempted with varying insert:vector molar ratios and 
ligation temperatures. Forty-six colonies picked from ligation plates were screened, 
most of which exhibited small (pin point) morphology (Section 2.14). Only two of the 
larger colonies contained the vector with the insert sequence. The two positive 
colonies were grown in 2 x 10ml LB-(100µl/ml Amp) as described in section 2.1.2. 
The pUC19 vectors were extracted from E coli DH5α and subjected to double and 
single digestion with BamHI-EcoRI and BamHI. Neither vector contained the desired 
cyaA insert sequence; only digest fragments of size ≈1.5kb and ≈0.7kb, were observed 
(Figure 3b.2.1a-b). 
  






















	    
Figure. 3b.2.1a. Agarose gel electrophoresis (0.8%) showing double 
and single digestion of a ligated fragment (pUC19 plus cyaA 
fragment) extracted from E coli DH5α. Lane 1, 1kb marker. Lane 2, 
double digestion of the ligated plasmid with BamHI and EcoRI 
showing two fragments: A fragment with expected size of pUC19 
(2.686kb), and a ≈1.5kb fragment. Lane 3, undigested pUC19. 
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Figure. 3b.2.1b. Gel electrophoresis showing double and single digestion of a 
ligated fragment with insert (ligation of pUC19 and the cyaA fragment insert) 
extracted from E coli DH5α. Lane 1, 1kb marker. Lane 2, single digestion of the 
ligate with BamHI. Lane3, double digestion of the ligate with BamHI and 
EcoRI showing two fragments: A fragment with expected size of pUC19, 
2.686kb, and a fragment with size of ≈0.8kb. Lane 4, undigested ligate. Lane 5, 
undigested pUC19. Lane 6, single digestion of pUC19 with BamHI. Lane 7, 
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3b.2.2.  Digestion and cloning of cyaA insert into pGEM-T Easy 
Vector System and subsequent subcloning of cyaA insert 
into pUC19 
	  
Difficulties experienced in cloning the cyaA insert directly into pUC19 led to use of 
the pGEM-T Easy Vector System II. The PCR amplified cyaA insert was double 
digested with BamHI and EcoRI. The excised cyaA fragment was isolated by gel 
electrophoresis purified as described previously, prior to cloning into the pGEM-T 
Easy Vector using the manufacturer’s instructions (Figure 2.14.1). The pGEM vector 
with its 1kb cyaA inserted fragment was again subjected to double digestion with 
BamHI and EcoRI and the cyaA insert fragment isolated and purified as previously 
described. The purified cyaA fragment was once again cloned into double digested 
pUC19 (BamHI and EcoRI). The pUC19 vector with its successfully incorporated 











1 2 3 4 
Figure.	  3b.2.2.	  Incorporation	  of	  the	  1kb	  CyaA	  fragment	  from	  the	  pGEM	  vector	  into	  the	  
pUC19	  vector.	  Lane	  1.	  1kb	  marker.	  Lane	  2,	  double	  digest	  of	  pUC19Cya	  with	  BamHI	  and	  
EcoRI.	   Showing	   two	   fragments-­‐the	   1kb	   Cya	   insert	   and	   the	   pUC19	   vector	   (2.648kb).	  
Lane	  3,	  undigested	  pUC19Cya	  vector.	  Lane	  4,	  the	  expected	  ≈	  3.7kb	  fragment	  following	  
digestion	  of	  the	  vector	  plus	  inserted	  fragment	  with	  EcoR1. 
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Figure. 3b.2.2b. Schematic drawing of vector pUC19CyaMut which was generated in 
this study. 
Following of unsuccessful direct cloning of CyaMut fragment into pUC19, the insert 
initially was cloned into the pGEM vector. The vector was subsequently cloned into 
pUC19 vector after its transformation to E coli DH5α, vector extraction, and excision 
of the insert from pGEM vector by BamHI and EcoRI restriction enzymes. Double 
digested CyaMut-(BamHI-EcoRI) and pUC19-( BamHI-EcoRI) were ligated the 
resulted pUC19CyaMut was used for subsequent experiments. 
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3b.3.  Mutation of lysine 58 to Methionine (AAA-to-
ATG) in the pUC19Cya vector 
	  
The purified pUC19Cya vector was subjected to site directed mutagenesis in an 
attempt to induce the desired K -> M mutation using the same procedures as 
described previously (Section 2.15). Twenty five colonies picked from the nutrient 
plate following the site directed mutagenesis procedure were screened (Section 
2.13.4) for the pUC19Cya mutated vector following transformation of XL10-Gold 
Ultracompetent Cells. All of the colonies tested contained the vector (Figure 3b.3). A 
colony of the transformed XL10-Gold Ultracompetent Cells was grown over night 
and the vector extracted. E coli DH5α was transformed with the extracted pUC19Cya 
mutant vector as a means of preserving the plasmid and for future use. 
	  
The pUC19CyaMut vector was extracted from the E coli DH5α and double digestion 
with BamHI and EcoRI. The product was isolated and purified as described 
previously and sequenced.  Sequencing of both the original 1kb Cya fragment and the 
pUC19Cya mutant vector confirmed that the desired mutation at lysine 58 codon 
(AAA-to-ATG) was present. The pUC19 vector harbouring the mutated cyaA 
fragment is referred to hereafter as pUC19CyaMut. This vector was then used to 
transform E coli SM10 λ pir for use in conjugation with B pertussis aroQ strains as 
described briefly below and more fully in chapter 2 in sections 16.4 and 17.3. 
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Figure 3b.3. Gel electrophoresis showing transformation of XL10-Gold 
Ultracompetent Cells with the pUC19CyaMut vector. Lane 1, 1 kb marker; Lanes 
2-6 showing the pUC19CyaMut vector (bands between 2kb and 3kb) and 
chromosomal DNA (bands above 10kb marker) extracted from six distinct 
transformed XL10-Gold Ultracompetent Cells colonies picked from site directed 
mutagenesis nutrient plates; Lane 7, pUC19 vector used as a control for 
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3b.4.  Discrimination between wild type and mutant B 
pertussis aroQ at the lysine 58 codon by PCR 
 
Three individual primers were designed to detect the mutated ATG codon in B 
pertussis aroQ mutant colonies following conjugation with the E coli SM10 λ pir 
harbouring the suicide vectors pJQ200mp 18-rspLCyaMut or pSS1129CyaMut 
vectors. Two oligonucleotides, (wild type 5’-3’ AAA, and mutant 5’-3’ ATG - 
identical except for the two nucleotides at their 3ʹ′ ends), were used as forward 
primers. The reverse primer (RvsATG) was used in conjunction with either of the two 
forward primers to discriminate between the wild type and mutant Cya fragment 
(Table 2 13a, Figure 3b.1).  The amplicon produced by these two PCR reactions were 
expected to be 210-bp for the mutated cyaA fragment and no amplicon product using 
the forward primer incorporating the AAA codon at its 3’ end. 
 
3b.4.1. Standardization of mutation detection by PCR 
	  
The wild type and mutant discriminatory primers described above (Table 2.13a) were 
also employed to detect the lysine (K-AAA) to methionine (M-ATG) mutation in 
conjugated variants of the aroQBP strain. At annealing temperatures ranging from 
570C to 640C the wild type forward primer did amplify the expected 210-base pair 
sequence (see Table 2.13c for cycling condition). However, PCR amplification with 
the mutant forward primer (FwATG) was greatly reduced or non-existent. These 
results are shown in Figure 3b.4.1. 
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Figure.3b.4.1. Detection of the lysine to methionine mutation in the CyaA fragment 
in aroQBP using PCR with the discriminatory primers. Each well contained 5µl of 
amplicon. 
 Row I. Lane 1, 100bp marker. Lanes 2-9, Gel electrophoresis showing the 210- 
base pair sequence from aroQBP strain with the native primer at annealing 
temperatures from 57-64
0
C, respectively.  Lane 10, negative control. 
Row II. Lane 1, 100bp marker. Lane 2-9 Absence of the expected 210-base pair 
sequence at annealing temperatures from 57-64
0
C with the mutant primer; Lane 
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3b.4.2.  Detection of the lysine to methionine mutation in vectors 
harbouring the non mutated and mutated Cya 
fragments. 
  
To confirm that the PCR reaction can discriminate between wild type and mutated 
Cya fragments within vectors, amplifications were performed on PSS1129CyaMut 
and pCU19Cya vectors (see Table 3b.4.1 for templates and primers). The results of 
this experiment are shown in Figure 3b.4.1 PCR of PSS1129 with the mutant specific 
primers showed the expected 210-base pair amplicons. However PCR with the wild 
type primers still resulted in 210-base pair amplicons but in much reduced 
concentrations. PCR amplifications using the pUC19Cya template showed strong 
amplification with the wild type primers and still present but in reduced 
concentrations with the mutant primer pair. It can be seen also that the PCRs were not 
sensitive to the annealing temperatures used. Although these PCRs were clearly not 
specific for the mutated versus the wild type Cya fragment, the differential 
concentrations of amplicon produced were considered useful as an internal control. 
Reasons for the lack of specificity are included in the discussion. 
 
 
Table 3b.4.1. Templates and primers used to amplify the 210-base pair sequence. 
 
Template pSS1129CyaMut pSS1129CyaMut pUC19Cya pUC19Cya 
Forward 
primer 



















1 2 3 4 5 6 7 8 9 10 11 
1 2 3 4 5 6 7 8 9 10 11 
Figure 3b.4.2 PCR amplification of mutated and wild type Cya fragments with 
native and mutant designed primer pairs. 
Row I. Amplification of the PSS1129CyaMut vector. Lane 1, 100bp marker. Lane, 
2-6 PCR amplification of pSS1129CyaMut using the mutant primers; with 




C. The expected 210-base pair band 
is present. Lane 6, negative control. Lane 8-10, amplification of pSS1129CyaMut 
with wild type primers using the same range of annealing temperatures. The 210-
base pair band is still present but at reduced concentrations. Lane 11, negative 
control.  
Row II. Amplification of the pUC19Cya vector. Lane 1, 100bp marker. Lane, 2-6 
PCR amplification of pUC19Cya using the mutant primer; with annealing 




C. The 210-base pair band is still present but 
at reduced concentrations. Lane 6, negative control. Lane 8-10, amplification of 
pUC1Cya with wild primers using the same range of annealing temperatures. The 
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3b.5.  Attempts to produce B pertussis aroQ variants by 
conjugation using two suicide vectors incorporating 
CyaMut 
 
Attempts to introduce the lysine to methionine mutation into the cyaA gene of 
aroQBP were performed by conjugation with E coli SM10 λ pir harbouring two 
suicide vectors. Two conjugation partners were used 
 
1) E coli SM10 λ pir harbouring pJQ200mp 18-rspLCyaMut. 
2) E coli SM10 λ pir harbouring pSS1129CyaMut.  
 
3b.5.1.  Ligation of cyaA mutant insert into pJQ200mp 18-rspL, 
Bordetella suicide vector, and transfer into aroQBP  by 
conjugation 
	  
Use of pJQ200mp 18-rspL Bordetella suicide vector represents the first strategy 
aimed at generating a B pertussis aroQ variant in which the adenylate cyclase gene 
has been altered so that its product is non-toxic. The pUC19CyaMut vector was 
extracted from an overnight culture of E coli DH5α in LB-(Amp100µg/ml) broth as 
described in Chapter 2, Section 11.12. Following double digestion (BamH1, EcoRI), 
isolation by gel electrophoresis and purification the CyaMut 1kbp fragment was 
cloned into double digested pJQ200mp 18-rspL with BamHI-EcoRI (Figure 3b.5.1a), 
(see Chapter 2, Section 16 for methodology). Successful cloning of CyaMut insert 
into pJQ200mp 18-rspL was confirmed by gel electrophoresis of a BamHI and EcoRI 
double digest as shown in Figure 3b.5.1. 
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Figure 3b.5.1a. Schematic drawing of vector pJQ200mp 18-rspLCyaMut which was 
generated in this study. 
The CyaMut fragment was excised pUC19CyaMut extracted from E coli DH5α by 
BamHI and EcoRI restriction enzymes. The CyaMut-(BamHI-EcoRI) insert and 
double digested pJQ200mp 18-rspL-(BamHI-EcoRI) vector were ligated. The resulted 
vector, pJQ200mp 18-rspLCyaMut, was exploited for introduction the mutant base 




































The	   constructed	   pJQ200mp	   18-­‐rspLCyaMut	   vector	   was	   transferred	   into	   E	   coli	  
SM10	  λ	  pir	  (Chapter	  2,	  Section	  16.4).	  Conjugation	  between	  the	  E	  coli	  SM10	  λ	  pir	  
harbouring	   pJQ200mp	   18-­‐rspLCyaMut	   and	   the	   aroQBP	   strain	   was	   then	  
performed	   in	   the	   expectation	   of	   creating	   an	   aroQBP	   variant	   carrying	   a	  
chromosomal	   copy	   of	   the	   cyaA	   mutated	   fragment	   (Chapter	   2,	   Section	   16.4).	  
Successful	   conjugation	  was	   identified	   by	   the	   differential	   growth	   of	   colonies	   on	  
CW-­‐aromix	  media	  with	   or	  without	   gentamicin.	   Only	  B	  pertussis	   containing	   the	  
constructed	  pJQ200CyaMut	  plasmid	  will	  grow	  in	  the	  presence	  of	  gentamicin	  on	  
CW-­‐aromix-­‐(Km50µg/ml,	   Sm200µg/ml,	   Gm10µg/ml).	   No	   such	   colonies	   were	  
observed	  after	  five	  days	  of	  incubation.	  However,	  growth	  was	  present	  by	  day	  two	  
for	  cultures	  on	  CW-­‐aromix-­‐(Km50µg/ml,	  Sm200µg/ml)	  without	  gentamicin.	  This	  
result	   indicates	  that	  the	  conjugation	  probably	  occurred	  and	  that	  recombination	  
may	  have	  taken	  place	  and	  the	  vector	  has	  been	  lost.	  
Thirty-three isolates colonies were picked up from CW-aromix-(Km50µg/ml, 
Sm200µg/ml) plates and used as templates for amplification of the 1kb cyaA insert by 
Figure 3b.5.1. Gel electrophoresis of the composite pJQ200mp 18-
rspLCyaMut vector (≈5.8kb) after double and single digestion with 
BamHI and EcoRI. Lane 1, 1kb marker. Lane 2, double digested 
pJQ200mp 18-rspLCyaMut showing two expected fragments, the 1kb 
CyaMut fragment and the original pJQ200mp 18-rspL vector size 
4.799kb (pJQ200mp 18-rspL vector). Lane 3, single digestion of 
pJQ200mp 18-rspLCyaMut with BamHI with expected size of ≈ 5.8kb. 
Lane 4, undigested pJQ200mp 18-rspLCyaMut vector. 
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the PCR using primer pair as discussed above (FwdCya and RvsCya). Sequencing of 
the amplified Cya insert did not reveal the expected mutation at the Lysine 58 codon 
(AAA to ATG). 
 
3b.5.2.  Ligation of cyaA mutant insert into pSS1129, Bordetella 
suicide vector, and transfer into aroQBP by conjugation 
 
Use of pSS1129 Bordetella suicide vector represents the second strategy aimed at 
generating aroQBP strain in which adenylate cyclase toxin has been detoxified. This 
plasmid has been used successfully to inactivate multiplicity of aroQ BP genes (Gross 
et al. 1992; Walker and Weiss 1994; Bannan et al. 1993). The pUC19CyaMut vector 
was extracted from an overnight culture of E coli DH5α of in LB-(Amp100µg/ml) 
broth as described in Chapter 2, Section 11.2. Following double digestion (BamH1, 
EcoRI), isolation by gel electrophoresis and purification the CyaMut 1kbp fragment 
was cloned into double digested pSS1129 with BamHI-EcoRI (see Chapter 2, Section 
17 for methodology). Successful cloning of CyaMut insert into pSS1129 was 
confirmed by gel electrophoresis of a BamHI and EcoRI double digest (≈10kb) as 
shown in Figure 3b.5.2. For reassurance, the composite vector was also extracted 
from cultures of E. coli SM10 λ pir with identical results as those obtained with E coli 
DH5α. Successful conjugation was identified by the differential growth of colonies on 
BG-aromix media with or without gentamicin. Only B pertussis containing with the 
constructed plasmid will grow in the presence of gentamicin on BG-aromix-
(Km50µg/ml, Sm200µg/ml, Gm10µg/ml) and ampicillin. No such colonies were 
observed after five days of incubation. However, growth was present by day two for 
cultures on BG-aromix-(Km50µg/ml, Sm200µg/ml) without gentamicin or ampicillin. 
This result indicates that the conjugation probably occurred and that recombination 
has taken place and the vector has been lost. Four hundred twenty two isolated 
colonies were detected on BG-aromix-(Km50µg/ml, Sm200µg/ml). 
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3b.5.2.1. Detection of the mutation in the lysine 58 codon of B pertussis aroQ 
strain 
 
Two methods (Chapter 2, Section 18.2-18.3) were employed to detect whether 
mutation has introduced into lysine 58 codon (AAA-to-ATG) of aroQBP. These are 
PCR amplification using mutant specific primer pairs and direct sequencing of the 
1kb cyaA fragment. 
 
All of the 422 isolated clones from BG-aromix-(Km50ug/ml, Sm200ug/ml) 
conjugation plates were picked and consolidated into in 42 groups with ten colonies 
per group, except one group which had eleven colonies. An aliquot of each group was 
suspended in 250µl PCR grade water and used as template for subsequent PCRs in 
conjunction with mutant FwATG and RvsATG primers (Chapter 2, Section 18.3). A 
210-base pair product was amplified in 12 of the 42 groups (Figure 3b.5.3). One of 
the 12 batches that showed the clearest 210-base pair target was selected for further 
investigation. Each of the ten individual clones comprising this batch was amplified 
and the product identified by gel electrophoresis (Figure 3b.5.3a). Nine of the ten 
clones produced 210-base pair amplicons (Figure 3b.5.3a). Three randomly selected 
positive clones producing the 210-base pair sequence were amplified, together with 
one clone from which the 210-base pair sequence was not be amplified. All four 
clones were then used as templates for PCR amplification of 1kb cyaA insert with the 
Figure 3b.5.2. Gel electrophoresis of the constructed pSS1129CyaMut vector (≈10kb) after 
double and single digestion with BamHI and EcoRI. Lane 1, 1kb marker. Lane 2, undigested 
vector. Lanes 3 and 4, double digested pSS1129CyaMut (BamHI and EcoRI) extracted from 
E coli DH544 and E coli SM10 respectively; bands at 1kb are CyaMut inserts. Lane 5, 
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FwdCya and RvsCya primers set (Table 2.13a). The expected 1kb Cya amplicon was 
obtained from all four PCRs. These four fragments were then sequenced. The 
expected mutation in the lysine 58 codon was not observed in these sequences. 
However one of the four sequences manifested a mutation at the lysine 58 codon 
resulting in a non-synonymous substitution of asparagine; the AAA codon being 
replaced by AAT. The expected ATG mutation described by Douglas et al. (1989) 
was unfortunately not found. Stocks of the clone was made and stored at -800C for 
subsequent characterisation. 
	  
As	   a	   final	   endeavour,	   1kb	   cyaA	   fragments	   were	   amplified	   from	   forty-­‐four	  
individual	   isolated	   clones	   picked	   from	   the	   BG-­‐aromix-­‐(Km50gµ/ml;	  
Sm200µg/ml)	   conjugate	   plates.	   Successful	   amplication	   was	   confirmed	   by	   gel	  
electrophoresis	   and	   the	   products	   submitted	   for	   sequencing.	   None	   of	   the	   44	  
fragments	  manifested	  the	  desired	  mutation	  for	  the	   lysine	  58	  position	  as	  shown	  
by	   a	  multiple	   sequence	   alignment.	   It	   is	   possible	   that	   other	   putative	  mutations	  
may	  also	  have	  occurred	  but	  pursuing	   this	  question	   is	  outside	   the	   scope	  of	   this	  
project.	  
  









Figure 3b.5.3. Electrophoresis of 42 pooled samples from the conjugation 
plate. Row I, lane 2-25 and Row II, lane 2-19, showing attempts to amplify 
the 210-base pair target following PCR with the mutant primer pair 
(FwATG) in putative aroQBP mutants from the conjugation plates. Only 12 
of the 42 samples gave an expected 210-base pair band, albeit very weakly. 
Row I, lane 1 and 26; Row II, lane 1 and 23 100bp marker. Row II, lane 20, 
amplification of the target sequence from pSS1129CyaMut in conjunction 
with the native (AAA) primer. Lane 21, amplification of the target sequence 
from pSS1129CyaMut in conjunction with the mutant (ATG) primer. Row II 
Lane 23, negative control. Bands other than the 210-base pair bands are due 
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Figure 3b.5.3a. Gel electrophoresis of the 10 individual colonies comprising batch 
23 from the conjugation plate. Lane 1, 100bp marker. Lane 2-11, showing gel 
electrophoresis of the PCR attempts to amplify the 210-base pair sequence from 
ten isolates in conjunction with wild type primer. The ten isolates were from the 
batch the 210-base pair sequence could not be amplified by PCR in conjunction 
with the mutant primer (see text for details). Lane 3, the 210-base pair sequence 
was not amplified from this isolate (which was subsequently shown to have the 
lysine to asparagine mutation). Lane 12, amplification of the 210-base pair 
sequence from pSS1129CyaMut vector in conjunction with the mutant primer. 
Lane 13, negative control. Each well contained 5µl of amplicon. Bands other than 
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3b.6. Discussion 
	  
Bordetella pertussis produces four exotoxins including PT, ACT, DNT and an 
endotoxin, LPS (Mills 2001; Marzouqi et al. 2010; Weiss et al. 1984; Roberts et al. 
1990). While the role of PT in the virulence of B pertussis in vivo has been well 
documented to induce lymphocytosis, histamine sensitivity and immunosuppression 
(Carbonetti et al. 2005) that of ACT has emerged only over the last decade. 
Production of ACT is now considered to be one of the major virulence determinants 
of B pertussis acting to promote immune evasion or suppression and hence 
subsequent colonisation of the host, albeit later than PT (Paccani et al. 2011; Mills 
2001; Ross et al. 2004; Boyd et al. 2005). Adenylate cyclase is a calmodulin-
sensitive, which enters animal cells and increases intracellular cAMP thereby 
contributing to the clinical manifestations of the disease. 
 
Gross et al. (1992) demonstrated that a mutant of B pertussis in which lysine at 
position 58 (bases 174-175, AAA) in the cyaA gene replaces methionine (ATG) 
abolished adenylate cyclase catalytic activity and decreased pathogenicity by over 
1000-fold relative to the wild type in newborn mice, clearly demonstrating the 
importance of this exotoxin for the virulence of B pertussis. More recently, Carbonetti 
et al. (2005) showed that failure to produce ACT by mutant strains of B pertussis in 
which the cyaA gene had been deleted resulted in a significant colonization defect in 
the mouse model. On the other hand, this defect was apparent two days earlier relative 
to B pertussis with in-frame-deleted PT mutations. 
 
One of the aims of the “Vaccine Development Laboratory” at Curtin University is to 
genetically modify the exotoxins produced by aroQBP vaccine candidate such that 
the toxicity of the vaccine candidate is eliminated or substantially reduced while 
retaining immunogenicity. Given the immunosuppression potentially mediated via 
apoptosis of macrophages and disengagement of immune response via binding of the 
ACT to T cells (Khelef, Zychlinsky, and Guiso 1993; Paccani et al. 2011) and the 
polarisation toward of immune response to Th2 type by these toxins (Boyd et al. 
2005; Ross et al. 2004), the importance of genetically detoxifying ACT is obvious in 
the development of any live attenuated vaccine that retains immunogenicity. 
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The key question is whether any non-reverting live attenuated B pertussis vaccine 
candidate will be suitable as a primary replacement vaccine for the aP component of 
DTaP, or as a booster for infants previously immunised with 1, 2 or 3 doses of the 
DTaP. Because the non-reverting aroQBP vaccine candidate has not yet been 
detoxified, its potential as booster for mice already vaccinated with DTaP was 
investigated to determine if the Th2-polarised immune response induced by DTaP 
could be polarized to a Th1 mediated CMI resulting in more prolonged protection 
than achieved with DTaP alone. 
 
The rational underpinning execution of the next phase of this study aimed at genetic 
detoxification of the aroQBP vaccine candidate were as follows: 
 
1) The clear demonstration in this study that booster vaccination of mice, previously 
vaccinated with DTaP, with the non-reverting aroQBP vaccine candidate result 
polarisation of the immune response from Th2 to Th1 type, and 
2)  the recently reported property of the ACT to disengage T cell function by binding 
to T cells (Carbonetti et al. 2005; Paccani et al. 2011). 
 
Because the genetic modification of PT had already been reported (Mielcarek et al. 
2006), it was decided to attempt to genetically modify ACT by site directed 
mutagenesis of the cyaA gene. This chapter reports the results of inactivation of cyaA 
gene using site directed mutagenesis directed to replace lysine with methionine at 
position 58 of the gene as originally described by Gross et al. (1992). This study 
focussed on a 1kb fragment of the cyaA gene containing lysine 58 rather than the 
entire cyaA gene. This fragment was cloned into the pUC19 vector and subjected to 
the site directed mutagenesis protocol. Presence of the desired mutation in the cyaA 
fragment was confirmed by direct sequencing. The mutated 1kb cyaA insert was 
excised from pUC19 and cloned into two different B pertussis suicide vectors, 
pJQ200mp-18 and pSS1129, to allow for conjugation and allelic exchange between 
the E coli SM10 λ pir harbouring these vectors with aroQBP chromosomal DNA. 
 
The creation of the original aroQBP mutant was achieved by partial deletion of the 
aroQ gene, followed by insertional inactivation of the aroQ gene, using selection 
	   128	  
based on a Km resistance gene similar to the way the aroA gene was generated 
(Roberts et al. 1990). In the present study, the use of a selection marker was not 
possible due to the requirement to abrogate toxicity of ACT while retaining 
immunogenicity.  This objective required that both the mutated cyaA gene fragment 
and the corresponding wild type fragment could both be cloned and sequenced. 
 
To circumvent the lack of a selection marker protocol, two alternative procedures 
were used to detect the AAA (K) à ATG (M) mutation in the cyaA fragment. In first 
method, the entire 1kb cyaA insert was PCR-amplified using FwdCya and RvsCya 
primers and sequenced. In the second method, a 210-base pair sequence within the 
cyaA gene fragment was amplified using two sets of primers such that only one 
amplicon would be present if the desired ATG mutation had not taken place. 
 
Although the experimental procedures reported in this chapter did generate plasmids 
containing the AAA (K) à ATG (M) mutation in the 1kb cyaA gene fragment as 
expected, however introduction of this mutation into the aroQBP chromosome by 
conjugation was not successful. Reason for this failure was not investigated due to 
time constraints. However a quite unexpected non synonymous AAA (K) to AAT (N) 
mutation was observed. The event could be attributed to random mutation, which is 
known to occur in bacterial populations with frequency of the order of 10-4 – 10-5 per 
base per generation (Cairns, Overbaugh, and Miller 1988; Jeremy W. D and Simon F. 
P 2004). 
 
It will be interesting to determine whether this mutation (K to N) affects the activity 
of the resulting adenylate cyclase toxin. Due to time constraints this question could 
not be addressed in this project. It will be resolved at a later time in Dr Mukkur’s 
laboratory. 
 
With the advantages of hindsight, it is interesting to reflect on the reasons why lysine 
to methionine mutated cyaA gene fragment was not isolated. Probable reasons include 
the following. 
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1) Conjugation between E coli SM10 λ pir and aroQ B pertussis may not have taken 
place despite the fact that the ampR and GmR selection markers were not present in 
the vectors of the Bordetella suicide vectors. Clearly, this procedure requires 
further effort. 
 
2) Expected recombination may not have taken place between the homologous 
sequences (1kb cyaA insert) of the vector(s) and aroQ B pertussis chromosomal 
DNA at the lysine codon. This may be coincidental or explained by sequence 
attributes at this locus.  
 
3) The flanking homology region (at 173bp corresponding to the AAA codon) was 
not long enough for the mutated sequence to cross from the vector(s) to the 
chromosomal DNA of cyaA of B pertussis aroQ. Support for this possibility has 
been suggested by Stibitz (Stibitz 1994) who reported that 500bp of homologous 
flanking region was sufficient for mutant sequence to cross over to incorporate a 
desired mutation from the suicide vector to the bacterial chromosomal DNA. 
However, a lower limit for homologous recombination was not determined. 
Regardless, it will be interesting to determine the effect of the random substitution 
of the lysine residue with asparagine on the toxicity of adenylate cyclase, 
notwithstanding the need to repeat the experiment but using the site-directed 
mutagenesis on longer segments of the cyaA gene. 
 
In conclusion, the work reported herein provides information and experience that will 
facilitate the generation of an ACT deficient aroQBP that retains adenylate cyclase 
antigenicity, whether this is due to the K to M mutation or indeed the fortuitous K to 
N mutation described above. The availability of a double mutated B pertussis variant 
with broad antigenicity will undoubtedly lead to a new generation of whooping cough 
vaccines eliciting protracted humoral and cell mediated immunity while being safe for 
use in humans. 
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Chapter 4: Conclusions and future directions 
	  
Even though the currently marketed DTaP whooping cough vaccine has been claimed 
to induce long-term protection against infection with B pertussis in the population, 
children vaccinated with DTaP become susceptible to the disease within 4-12 years 
(Cherry 2005; Tan et al. 2005) notwithstanding the contribution made by lack of 
compliance with the recommended vaccination schedule to the recent increases in 
incidence in many countries due either to side reactions (Jackson et al. 2002; Gold et 
al. 2003; Rennels et al. 2000; Rowe et al. 2005). Even fully vaccinated populations 
have now been reported and accepted to acquire infection with B pertussis (Mooi, 
Van Loo, and King 2001; He and Mertsola 2008; Mooi et al. 2009; de Melker et al. 
1997). As a result, there is need for development of side reaction-free and more 
effective vaccines capable of inducing long-term protection against whooping cough. 
However, for this objective to be realised, an ideal future pertussis vaccine must also 
induce CMI, latter being considered to be necessary for induction of long-term 
immunity (Redhead et al. 1993; Mills 2001; Mascart et al. 2003). Protection offered 
by vaccination with acellular pertussis vaccines is now accepted to be due 
predominantly to antibodies induced by Th2-polarisation of immune response 
(Canthaboo, Williams, et al. 2000). However, it is also generally accepted that 
induction of CMI induced via Th1-polarisation of immune response is necessary for 
long-term protection against whooping cough (Redhead et al. 1993; Mills 2001; 
Mascart et al. 2003). 
 
DNA vaccines against pertussis have yielded controversial results with one laboratory 
claiming induction of both antibodies and CMI prepared using pcDNA3.1 eukaryotic 
plasmid (Kamachi, Konda, and Arakawa 2003) as compared to another laboratory 
reporting induction of only CMI using a construct prepared using the same plasmid 
(Fry et al. 2008). While a 3rd laboratory (Li et al. 2006) claimed induction of both 
antibodies and CMI with a DNA vaccine using a different plasmid (pVAX1), research 
in a different laboratory showed that boosting of mice with recombinant proteins was 
necessary for induction of high antibody responses and induction of protection against 
pertussis (Fry 2006). 
Enthusiasm for DNA vaccination in humans is tempered by the concern on the 
possibility vaccine's DNA integrating into host chromosomes potentially leading to 
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turning on of the oncogenes or turning off the tumor suppressor genes. This is not 
withstanding the concern of provoking chronic inflammation or autoantibody 
production due to continued immunostimulation (http://virology-
online.com/general/typesofvaccines.htm.). 
 
It has been reported that live attenuated pertussis vaccines may constitute ideal 
candidates for imparting long-term protection because they mimic natural infection 
(Locht et al. 2004; Mielcarek et al. 2010) providing the potential of inducing immune 
responses to all the virulence antigens. The currently used DTaP vaccines contain 
only 3-5 of B pertussis protective antigens, depending upon the vaccine manufacturer, 
with only one of the major toxins, pertussis toxin, being covered for neutralisation. 
 
Mukkur et al. (2005) has reported the development of a B pertussis vaccine candidate 
in which the aroQ gene of the aromatic biosynthesis pathway had been deleted and 
insertionally inactivated. It has been reported aroQBP can colonise airways of mice 
efficiently and induce immunity both humoral and cell mediated immunity without 
causing disease (Cornford-Nairn, PhD Thesis [under embargo, University of Southern 
Queensland]; Mukkur et al, 2005; Mukkur, Personal communication). Mice 
immunised with a single dose aroQBP were protected against an intranasal challenge 
with parent virulent B pertussis. Serum anti-B pertussis antibodies of the IgG1 and 
IgG2 isotypes were induced which were enhanced post-challenge with the virulent 
parent strain. Vaccination of mice with two and three of the aroQBP vaccine further 
enhanced IgG1 and IgG2 levels and also induced anti-B pertussis pulmonary IgA 
levels. 
 
Given the recent outbreaks despite extensive coverage with the acellular pertussis 
vaccine in developed world, it was important to determine whether the Th2-polarised 
immune response induced by the acellular pertussis vaccine could be polarised 
towards Th1 type using aroQBP vaccine as booster with a view to prolonging the 
duration of immunity originally induced by the acellular pertussis vaccines thus 
eliminating or reducing the need for repeated boosters. 
 
In this study it was established that booster vaccination of mice, previously vaccinated 
with DTaP, with the aroQBP vaccine candidate resulted in polarisation of immune 
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response from Th2 type to Th1 type as judged by the production of IgG2a and IFN-γ 
used as an indirect indicator of CMI. Mice booster-immunised with two-doses of the 
aroQBP vaccine yielded significantly higher levels of IgG, IgG1, and IgG2a as 
compared with the one-dose booster. Immunisation of mice with two-doses of the 
aroQBP vaccine as the primary vaccine also yielded high levels of anti-BPWC 
antibodies as observed with the DTaP-aroQBP booster vaccinated mice. However, 
the serum and mucosal IgA responses against BPWC were low. On the other hand, 
whereas anti-whole cells B pertussis IgG2a was not detectable in the lung 
homogenates of mice vaccinated with the aroQBP vaccine candidate, low levels of 
this antibody isotype were detectable in mice either immunised with two-doses of the 
aroQBP vaccine or in DTaP-immunised mice subjected to booster vaccination with 
one or two doses of the aroQBP vaccine. Low levels of IgA observed in the lung 
homogenates of immunised mice regardless of the immunisation regime were 
consistent with low serum IgA levels. 
 
Induction of high levels of IFN-γ by BPWC and FHA, used as a purified B pertussis 
model antigen, stimulated splenocyte of DTaP-vaccinated mice following booster-
vaccination with either one or two doses of live attenuated aroQBP vaccine candidate 
clearly indicated polarisation of immune response to Th1-type. 
 
Given the ability of the aroQBP vaccine candidate to polarise the immune response 
from Th2 type to Th1 type laid the foundation for further attenuation of this non-
reverting vaccine candidate particularly with respect to the immunosuppressive toxins 
particularly adenylate cyclase and pertussis toxin in the first instance. Genetic 
detoxification of the adenylate toxin was given priority because a method for genetic 
detoxification of pertussis toxin had already been reported (Mielcarek, Debrie, Raze, 
Quatannens, et al. 2006). Genetic detoxification of ACT was attempted using 2 
different Bordetella suicide vectors harboring site-directed mutagenized 1kb cyaA 
gene fragment by introducing methionine in place of lysine base at position 58 in the 
cyaA of bacterium genome. Unfortunately, the desired mutation was not achieved; 
instead, one clone in which a mutation at position 174 (A-to-T) which resulted in 
replacement of lysine to asparagine (AAT codon) was isolated. This clone is now 
ready to be tested on its toxic properties to determine if this unexpected random 
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substitution has resulted in detoxification. Unfortunately, answer to this question has 
not been obtained in this study due to time constraints.  
 
In this study, it was proven that Th2 immune response in mice previously immunised 
with an acellular pertussis vaccine such as the DTaP can be polarised to Th1 type 
immune response by one or two booster of doses of the live metabolite-deficient 
aroQBP delivered by the intranasal route providing an opportunity for the 
development of vaccine ideal for induction of long-term immunity. 
 
Considering the findings of this study, future studies aimed at genetically detoxifying 
adenylate cyclase toxin need to be carried out by allelic exchange using at least 500bp 
upstream of ATG (lysine 58) of cyaA gene sub-cloned in the Bordetella suicide 
vectors for successful homologous recombination leading to the generation of an 
inconsequentially toxic aroQBP vaccine candidate. If successful, the next step should 
be genetic detoxification of pertussis toxin as reported for a different live attenuated, 
albeit potentially reverting strain (Mielcarek, Debrie, Raze, Quatannens, et al. 2006) 
prior to the characterisation of its safety and immunogenicity in immunocompetent 
and in immunodeficient mice. 
 
Since innate immunity is critical to the development of acquired antibody and cell-
mediated immune responses, future studies should also include identification of 
dendritic cell subpopulations including other antigen-presenting cells and their ability 
to drive the vaccine-induced Th2-mediated and  Th1-mediated responses. This could 
be facilitated by quantification of the broad spectrum of proinflammatory and 
regulatory cytokines, such as IL-4, IL-10 produced including analysis of regulatory T 
cell responses measured by estimation of IL-17 produced by Th17 lymphocytes, as 
reported previously for a different live attenuated B pertussis vaccine candidate with 
potential to revert back to virulence. These studies should not only be carried out in 
the pertussis mouse model, the most commonly used model for assessing the potency 
of different pertussis vaccines (see section 1.5.1) but also using an ex-vivo model 
using human monocyte derived dendritic cells (Fedele et al. 2011) or using human 
peripheral blood mononuclear cells (Rowe	  et	  al.	  2005). 
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Appendix A: Media 
	  







Tris base 304mg 




The pH of medium adjusted to 7.5 with 1N HCl; the medium aliquoted in 10mls in 
McCartney bottles and was autoclaved. Upon cooling the bottles’ cap sealed with 
paraffin and were stored at -200C for up to six months. 
 
Stock Solution: 10ml 
	  
Ascorbic acid 20mg 






The solution dissolved on stirring plate and was filter sterilised (FS) by 0.2µm filter.  
The stock stored at -200C. 
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Cyclodextrin	  Stock	  (1mg/ml):	  10ml 
	  
10mg of Cyclodextrin dissolved in 10ml distilled water and filtered sterilised and was 
stored at -200C. 
To make SS medium, SS without supplement, and the stocks (above) thawed and 
100µl of the stock solution and 200µl of Cyclodextrin stock were added to SS 
medium. 
 




Na2HPO4 (Dibasic sodium phosphate) 100mg 
MgCl2 20mg 
NaCl 500mg 
Tris base 1220mg 
L-Glutamic acid monosodium salt 2140mg 
L-Proline 48mg 




The pH of medium adjusted to 7.5 with 1M HCl; the medium aliquoted in 10mls in 
McCartney bottles and was autoclaved.  Upon cooling the bottles’ cap sealed with 
paraffin and were stored at -200C for up to six months. 
To make CL, the stock medium without supplement and stock solution (same stock 
solution as for the SS medium) thawed and 200µl of stock solution was added to CL 
without supplement. 
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Bordet Gengou (BG) agar: 
	  
Bordet Gengou agar was made according to manufacturer’s instruction except in that 
the medium contained 15% (v/v) sheep blood instead of 12% (v/v). The medium was 
supplemented with aromix and antibiotic(s) accordingly (see Section 2.1.2). 
 
Cohen Wheeler (CW) agar: 1L 
	  
Casamino acid 10g 
NaCl 2.5g 
Na2HPO4 (Dibasic sodium phosphate) 0.50g 
MgCl2.6H2O 0.40g 
Starch 1.50g 
CaCl2 1% (see blow) 1ml 
FeSO4.5H2O 0.5% (see below) 2ml 
CuSO4.5H2O 0.5% (see below) 1ml 
L-Cysteine 1% (see below) 2.5ml 
Yeast extract 5 
Bacteriological agar 10 
d.H2O 800ml 
 
The PH of the medium adjusted to 7.3 with 1M NaOH and the ingredient dissolved on 
hot stirring plate. The medium aliquoted into 170mls in McCartney bottles and was 
autoclaved. Cap of the bottles containing the agar were sealed with paraffin and 
stored at 40 C degree. When needed the medium melted in steam boiler and upon 
cooling to 50-550 C, supplemented with 15% (v/v) blood, aromix, and antibiotic(s) 
accordingly (Section 2.1.2.) 
 
1% CaCl2: 10ml 
	  
0.10g of CaCl2 dissolved in 10ml d.H2O filter sterilised with 0.2µm filter and was 
stored at 40C. 
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0.5% FeSO4.7H2O (Ferrous sulfate): 100ml 
	  
0.50g of FeSO4.7H2O dissolved in 100ml d.H2O filter sterilised with 0.2µm filter and 
was stored at 40 C. 
 
 0.05% copper sulfate (CuSO4.5H2O): 100ml 
	  
0.05g of CuSO4.5H2O dissolved in 100ml d.H2O filter sterilised with 0.2µm filter and 
was stored at 40 C. 
 
1% L-Cysteine: 10ml 
	  
0.10g of L-Cysteine dissolved in 10ml d.H2O filter sterilised with 0.2µm filter and 
was stored at 40 C. 
	  
Luria Bertani (LB) 1% Agar: 1L 
	  
Trypton 10g 
Yeast extract 5.0g 
Sodium chloride 10g 
Bacteriological agar 10g 
d.H2O2 1000ml 
 
The medium kept on stirring hot plate and brought to boiling point. The medium 
cooled down to 60-500C and aliquoted into 200ml or 100ml in McCartney bottles; the 
medium were autoclaved. Upon solidification of medium the bottles’ cap sealed with 
paraffin and stored at 40C. When needed stock medium melted in steam boiler and 
antibiotic(s) was added to the medium at temperature between 45-500C. The medium 




Composition of LB broth was as same as LB agar except it did not contain agar. 
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LB agar-(Amp/IPTG/X-Gal): 200ml 
	  
LB agar supplemented with 0.5mM Isopropyl Thiogalactoside (IPTG) and 80µg/ml 5-
bromo-4-chloro-3-indolyl-β-D-glactopyranoside (X-Gal) 
 
IPTG 0.1M  1ml 
X-Gal [50mg/ml] 320µl   
 
The reagents were added to LB medium at temperature about 500 C to 200ml final 
volume. 
 
SOB Medium: 200ml 
	  
Trypan 4g 
Yeast extract (auto lysed) 1g 
Sodium chloride 0.1g 
d.H2O 190ml 
 
The ingredient dissolved on stirring plate and 1ml of 250mM solution of KCl was 
added to the broth.  The pH adjusted to 7.0 with 1M NaOH. The volume made up to 
200ml with distilled water.  The broth was aliquoted into 5mls in McCartney bottles 
and autoclaved. Upon cooling the bottles’ cap were sealed with paraffin film and 
stored at 40C. 
 
SOC Medium: 5ml 
 
SOC is identical to SOB except contains 20mM glucose and 50mM MgCl2. 
When SOC medium 100µl of 1M glucose (FS) and 25µl 2M MgCl2 were added to 
5ml SOB stock at room temperature. 
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Appendix B: Aromix stock solutions 
 
Phenylalanine 10mg/ml in d.H2O  
Tyrosine 5mg/ml in 50:50 in d.H2O:1M NaOH 
Tryptophan 4mg/ml in d.H2O  
Para-aminobenzoic acid 4mg/ml in d.H2O 
Dihydroxybenzoic acid 4mg/ml in d.H2O 
Para-hydroxybenzoic acid 4mg/ml in d.H2O 
 
The ingredients were dissolved on hot stirring plate with additional of about 200µl of 
1M NaOH to all solutions except for tyrosine. Upon cooling 500µl chloroform added 
to each stock and stored at 40C. 
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Appendix C: Buffers and Reagents 







The solution left on stirring plate until the solutes dissolved; PH adjusted to 7.2 and 
volume was made up to 1L with distilled water. 1%PBS prepared in distilled water 
when needed from the stock and autoclaved. 
 
50X TAE (Tris-acetate-EDTA) buffer: 1L 
	  
Tris bas 242g 
Glacial acetic acid 57.1ml 
EDTA (0.5M) (see below) 100ml 
 
The volume made to 1L with d.H2O.  1X TAE was made from the stock by adding 
20ml of 50X TAE stock to 980ml d.H2O. 
 
0.5M EDTA (Ethylenediamine tetraacetic acid): 500ml 
	  






The solution mixed on stirring plate and pH was adjusted to 8.0 with about 10g of 
NaOH pellets. The volume of buffer adjusted to 500ml with d.H2O and was 
autoclaved. 
250mM KCl: 100ml 
	  
1.86g of KCl dissolved in 10ml d.H2O autoclaved. and was stored at 40C. 
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1M Glucose: 10ml 
	  
1802mg of D-glucose dissolved in 10ml d.H2O filter sterilised with 0.2µm filter and 
was stored at 40C. 
 
 2M MgCl2: 50ml 
	  
9.52g of MgCl2 dissolved in 10ml d.H2O autoclaved and was stored at 40C. 
 
0.1M CaCl2: 100ml 
	  
1110mg of CaCl2 dissolved in 10ml d.H2O filter sterilised with 0.2µm filter and was 
stored at 40C. 
 
80mM MgCl2, 20mM CaCl2: 100ml 
	  
762mg of MgCl2 dissolved in 100ml d.H2O and 22mg of CaCl2 added to the solvent 
on stirring plate. The solution filter sterilised with 0.4µm filter and was stored at 40C. 
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Appendix D:  Optical Density measurement of 
aroQBP in SS-(Km-50µg/ml, Sm-
200µg/ml) medium at different time 




Growth of aroQBP in SS-(Km-50µg/ml, Sm-200µg/ml) medium until the 
growth curve approximately reached log phase. 
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Appendix E:  Optical Density measurement of E coli 
SM10 λ  pir harbouring pJQ200mp 18-
rspLCyaMut growth in SS -
(Gm10µg/ml, Km 50µg/ml) and SM10 λ  
pir harbouring pJQ200mp 18-
rspLCyaMut growth in SS -(Amp100 
µg/ml Gm10µg/ml, Km 50µg/ml) broth 
	  
E coli SM10 λ pir harbouring pJQ200mp 18-rspLCyaMut growth in 
10ml SS -(Gm10µg/ml, Km 50µg/ml) SM10 λ pir harbouring pJQ200mp 
18-rspLCyaMut growth in SS -(Amp100 µg/ml Gm10µg/ml, Km 
50µg/ml) broth until the growth reaches log phase. 
 
 













*At 340minutes about 3ml SS medium was added to the growth broth. 
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Appendix F:  Optical Density measurement of 
aroQBP in CL-(Km50µg/ml, 
Sm200µg/ml) medium at different time 




Growth of aroQBP in CL-(Km50µg/ml, Sm200µg/ml) broth until the 
growth of bacterium got to log phase. 
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Appendix G: ELISA Reagents 
	  
Carbonate bicarbonate Coating Buffer (CB): 1L 
	  
Na2CO3 1.59g 
NaHCO3  2.94g 
d.H2O 900ml 
 
PH adjusted to 9.6 with 1M NaOH and volume was made to 1L.  The buffer was 
stored at 40C. 
 
Blocking Buffer (BB) stock: 1L 
	  





The stock stored at 40C. BB with 5% skimmed milk prepared fresh by dissolving 1g 
of skimmed milk into 20ml BB stock by sprinkling so no clomps were formed. 
 
Diethanolamine Buffer (Substrate Buffer): 1L 
	  
Diethanolamine 106g 
MgSO4 .7H2O 0.249g 
d.H2O 800ml 
 
PH adjusted to 10 and the volume made up to 1L with d.H2O. The stock stored at 40C. 
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Appendix H:  Dulbecco’s Modified Eagle Medium 
(CDMEM): 100ml 
	  
HEPES (1M) 0.25ml 
2 mercaptoethanol 0.90ml 




For culture Fetal Calf Serum (FBS) was added to a concentration of 10%. 
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Appendix I: Serum antibody isotypes against 
inactivated aroQBP 
 
Antigen-specific immune response of mice vaccinated with three 
doses of DTaP and two booster doses of live aroQBP. 
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IgG1 titers 
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IgG2a titers 
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IgA [Single point titers] 
 








Antigen-specific immune response of mice vaccinated with three 




















































































































































































































































IgA [Single point titers] 
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Antigen-specific immune response of mice vaccinated with two doses 
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IgG1 titers 
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IgG2a titers 
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IgA titers 
 








Antigen-specific immune response of mice vaccinated with one dose 


















































































































































IgA [Single point titers] 
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Appendix J:  Lungs antibody isotypes against  
          inactivated aroQBP 
 
Antigen-specific immune response of mice vaccinated with three 
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IgG1 titers 
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IgG2a titers 
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IgA [Single point titers] 
 








Antigen-specific immune response of mice vaccinated with three 































































































































































































































IgG2a [Single point titers except for M3 titer, three-point extrapolation] 
 
































IgA [Single point titeration] 
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Antigen-specific immune response of mice vaccinated with two doses 










































































IgG1 [Single point titers except for M5 titer, three-points extrapolation] 
 











































































































































































	   221	  
Antigen-specific immune response of mice vaccinated with one dose 
of live aroQBP. 
	  
IgG [single point titers except for M2 titer determined by the 3-points 
extrapolation] 
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IgG1 [Single point titers] 
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Appendix K:  Serum antibody isotypes against 
purified pertussis toxin 
 
Antigen-specific immune response of three doses DTaP and one dose 
booster of live aroQBP. 
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IgG1 titers 
 
Mice Number  Serum IgG1 titers 
M1 1670 
M2 2560 (4 point titer) 



































































Titer	  	  1230	  




IgG2a [Single point titers] 
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IgA [Single point titers] 
 








Antigen-specific immune response of mice vaccinated with three 


















































































































































































Titer	  3450	  	  












































IgG2a [Single point titers] 
 








IgA [Single point titers] 
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Antigen-specific immune response mice vaccinated with two doses of 
live aroQBP. 
 
IgG [Single point titers] 
 








IgG1 [Single point titers] 
 








IgG2a [Single point titers] 
 







*No IgA isotype was detected. 
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Antigen-specific immune response of mice vaccinated with one dose 
of live aroQBP. 
	  
IgG [Single point titers] 
 








IgG1 [Single point titers] 
 








IgG2a [Single point titers] 
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Appendix L:  Serum antibody isotypes against 
purified filamentous haemagglutinin 
 
Antigen-specific immune response of mice vaccinated with three 
doses of DTaP and one booster dose of live aroQBP. 
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IgG1 titers 
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Antigen-specific immune response of mice vaccinated with three 
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IgG1 titers 
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IgG2a titers 
 







*No IgA isotype detected. 
 
	  
Antigen-specific immune response of vaccinated with two doses of 
live aroQBP. 
 
IgG [Single point titers] 
 







*No IgG1, IgG2a, and IgA isotypes detected. 
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Antigen-specific immune response of mice vaccinated with one dose 
of live aroQBP. 
	  
	  
IgG [Single point titers] 
 







*No IgG1, IgG2a, and IgA isotypes detected. 
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 Schematic drawing of vector pUC19. The vector is a small, high-copy number E 
coli plasmid cloning vector.  The vector contains lacZα gene within frame with 
multiple cloning site and allows screening for insert utilizing blue/white colony 
color. Restriction sites, BamHI and EcoRI, used to clone the Cya sequence 
fragment into the vector.  
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 Schematic drawing of pGEM®-T Easy Vector. The vector is constructed by digestion 
of pGEM-T Easy Vector with EcoRV and addition of a 3ʹ′ terminal thymidine (T) to 
of both ends. Thymidine overhangs of the vector are compatible to deoxyadenine 
overhangs of PCR products generated by thermostable polymerase (Promega). The 
3ʹ′-T overhangs prevent recirculation of the vector during ligation reaction and 
improves ligation of PCR products into the pGEM-T Easy Vector (Promega). 
Source: Promega Technical Manual No. 042. 
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Appendix O:  Schematic drawing of pJQ200mp 18-
rspL Vector  
 
	  
Schematic	  drawing	  of	  vector	  pJQ200mp	  18-­‐rspL.	  The	  vector	  is	  a	  B	  pertussis	  
suicide	  vector	  it	  is	  one	  of	  the	  vectors	  used	  to	  introduce	  the	  mutated	  lysine	  codon,	  
ATG,	  into	  aroQBP.	  The	  vector	  belongs	  to	  ColE1	  plasmid	  family	  with	  inserted	  
gentamicin	  cassette.	  
Source: Courtesy of Camille Locht, Pasteur institute, lille, France.  
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Appendix P:  Schematic drawing of pSS1129 
	  
Figure 2.10.1.4. Schematic drawing of Vector pSS1129. The vector is a B pertussis 
suicide vector it carries a gentamicin-resistance cassette insert. The vector is the 
second vector that was used in the study to introduce the mutated lysine codon, ATG, 
into aroQBP. 
	  
Source: Stibitz, Scott (1994). 
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Appendix Q:  Blast analysis of B pertussis Tohama I 
cyaA 
 
Blast analysis of Bordetella Tohama I cyaA sequence (5121bp) 
(http://www.ncbi.nlm.nih.gov) against Bordetella pertussis (776228-781384) (www. 















ATGCAGCAATCGCATCAGGCTGGTTACGCAAACGCCGCCGACCGGGAGTCTGGCATCCCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATGCAGCAATCGCATCAGGCTGGTTACGCAAACGCCGCCGACCGGGAGTCTGGCATCCCC 
GCAGCCGTACTCGATGGCATCAAGGCCGTGGCGAAGGAAAAAAACGCCACATTGATGTTC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCAGCCGTACTCGATGGCATCAAGGCCGTGGCGAAGGAAAAAAACGCCACATTGATGTTC 
CGCCTGGTCAACCCCCATTCCACCAGCCTGATTGCCGAAGGGGTGGCCACCAAAGGATTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCCTGGTCAACCCCCATTCCACCAGCCTGATTGCCGAAGGGGTGGCCACCAAAGGATTG 
GGCGTGCACGCCAAGTCGTCCGATTGGGGGTTGCAGGCGGGCTACATTCCCGTCAACCCG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGTGCACGCCAAGTCGTCCGATTGGGGGTTGCAGGCGGGCTACATTCCCGTCAACCCG 
AATCTTTCCAAACTGTTCGGCCGTGCGCCCGAGGTGATCGCGCGGGCCGACAACGACGTC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AATCTTTCCAAACTGTTCGGCCGTGCGCCCGAGGTGATCGCGCGGGCCGACAACGACGTC 
AACAGCAGCCTGGCGCATGGCCATACCGCGGTCGACCTGACGCTGTCGAAAGAGCGGCTT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AACAGCAGCCTGGCGCATGGCCATACCGCGGTCGACCTGACGCTGTCGAAAGAGCGGCTT 
GACTATCTGCGGCAAGCGGGCCTGGTCACCGGCATGGCCGATGGCGTGGTCGCGAGCAAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACTATCTGCGGCAAGCGGGCCTGGTCACCGGCATGGCCGATGGCGTGGTCGCGAGCAAC 
CACGCAGGCTACGAGCAGTTCGAGTTTCGCGTGAAGGAAACCTCGGACGGGCGCTATGCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CACGCAGGCTACGAGCAGTTCGAGTTTCGCGTGAAGGAAACCTCGGACGGGCGCTATGCC 
GTGCAGTATCGCCGCAAGGGCGGCGACGATTTCGAGGCGGTCAAGGTGATCGGCAATGCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GTGCAGTATCGCCGCAAGGGCGGCGACGATTTCGAGGCGGTCAAGGTGATCGGCAATGCC 
GCCGGTATTCCACTGACGGCGGATATCGACATGTTCGCCATTATGCCGCATCTGTCCAAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCCGGTATTCCACTGACGGCGGATATCGACATGTTCGCCATTATGCCGCATCTGTCCAAC 
TTCCGCGACTCGGCGCGCAGTTCGGTGACCAGCGGCGATTCGGTGACCGATTACCTGGCG              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTCCGCGACTCGGCGCGCAGTTCGGTGACCAGCGGCGATTCGGTGACCGATTACCTGGCG 
CGCACGCGGCGGGCCGCCAGCGAGGCCACGGGCGGCCTGGATCGCGAACGCATCGACTTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCACGCGGCGGGCCGCCAGCGAGGCCACGGGCGGCCTGGATCGCGAACGCATCGACTTG 
TTGTGGAAAATCGCTCGCGCCGGCGCCCGTTCCGCAGTGGGCACCGAGGCGCGTCGCCAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTGTGGAAAATCGCTCGCGCCGGCGCCCGTTCCGCAGTGGGCACCGAGGCGCGTCGCCAG 
TTCCGCTACGACGGCGACATGAATATCGGCGTGATCACCGATTTCGAGCTGGAAGTGCGC              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTCCGCTACGACGGCGACATGAATATCGGCGTGATCACCGATTTCGAGCTGGAAGTGCGC 
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GAGCAGAACAATCCTTTCCCGGAGGCAGATGAGAAGATTTTCGTCGTATCGGCCACCGGT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAGCAGAACAATCCTTTCCCGGAGGCAGATGAGAAGATTTTCGTCGTATCGGCCACCGGT 
GAAAGCCAGATGCTCACGCGCGGGCAACTGAAGGAATACATTGGCCAGCAGCGCGGCGAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAAAGCCAGATGCTCACGCGCGGGCAACTGAAGGAATACATTGGCCAGCAGCGCGGCGAG 
GGCTATGTCTTCTACGAGAACCGTGCATACGGCGTGGCGGGGAAAAGCCTGTTCGACGAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCTATGTCTTCTACGAGAACCGTGCATACGGCGTGGCGGGGAAAAGCCTGTTCGACGAT  
GGGCTGGGAGCCGCGCCCGGCGTGCCGAGCGGACGTTCGAAGTTCTCGCCGGATGTACTG              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGGCTGGGAGCCGCGCCCGGCGTGCCGAGCGGACGTTCGAAGTTCTCGCCGGATGTACTG 
GAAACGGTGCCGGCGTCACCCGGATTGCGGCGGCCGTCGCTGGGCGCAGTGGAACGCCAG              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAAACGGTGCCGGCGTCACCCGGATTGCGGCGGCCGTCGCTGGGCGCAGTGGAACGCCAG 
GATTCCGGCTATGACAGCCTTGATGGGGTGGGATCGCGATCGTTCTCGTTGGGCGAGGTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GATTCCGGCTATGACAGCCTTGATGGGGTGGGATCGCGATCGTTCTCGTTGGGCGAGGTG 
TCCGACATGGCCGCCGTGGAAGCGGCGGAACTGGAAATGACCCGGCAAGTCTTGCACGCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCCGACATGGCCGCCGTGGAAGCGGCGGAACTGGAAATGACCCGGCAAGTCTTGCACGCC 
GGGGCGCGGCAGGACGATGCCGAGCCGGGCGTGAGCGGTGCGTCGGCGCACTGGGGGCAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGGGCGCGGCAGGACGATGCCGAGCCGGGCGTGAGCGGTGCGTCGGCGCACTGGGGGCAG 
CGGGCGCTGCAGGGCGCCCAGGCGGTGGCGGCGGCGCAGCGGCTGGTTCATGCCATTGCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGGGCGCTGCAGGGCGCCCAGGCGGTGGCGGCGGCGCAGCGGCTGGTTCATGCCATTGCC 
CTGATGACGCAATTCGGCCGGGCCGGTTCCACCAACACGCCGCAGGAAGCGGCCTCGTTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGATGACGCAATTCGGCCGGGCCGGTTCCACCAACACGCCGCAGGAAGCGGCCTCGTTG 
TCGGCGGCCGTGTTCGGCTTGGGCGAGGCCAGCAGCGCCGTGGCCGAAACCGTGAGCGGT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCGGCGGCCGTGTTCGGCTTGGGCGAGGCCAGCAGCGCCGTGGCCGAAACCGTGAGCGGT  
TTTTTCCGCGGGTCTTCGCGCTGGGCCGGCGGTTTCGGCGTGGCTGGCGGCGCGATGGCG                
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
TTTTTCCGCGGGTCTTCGCGCTGGGCCGGCGGTTTCGGCGTGGCTGGCGGCGCGATGGCG  
CTGGGAGGCGGCATCGCCGCGGCCGTTGGCGCCGGGATGTCGTTGACCGATGACGCGCCG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGGGAGGCGGCATCGCCGCGGCCGTTGGCGCCGGGATGTCGTTGACCGATGACGCGCCG 





GAGCTGGCTTCTTCCATCGCGTTGGCGCTGGCCGCGGCGCGCGGCGTGACCAGCGGCTTG    
CAGGTGGCCGGGGCGTCGGCCGGGGCGGCTGCCGGCGCATTGGCCGCGGCGCTCAGTCCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGGTGGCCGGGGCGTCGGCCGGGGCGGCTGCCGGCGCATTGGCCGCGGCGCTCAGTCCC 
ATGGAGATCTACGGCCTGGTGCAGCAATCGCACTATGCGGATCAGCTGGACAAGCTGGCG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATGGAGATCTACGGCCTGGTGCAGCAATCGCACTATGCGGATCAGCTGGACAAGCTGGCG 
CAGGAATCGAGCGCATACGGTTACGAGGGCGACGCCTTGCTGGCCCAGCTGTATCGCGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGGAATCGAGCGCATACGGTTACGAGGGCGACGCCTTGCTGGCCCAGCTGTATCGCGAC 
AAGACGGCCGCCGAGGGCGCCGTCGCCGGCGTCTCCGCCGTCCTGAGCACGGTGGGGGCG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAGACGGCCGCCGAGGGCGCCGTCGCCGGCGTCTCCGCCGTCCTGAGCACGGTGGGGGCG 
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TTGCTGACCGGGGCTCTCAACGGCATCCTGCGCGGCGTGCAGCAGCCCATCATCGAAAAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTGCTGACCGGGGCTCTCAACGGCATCCTGCGCGGCGTGCAGCAGCCCATCATCGAAAAG 
CTGGCCAACGATTACGCTCGCAAGATCGACGAGCTGGGCGGGCCGCAAGCGTACTTCGAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGGCCAACGATTACGCTCGCAAGATCGACGAGCTGGGCGGGCCGCAAGCGTACTTCGAG 
AAAAACCTGCAGGCGCGTCACGAACAACTGGCCAATTCGGACGGCCTACGGAAAATGCTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAAAACCTGCAGGCGCGTCACGAACAACTGGCCAATTCGGACGGCCTACGGAAAATGCTG 
GCCGACCTGCAGGCCGGTTGGAACGCCAGCAGCGTGATCGGGGTGCAGACGACAGAGATC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCCGACCTGCAGGCCGGTTGGAACGCCAGCAGCGTGATCGGGGTGCAGACGACAGAGATC 
TCCAAGTCGGCGCTCGAACTGGCCGCCATTACCGGCAACGCGGACAACCTGAAATCCGTC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCCAAGTCGGCGCTCGAACTGGCCGCCATTACCGGCAACGCGGACAACCTGAAATCCGTC 
GACGTGTTCGTGGACCGCTTCGTCCAGGGCGAGCGGGTGGCCGGCCAGCCGGTGGTCCTC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACGTGTTCGTGGACCGCTTCGTCCAGGGCGAGCGGGTGGCCGGCCAGCCGGTGGTCCTC 
GACGTCGCCGCCGGCGGCATCGATATCGCCAGCCGCAAGGGCGAGCGGCCGGCGCTGACG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACGTCGCCGCCGGCGGCATCGATATCGCCAGCCGCAAGGGCGAGCGGCCGGCGCTGACG 
TTCATCACGCCGCTGGCCGCGCCAGGAGAAGAGCAGCGCCGGCGCACGAAAACGGGCAAG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTCATCACGCCGCTGGCCGCGCCAGGAGAAGAGCAGCGCCGGCGCACGAAAACGGGCAAG 
AGCGAATTCACCACATTCGTCGAGATCGTGGGCAAGCAGGACCGCTGGCGCATCCGGGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGCGAATTCACCACATTCGTCGAGATCGTGGGCAAGCAGGACCGCTGGCGCATCCGGGAC 
GGCGCGGCCGACACCACCATCGATCTGGCCAAGGTGGTGTCGCAACTGGTCGACGCCAAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGCGGCCGACACCACCATCGATCTGGCCAAGGTGGTGTCGCAACTGGTCGACGCCAAT 
GGCGTGCTCAAGCACAGCATCAAACTGGATGTGATCGGCGGAGATGGCGATGACGTCGTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGTGCTCAAGCACAGCATCAAACTGGATGTGATCGGCGGAGATGGCGATGACGTCGTG 
CTTGCCAATGCTTCGCGCATCCATTATGACGGCGGCGCGGGCACCAACACGGTCAGCTAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTTGCCAATGCTTCGCGCATCCATTATGACGGCGGCGCGGGCACCAACACGGTCAGCTAT 
GCCGCCCTGGGTCGACAGGATTCCATTACCGTGTCCGCCGACGGGGAACGTTTCAACGTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCCGCCCTGGGTCGACAGGATTCCATTACCGTGTCCGCCGACGGGGAACGTTTCAACGTG 
CGCAAGCAGTTGAACAACGCCAACGTGTATCGCGAAGGCGTGGCTACCCAGACAACCGCC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCAAGCAGTTGAACAACGCCAACGTGTATCGCGAAGGCGTGGCTACCCAGACAACCGCC 
TACGGCAAGCGCACGGAGAATGTCCAATACCGCCATGTCGAGCTGGCCCGTGTCGGGCAA               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TACGGCAAGCGCACGGAGAATGTCCAATACCGCCATGTCGAGCTGGCCCGTGTCGGGCAA 
CTGGTGGAGGTCGACACGCTCGAGCATGTGCAGCACATCATCGGCGGGGCCGGCAACGAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGGTGGAGGTCGACACGCTCGAGCATGTGCAGCACATCATCGGCGGGGCCGGCAACGAT 
TCGATCACCGGCAATGCGCACGACAACTTCCTAGCCGGCGGGTCGGGCGACGACAGGCTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCGATCACCGGCAATGCGCACGACAACTTCCTAGCCGGCGGGTCGGGCGACGACAGGCTG 
GATGGCGGCGCCGGCAACGACACCCTGGTTGGCGGCGAGGGCCAAAACACGGTCATCGGC           
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GATGGCGGCGCCGGCAACGACACCCTGGTTGGCGGCGAGGGCCAAAACACGGTCATCGGC 
GGCGCCGGCGACGACGTATTCCTGCAGGACCTGGGGGTATGGAGCAACCAGCTCGATGGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGCCGGCGACGACGTATTCCTGCAGGACCTGGGGGTATGGAGCAACCAGCTCGATGGC 
GGCGCGGGCGTCGATACCGTGAAGTACAACGTGCACCAGCCTTCCGAGGAGCGCCTCGAA               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGCGGGCGTCGATACCGTGAAGTACAACGTGCACCAGCCTTCCGAGGAGCGCCTCGAA	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CGCATGGGCGACACGGGCATCCATGCCGATCTTCAAAAGGGCACGGTCGAGAAGTGGCCG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCATGGGCGACACGGGCATCCATGCCGATCTTCAAAAGGGCACGGTCGAGAAGTGGCCG 
GCCCTGAACCTGTTCAGCGTCGACCATGTCAAGAATATCGAGAATCTGCACGGCTCCCGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCCCTGAACCTGTTCAGCGTCGACCATGTCAAGAATATCGAGAATCTGCACGGCTCCCGC 
CTGAACGACCGCATCGCCGGCGACGACCAGGACAACGAGCTCTGGGGCCACGATGGCAAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGAACGACCGCATCGCCGGCGACGACCAGGACAACGAGCTCTGGGGCCACGATGGCAAC 
GACACGATACGCGGCCGGGGCGGCGACGACATCCTGCGCGGCGGCCTGGGCCTGGACACG             
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACACGATACGCGGCCGGGGCGGCGACGACATCCTGCGCGGCGGCCTGGGCCTGGACACG 
CTGTATGGCGAGGACGGCAACGACATCTTCCTGCAGGACGACGAGACCGTCAGCGATGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGTATGGCGAGGACGGCAACGACATCTTCCTGCAGGACGACGAGACCGTCAGCGATGAC	  
ATCGACGGCGGCGCGGGGCTGGACACCGTCGACTACTCCGCCATGATCCATCCAGGCAGG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATCGACGGCGGCGCGGGGCTGGACACCGTCGACTACTCCGCCATGATCCATCCAGGCAGG 
ATCGTTGCGCCGCATGAATACGGCTTCGGGATCGAGGCGGACCTGTCCAGGGAATGGGTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATCGTTGCGCCGCATGAATACGGCTTCGGGATCGAGGCGGACCTGTCCAGGGAATGGGTG 
CGCAAGGCGTCCGCGCTGGGCGTGGACTATTACGATAATGTCCGCAATGTCGAAAACGTC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCAAGGCGTCCGCGCTGGGCGTGGACTATTACGATAATGTCCGCAATGTCGAAAACGTC 
ATCGGTACGAGCATGAAGGATGTGCTCATCGGCGACGCGCAAGCCAATACCCTGATGGGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATCGGTACGAGCATGAAGGATGTGCTCATCGGCGACGCGCAAGCCAATACCCTGATGGGC 
CAGGGCGGCGACGATACCGTGCGCGGCGGCGACGGCGATGATCTGCTGTTCGGCGGCGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGGGCGGCGACGATACCGTGCGCGGCGGCGACGGCGATGATCTGCTGTTCGGCGGCGAC 
GGCAACGACATGCTGTATGGCGACGCCGGCAACGACACCCTCTACGGGGGGCTGGGCGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCAACGACATGCTGTATGGCGACGCCGGCAACGACACCCTCTACGGGGGGCTGGGCGAC 
GATACCCTTGAAGGCGGCGCGGGCAACGATTGGTTCGGCCAGACGCAGGCGCGCGAGCAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GATACCCTTGAAGGCGGCGCGGGCAACGATTGGTTCGGCCAGACGCAGGCGCGCGAGCAT 
GACGTGCTGCGCGGCGGAGATGGGGTGGATACCGTCGATTACAGCCAGACCGGCGCGCAT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACGTGCTGCGCGGCGGAGATGGGGTGGATACCGTCGATTACAGCCAGACCGGCGCGCAT 
GCCGGCATTGCCGCGGGTCGCATCGGGCTGGGCATCCTGGCTGACCTGGGCGCCGGCCGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCCGGCATTGCCGCGGGTCGCATCGGGCTGGGCATCCTGGCTGACCTGGGCGCCGGCCGC 
GTCGACAAGCTGGGCGAGGCCGGCAGCAGCGCCTACGATACGGTTTCCGGTATCGAGAAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GTCGACAAGCTGGGCGAGGCCGGCAGCAGCGCCTACGATACGGTTTCCGGTATCGAGAAC 
GTGGTGGGCACGGAACTGGCCGACCGCATCACGGGCGATGCGCAGGCCAACGTGCTGCGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GTGGTGGGCACGGAACTGGCCGACCGCATCACGGGCGATGCGCAGGCCAACGTGCTGCGC 
GGCGCGGGTGGCGCCGACGTGCTTGCGGGCGGCGAGGGCGACGATGTGCTGCTGGGCGGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGCGGGTGGCGCCGACGTGCTTGCGGGCGGCGAGGGCGACGATGTGCTGCTGGGCGGC 
GACGGCGACGACCAGCTGTCGGGCGACGCCGGACGCGATCGCTTGTACGGCGAAGCCGGT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACGGCGACGACCAGCTGTCGGGCGACGCCGGACGCGATCGCTTGTACGGCGAAGCCGGT 
GACGACTGGTTCTTCCAGGATGCCGCCAATGCCGGCAATCTGCTCGACGGCGGCGACGGC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACGACTGGTTCTTCCAGGATGCCGCCAATGCCGGCAATCTGCTCGACGGCGGCGACGGC 
CGCGATACCGTGGATTTCAGCGGCCCGGGCCGGGGCCTCGACGCCGGCGCAAAGGGCGTA               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CGCGATACCGTGGATTTCAGCGGCCCGGGCCGGGGCCTCGACGCCGGCGCAAAGGGCGTA	  




	    
TTCCTGAGCTTGGGCAAGGGGTTCGCCAGCCTGATGGACGAACCCGAAACCAGCAACGTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTCCTGAGCTTGGGCAAGGGGTTCGCCAGCCTGATGGACGAACCCGAAACCAGCAACGTG 
TTGCGCAATATCGAGAACGCCGTGGGCAGCGCGCGTGATGACGTGCTGATCGGCGACGCA               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTGCGCAATATCGAGAACGCCGTGGGCAGCGCGCGTGATGACGTGCTGATCGGCGACGCA 
GGCGCCAACGTCCTCAATGGCCTGGCGGGCAACGACGTGCTGTCCGGCGGCGCTGGCGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCGCCAACGTCCTCAATGGCCTGGCGGGCAACGACGTGCTGTCCGGCGGCGCTGGCGAC 
GATGTGCTGCTGGGCGACGAGGGCTCGGACCTGCTCAGCGGCGATGCGGGCAACGACGAT              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GATGTGCTGCTGGGCGACGAGGGCTCGGACCTGCTCAGCGGCGATGCGGGCAACGACGAT 
CTGTTCGGCGGGCAGGGCGATGATACTTATCTGTTCGGGGTCGGGTACGGGCACGACACG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGTTCGGCGGGCAGGGCGATGATACTTATCTGTTCGGGGTCGGGTACGGGCACGACACG 
ATCTACGAATCGGGCGGCGGCCATGACACCATCCGCATCAACGCGGGGGCGGACCAGCTG               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ATCTACGAATCGGGCGGCGGCCATGACACCATCCGCATCAACGCGGGGGCGGACCAGCTG 
TGGTTCGCGCGCCAGGGCAACGACCTGGAGATCCGCATTCTCGGCACCGACGATGCACTT               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGGTTCGCGCGCCAGGGCAACGACCTGGAGATCCGCATTCTCGGCACCGACGATGCACTT 
ACCGTGCACGACTGGTATCGCGACGCCGATCACCGGGTGGAAATCATCCATGCCGCCAAC              
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
ACCGTGCACGACTGGTATCGCGACGCCGATCACCGGGTGGAAATCATCCATGCCGCCAAC 
CAGGCGGTAGACCAGGCAGGCATCGAAAAGCTGGTCGAGGCAATGGCGCAGTATCCGGAC               
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGGCGGTAGACCAGGCAGGCATCGAAAAGCTGGTCGAGGCAATGGCGCAGTATCCGGAC 







	   261	  




Bordet-Gengou agar Becton	  Dickinson	  (BD) 
Casein digest (Enzymatic digest) "	  
Skim milk "	  
Bacteriological agar Acorn Biological (Oxoid) 
Trypton " 
Yeast extract (hydrolysate) " 
Luria broth " 
Casamino acids (Technical grade) " 
Sheep blood Animal Biological Collection and 
Delivery Enterprises 
D-glucose Ar grade Thermo fisher scientific 
Sodium chloride Sigma-Aldrich 
Potassium chloride  " 
Potassium hydroxide " 
Monopotassium phosphate (KH2PO4) " 
Magnesium chloride hexhydrate 
(MgCl2.6H2O) 
" 
Magnesium sulphate " 
Ferrous sulfate hexhydrate (FeSO4.7H2O) " 
Copper sulfate (CuSO4) " 
Calcium chloride anhydrase " 




BCIP/NBT liquid substrate system " 
Sodium bicarbonate (NaHCO3) " 
Sodium citrate " 
Sodium sulphate " 
Cysteine hydrochloride " 
Monosodium glutamate " 
Nicotonic Acid  " 
2,6-O-methyl-ß-cyclodextrin  " 
L-Cysteine " 
L-Glutathione reduced " 
L-Glutamic Acid " 
L-Proline " 
Dihydroxybenzoic	  acid " 
Para-­‐aminobenzoic	  acid " 
Para-­‐hydroxybenzoic	  acid " 
L-­‐Phenylalanine	   " 
L-­‐Tryptophan " 
L-­‐Tyrosine " 
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Tween-­‐20	   " 
Ampicillin sodium salt " 
Kanamycin sulfate " 
Streptomycin sulfate salt " 
Phenol: chloroform: Isoamyl Alcohol 
25:24:1 Saturated with 10mM Tris, PH-
8.0, 1mM EDTA-for molecular biology 
" 
Para-nitrophenyl phosphate disodium salt 
hexahydrate 
" 
Protease inhibitor cocktail " 
Albumin from bovin serum " 
Diethanolamine (Bioultra) " 
Polymyxin B solution " 
Trypan blue " 
Gentamycin sulfate " 
Jackson alkaline phosphatase affinipure 
goat anti-mouse IgG subclass1 
Astral Scientific 
Agarose biotechnology grade I " 
Jackson alkaline phosphatase affinipure 
goat anti-mouse IgG subclass 2a 
Abacus Als 
Jackson alkaline phosphatase affinipure 
goat anti-mouse IgG subclass 2b 
" 
Nuclease free water  
1kb DNA step ladder Promega 
Lambda DNA/HindIII marker " 
100bp DNA ladder (low) " 
HyperLadder I " 





thioglactopyranoside), Dioxane free 
" 
T4 DNA ligase " 
T4 DNA ligase buffer " 
BamHI-HF (100,000 U/ml) " 
EcoRI-HF (100,000 U/ml) Genesearch 
ZraI (10,000 U/ml) " 
pUC19 DNA " 
Komabiotec Ezway Direct Taq PCR 
mastermix 
" 
Quikchange II XL Site-Directed 
mutagenesis kit 
Fisher biotec 
Dneasy Blood and Tissue kit Integrated Sciences 
QIAquick PCR purification kit QIAGEN 
QIAquick Gel Extraction " 
QIAprep Spin miniprep " 
RNase A " 
Pertussis toxin salt free " 
Filamentous haemagglutinin Sapphire Bioscience 
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Murine IFN-gamma ELISA kit (abcam) " 
DMEM medium " 
2-mercapto ethanol (2ME) Invitrogen 
Hepes buffer solution " 
Fetal bovine serum " 
Ultra pure Dnase/Rnase-free distilled 
water 
" 
15ml ultra series disposable tissue grinder " 
14ml BD falcon polypropylene round-
bottom tube 
Quantum Scientific 
Disposable inoculating loops, 10µl " 
Dacron Swab BD 
Cell strainer, 40µl, Nylon " 
Microtiter plate F96 maxisorp (Nunc) " 
CryoCare preserver Thermo Scientific 
Nitrocellulose membrane 0.45µm Blackabyd Diagnostics 
Acrodisc 32mm syringe filter with 0.2µm 
super membrane non-pyrogenic 
Bio Rad 
Acrodisc 32mm syringe filter with 
0.45um super membrane non-pyrogenic 
Row Scientific 
Tissue culture 24-well flat bottom with 
lid 
" 
Axygen 96 well PCR amplification plate 
with a single notch, half skirt 
Sarstedt Australia 
Axygen cycler sealer PCR sealing film  Fisher Biotec 
Semi micro cuvettes, 1.5ml " 
 Interpath 
